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Abstract 
Fenofibrate is a PPARα agonist, used to treat dyslipidemia.  Unpublished work 
that has been previously carried out in our group has identified that fenofibrate 
also displays affinity for the cannabinoid receptors, CB1 and CB2. 
A dual receptor ligand, with the PPARα agonist activity of fenofibrate, 
combined with antagonist activity at the CB1 receptor, or agonist activity at the 
CB2 receptor, could reduce appetite, decrease plasma triglyceride levels, 
increase high density lipoprotein (HDL) levels, lower low density lipoprotein 
(LDL) levels and reduce atherosclerosis.  This could enable the multi-
symptomatic treatment of obesity with the advantage of avoiding side effects 
associated with taking multiple medications.  However, whilst fenofibrate has 
affinity for the cannabinoid receptors, only its active metabolite; fenofibric acid 
(10b) activates PPARα.  This project sought to develop novel ligands for the 
cannabinoid receptors that retain activity at PPARα.   
A series of amide derivatives of fenofibrate were synthesised, and 
pharmacological testing revealed that the piperidinyl (48g) and morpholino 
(48h) derivatives had agonist activity and a higher affinity for the cannabinoid 
receptors than fenofibrate.  However these derivatives failed to bind and 
activate PPARα.  Although a dual PPARα / cannabinoid receptor ligand has 
not been found with these amide derivatives, the compounds synthesised could 
provide a platform for the further development of cannabinoid receptor ligands 
of this novel class.  This was demonstrated by further modifications to 
compounds (48g) and (48h) which indicated that activity at the cannabinoid 
receptors is tuneable. 
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1.     Introduction 
1.1. Potential Dual PPAR/ Cannabinoid Receptor Ligands 
During the past two decades, both Cannabinoid receptors and Peroxisome 
Proliferator Activated Receptors (PPARs) have been the subject of 
considerable research efforts. 
 PPARs are ligand-regulated transcription factors, and have been shown to 
regulate glucose homeostasis1, lipid and lipoprotein metabolism2, and cellular 
differentiation1.  They also exhibit inhibitory effects in the inflammation 
process3. 
Cannabinoid receptors, however, belong to the transmembrane G-protein 
coupled receptor (GPCR) super family, which are modulators of various 
signalling cascades.  The cannabinoid receptor family consists of the CB1 and 
CB2 receptors.  The CB1 receptor is expressed mainly in the brain, whereas the 
CB2 receptor is predominantly localised in the cells of the immune system. 
There is growing evidence that some cannabinoid ligands will also bind to 
PPARs4, 5.  A compound with antagonist activity at the CB1 receptor, and 
agonist activity at both PPARα and the CB2 receptors, could reduce appetite, 
decrease plasma triglyceride levels, increase high density lipoprotein (HDL) 
levels, lower low density lipoprotein (LDL) levels and reduce atherosclerosis.  
With this in mind, it would be desirable to develop a ligand with affinity for 
both of these types of receptor, as there is potential for multi-symptom 
treatment of certain diseases, such as obesity. 
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1.2. Peroxisome Proliferator Activated Receptors  
PPARs belong to the nuclear receptor family, and were first identified in mice 
in 1990.6 Two years later, three subtypes of PPARs were identified and cloned 
from a Xenopus cDNA library7. These three subtypes  (α, γ, and δ) share 60 to 
70 % sequence identity8 and are found in various areas of the body. They have 
roles in glucose homeostasis, lipid and lipoprotein metabolism, cellular 
differentiation and inflammation processes1. 
PPARα is predominantly found in tissues involved in fatty acid catabolism, 
such as the liver, kidney, heart and skeletal muscle9. With the use of fibrates, 
PPARα has proven to be an effective target in the treatment of dyslipidemia.   
PPARγ has three further subtypes; PPARγ1, PPARγ2 and PPARγ3.  PPARγ1 
is found in a wide range of tissues such as the kidneys, spleen, heart, and both 
small and large intestines, whereas PPARγ2 is found mainly in adipose tissue.  
PPARγ3 is found in macrophages, adipose tissue and colon epithelium.  The 
PPARγ receptors are a target for thiazolidinediones, which sensitise tissues to 
insulin in the treatment of Type 2 Diabetes mellitus (T2DM).  
The third PPAR subtype, PPARδ, is less understood and almost ubiquitously 
expressed.  It is thought to be involved in fatty acid metabolism and 
reproduction1. 
1.2.1. PPAR Structure  
PPARs consist of a ligand binding domain (LBD), DNA binding domain 
(DBD), ligand dependent activating domain (AF-2) and a ligand independent 
activating domain (AF-1) (Figure 1-1). 
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Figure 1-1-Representation of the different PPAR Domains (adapted from Henke et al10) 
 
The ligand binding domain is formed from 13 α-helices and a small, four 
stranded β-sheet.  
1.2.2. Activation Mechanism 
Binding of a ligand (L) to the LBD induces stabilisation of the AF-2 region, 
and then recruitment of a co-activator (A) such as; CBP, p300 or SRC-11.  The 
co-activator binds at a hydrophobic cleft on the surface of the PPAR11, and the 
PPAR then forms a dimer with retinoid x receptor (RXR).  There are three 
isoforms of RXR (as for PPARs), and they are activated by the endogenous 
ligand 9-cis retinoic acid.  
 
Figure 1-2-Representation of the active complex bound to the PPRE (adapted from Henke et 
al10) 
 
The PPAR/RXR heterodimer then binds to a Peroxisome Proliferator Response 
Element (PPRE) via the DBD using two zinc finger motifs (Figure 1-2).  The 
PPRE is a sequence of two hexanucleotides, separated by any nucleotide (X) 
AGGTCAXAGGTCA1.  It is located in the promoter region of genes, and once 
the activated PPAR/RXR heterodimer is bound, gene transcription can be 
initiated. 
4 
1.2.3. PPARα  
PPARα is involved in the β-oxidation of fatty acids, and the uptake of fatty 
acids into cells, by regulating the expression of fatty acid transport protein 
(FATP) and fatty acid translocatase (FAT)12.  In the liver it regulates enzymes 
involved in the metabolism of triglycerides,  and components that form HDL12, 
and in the heart it regulates energy supply by regulating lipoprotein lipase 
levels, and also fatty acid oxidation12.  
PPARα also has a role in inflammation and macrophage signalling.  In 
macrophages it stimulates cholesterol efflux via the ABC-A1 (ATP-binding 
cassette transporter) pathway and also may induce the expression of liver-x-
receptor (LXR) which mediates the expression of ABC-A113.  PPARα has been 
shown to suppress Nuclear Factor κB (NF-κB) signalling1, 14.  This is 
significant as many pro-inflammatory genes are under the control of NF-κB.  
Inducer of nuclear factor-κB (IκB) is an inhibitor of NF-κB and is also 
regulated by PPARα.  IκB levels are increased with PPARα activation causing 
retention of NF-κB in its inactive form.  This leads to a decrease in NF-κB 
DNA binding and a reduction in the NF-κB induced inflammatory response15. 
In vivo the role of PPARα in inflammation has been demonstrated.  Patients 
with atherosclerosis, treated with fenofibrate, demonstrated a decrease in IL-6, 
(a cytokine released in response to inflammation) and also the acute phase 
proteins fibrinogen and C-reactive protein (CRP)14 .  Another study found that 
patients with hyperlipidemia, also treated with fenofibrate, had reduced plasma 
levels of the cytokines interferon-γ (INFγ) and tumour necrosis factor-α 
(TNFα)16. 
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1.2.4. Ligands for PPARα 
The ligand binding pocket in PPARα is a T-shaped cavity and has a volume of 
approximately 1300 Å3 11.  Due to the large size of the binding pocket a wide 
variety of compounds with widely differing structures can bind.  A 
representation of an hPPARα LBD in complex with the PPARα/γ agonist 
AZ242 is shown in Figure 1-3.  
 
Figure 1-3–Representation of a crystal structure of a PPARα LBD in complex with AZ242 
(adapted from Cronet et al,17 1I7G in protein data bank).   
The detergent DBC is shown in cyan and AZ242 in blue. 
The ligand binding pocket is in the centre of the ligand binding domain, and is surrounded by 
helices 3, 5, 7, 11 and 1317. 
 
1.2.4.1. Agonist Binding in the Ligand Binding Domain 
Crystal structures of PPAR LBDs have revealed that the carboxylic head group 
is important for both natural and synthetic agonist activation11, 17, 18.  In the 
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PPARα LBD the carboxylic acid forms a hydrogen bond with a tyrosine 
residue (Tyr464) in the AF2 helix, and also hydrogen bonds with Ser280, Tyr314, 
and His440 which are part of the coactivator binding site (Figure 1-4).  Xu et al 
suggested that the interactions with Tyr464 and Tyr314 stabilise the AF2 helix 
generating a salt bridge between Glu462 and Lys292 which allows a coactivator 
to bind to the receptor.  
 
Figure 1-4- Structure of AZ242 and residues involved in hydrogen bonding to the carboxylic 
acid (protein structure & ligand from the protein data bank 1I7K) 
 
The importance of the acid head group was investigated further by Xu et al. 
and in this next study, the carboxylic acid of the PPARα agonist GW409544 
(1)  was  changed to a large amide group to give an antagonist (GW6471 (2)).  
This alteration reversed the amide and also moved the amide group out by one 
carbon relative to the carboxylic acid.  GW6471 (2) was then crystallised with 
a hPPARα LBD19, which showed that hydrogen bonding to Tyr464 and  also 
AF-2 stabilisation were prevented. This inhibited activation of the LBD.  Xu et 
al. also found that when GW6471 (2) binds, a larger pocket is created at the 
hydrophobic cleft where co-activators and co-repressors bind.  This increase in 
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size could allow co-repressors to bind more easily19 preventing PPAR 
activation.  
 
Figure 1-5 Structures of the PPARα ligands GW409544 and GW6471 
 
1.2.4.2.  Natural Ligands 
Natural ligands, with agonist activity at PPARα, consist of fatty acids and 
eicosanoids such as linoleic acid (3) and icosapentanoic acid20. None of the 
natural ligands have high affinity for PPARα, so it is thought that the receptor 
acts as a sensor of fatty acid levels18.  
 
Figure 1-6 Examples of endogenous agonists of PPARα 
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1.2.4.3. Synthetic Ligands 
1.2.4.3.1. Fibrates 
Fibrates are synthetic PPARα agonists (Figure 1-7), and are effective in the 
treatment of some types of dyslipidemia, such as atherogenic dyslipidemia.  
This type is found in patients with metabolic syndrome and T2DM, and is 
associated with high levels of triglycerides, low HDL levels, and small dense 
LDL particles21.  
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Figure 1-7 Examples of fibrates with agonist activity9, 10, 22 
The first fibrate to be reported was clofibrate (7) in 1961.23 In rats, it was 
observed to reduce lipid and cholesterol levels24 in both the blood and liver; 
however it caused hepatic peroxisome proliferation, hepatomegaly, and 
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hepatocarcinogenesis25.  None of these toxic effects however are mirrored in 
humans9. Subsequent to the development of clofibrate (7); fenofibrate, 
gemfibrozil (8), bezafibrate (11) and ciprofibrate (12) were brought to the 
market.   
1.2.4.3.2. Fenofibrate 
Fenofibrate (10a) was developed in the 1970s by Groupe Fournier SA26.  It is a 
PPARα agonist, and is widely used as a hypolipidemic drug.  Although 
fenofibrate (10a) itself has low activity at PPARα, it is a prodrug and becomes 
active once the ester is hydrolysed, to give fenofibric acid (10b).   
In a randomised controlled trial with 9795 patients with T2DM, the drug was 
proven to be effective in lowering triglyceride levels and raising HDL levels27 
through mechanisms described below in section 1.2.4.4. It was also found to be 
effective in reducing the number of cardiovascular events, including non-fatal 
myocardial infarctions and stroke27. 
1.2.4.4. Effect of Fibrates on Lipid Metabolism   
Fibrates have been utilised in the clinic for over forty years to treat 
dyslipidemias, and are thought to operate via several mechanisms to alter lipid 
metabolism.  The following mechanisms describe how fibrates affect lipid 
metabolism: 
Firstly, the expression of lipoprotein lipase is increased, and expression of 
apolipoprotein CIII (an inhibitor of lipoprotein lipase) is decreased,  which 
leads to an increase in triglyceride metabolism, and therefore a lowering of 
plasma triglyceride levels28 21.  Fibrates also inhibit the synthesis of hepatic 
triglycerides and Very Low Density Lipoproteins (VLDL) 28, and increase 
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hepatic fatty acid uptake.  They increase the clearance of LDL and reduce the 
level of small dense LDL.  By increasing the size of LDL, affinity of LDL for 
the LDL receptor is augmented, and is less likely to be oxidised 21.  Lastly, 
fibrates increase the levels of HDL and increase reverse cholesterol transport.  
The HDL levels are increased by augmenting the expression of the main 
components of HDL; ApoA-I and ApoA-II 21, 29. 
Fibrates have been shown to lower plasma triglyceride levels by 20-50% and 
raise HDL levels by 10-35%.29 
1.2.4.5. Other Synthetic Ligands 
Other synthetic PPARα agonists, developed after the fibrates, include 
WY14643 (13) and BR-931 (14).  WY14643 (13) is a pyrimidine derivative 
and was first reported in 1974.  BR-931 (14) is an ethanolamide analogue of 
WY14643 (13).  Both of these compounds have shown to be effective 
hypolipidemic agents30, 31. 
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Figure 1-8 Examples of synthetic PPARα agonists 
 
All of the synthetic PPARα ligands described so far were developed without 
the knowledge that they were active at PPARs.  Subsequent to the cloning of 
PPARs and the identification of ligands for these receptors, a new class of 
ligands was designed.  These were urea-substituted thioisobutyric acids, and 
gave rise to the first selective PPARα agonists and antagonists.  The 
development of these ligands was initiated with the synthesis of ureido-
fibrates.  Using combinatorial chemistry a library of 480 compounds was 
synthesised32, in which 20-50% of the compounds had affinity for PPAR32.  
However, there was low sub-type selectivity at murine and human PPARs32 so 
Brown et al. substituted the fibrate head group with thioisobutyric acid33.  This 
led to the synthesis of GW9578 (16), which displayed a 300-fold selectivity for 
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murine PPARα and 20-fold selectivity for human PPARα33 over other 
subtypes.  To improve the selectivity at PPARα, two further combinatorial 
libraries were synthesised by Brown et al.  Ten compounds were identified as 
having nanomolar or lower activity at PPARα, and selectivity of more than 100 
fold.  GW7647 (15) was identified as having the highest activity and being the 
most selective for hPPARα34; it has 200-fold selectivity and also exhibits in-
vivo lipid lowering activity34. 
1.3. G-Protein Coupled Receptors 
There are approximately 800 known G-Protein Coupled Receptors (GPCRs), 
and they are divided into five families based on sequence conservation.  The 
families are; Glutamate (G), Rhodopsin (R), Adhesion (A), Frizzled/Taste (F) 
and Secretin (S)35.  The largest family is the Rhodopsin family which is 
comprised of 672 receptors35.  GPCRs are located in cell membranes, and 
allow transmission of a low level extracellular signal to the inside of the cell, 
where the signal is amplified.  They are responsible for approximately 80% of 
signal transduction into cells35. 
1.3.1. GPCR Structure  
GPCRs are made up of seven transmembrane (7TM) alpha helices, joined by 
three intracellular and three extracellular loops.  The N-terminus is on the 
exoplasmic side of the cell membrane and the C-terminus resides on the 
cytosolic side of the plasma membrane36. 
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Figure 1-9-Representation of a GPCR structure (adapted from molecular cell biology, 5ed37)  
 
GPCRs are linked to a G-protein, which consists of three subunits Gα, Gβ and 
Gγ, with Gα bound to guanosine 5’- diphosphate (GDP) in the inactive state38.  
The G-protein is on the interior of the cell, with the Gα, and Gγ subunits 
attached to the cell membrane via lipid anchors39.  There are four types of the 
Gα subunit, which are; Gαi, Gαs, Gα12/13 and Gαq/11.  Gβγ exists as a dimer and 
there is only one type39.  Gαi/o is an inhibitory G-protein which was initially 
demonstrated to inhibit adenylyl cyclase but was later shown to also interact 
with other effector enzymes39.   Gαs activates adenylyl cyclase, Gαq/11 activates 
phospholipase C-β, and Gα12/13 may be involved in the regulation of small GTP 
binding proteins39 such as members of the rho family of GTPases40. 
1.3.1.1. GPCR Structure Determination 
GPCR structures are difficult to elucidate as they are membrane bound 
receptors, and rely on the cell membrane for their structure.  This causes 
difficulty in isolating, and crystallising them.  Early homology models of 
GPCR structures were based on various studies of bacteriorhodopsin in its 
inactive state 41-43.  
The first mammalian GPCR crystal structure was solved in 2000 by Palczewski 
et al44.  The GPCR studied was bovine rhodopsin, with 11-cis-retinal bound, 
which maintains the transmembrane region in an inactive conformation.  The 
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2.8Å crystal structure revealed differences from the bacteriorhodopsin 
structure.  One of these is the differing arrangement of helices between the two 
receptors44. 
Further advances in GPCR structure determination came in 2007 when two 
research groups reported the crystal structure of the β2-adrenoceptor bound to 
the partial inverse agonist carazolol45, 46.  Rasmussen et al crystallised the 
human β2-adrenoceptor in a lipid environment, and with a monoclonal antibody 
fragment (Fab-5) bound to the third intracellular loop46.  The antibody 
fragment helped to stabilise the receptor whilst not affecting ligand binding.  
They successfully resolved the ends of the transmembrane segments and 
connecting loops, however the extracellular regions could not be resolved46.  
Similarities and differences between the bovine rhodopsin structure and the 
human β2-adrenoceptor were revealed by overlaying the two crystal structures.  
The two receptors share a similar overall 7TM structure, but the cytoplasmic 
ends of the transmembrane segments differ, and the β2-adrenoceptor has a more 
open structure46.  The two receptors have differing basal activities, as the β2-
adrenoceptor has a high basal activity, whereas rhodopsin has no detectable 
basal activity46.  Even bound with an inverse agonist, the β2-adrenoceptor 
displays 50% activity46.  The more open structure could explain the high basal 
activity, as the β2-adrenoceptor could be deficient in some of the hydrogen 
bonds, Van der Waals interactions and ionic interactions present in the inactive 
rhodopsin structure46.  Cherezov et al modified the β2-adrenoceptor (β2-AR) 
structure by inserting a T4 lysozyme sequence in place of the third intracellular 
loop45.  This change again stabilised the receptor and was shown not to affect 
ligand binding.  Unlike the 3.4/3.7 Å crystal structure of the β2-adrenoceptor 
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obtained by Rasmussen et al, Cherezov et al. were able to resolve the 
extracellular regions, in addition to achieving a resolution of 2.4 Å. 
On comparison of the higher resolution β2-AR structure, with the bovine 
rhodopsin structure, several differences were revealed.  There is a difference in 
the transmembrane helices as 2, 5, 6 and 7 have a kink, and the second 
extracellular loop has an extra helix which is not present in rhodopsin45. 
The differences in the crystal structures of the β2-adrenoceptor, and that of 
bovine rhodopsin, highlights shortcomings in homology models of various 
GPCRs that are solely based on rhodopsin. 
1.3.1.2. G-protein Activation 
The G-protein in its inactive state exists as a heterodimer with GDP bound to 
the Gα subunit.  On G-protein activation, the GDP dissociates and guanosine 
5’-triphosphate (GTP) binds to the Gα subunit.  This causes the Gα-GTP dimer 
to dissociate and bind to an effector enzyme such as adenylyl cyclase36.  
The GTP is gradually hydrolysed back to GDP by the inherent GTPase activity 
of the Gα subunit.  This GTPase activity can be increased by regulators of G-
protein signalling (RGS) proteins38.  The Gα unit with GDP is then able to 
reassociate with Gβγ to form the inactive Gαβγ trimer38 which stops the 
activity of the Gα subunit on the effector enzyme38.  
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Figure 1-10-Representation of a GPCR activation mechanism (adapted from Barren et al38) 
1.4. Cannabinoid Receptors  
Cannabinoid receptors belong to the Rhodopsin-like family of GPCRs and 
there are two recognised sub-types; CB1 and CB2.  The first compounds 
identified as cannabinoid receptor ligands, were isolated from the plant 
Cannabis sativa.  There are approximately 60 cannabinoid compounds present 
in the Cannabis plant and the first compounds isolated47 were cannabinol (Ki = 
211 nM at CB1 and 126 nM at CB2)48 and cannabidiol ((17) refer to Figure 1-
11).  The compound which gives the plant its psychoactive properties, was 
identified as )9-Tetrahydrocannabindiol ()9-THC (26) refer to Figure 1-14) by 
Mechoulam et al. in 196449 and is an agonist at both the cannabinoid receptors. 
17 
1.4.1. CB1 Receptor 
The CB1 receptor (CB1R) was identified in 1988 by Devane et al. and then 
cloned in 199050, 51.  It has since been cloned from mouse52 and human53 tissues 
and there is 97-99% sequence identity between them54. In humans the CB1 
receptor is found predominantly in the brain in several areas including the 
hypothalamus, amygdala and the hippocampus55.  It is found peripherally in 
adipocytes, liver and on both central and peripheral nerve terminals.  
Activation of the CB1 receptor suppresses release of acetylcholine, 
norepinephrine, dopamine, 5-hydroxytryptamine, GABA, glutamate and 
aspartate54. 
The CB1 receptor is a Gi/o coupled receptor, and its activation causes the 
inhibition of adenylyl cyclase activity and activation of MAP kinase54.  
Adenylyl cyclase is a membrane-bound enzyme that facilitates formation of 
cyclic AMP from ATP.  The CB1 receptor is also coupled to other effectors 
such as potassium and calcium channels56.  
1.4.2. CB2 Receptor 
The CB2 receptor (CB2R) was the second cannabinoid receptor to be identified 
and cloned in humans, rats and mice.,53, 57, 58 The human CB2 receptor has 81% 
and 82% sequence identity with mouse and rat CB2 receptors respectively.  It is 
found in the cells of the immune system, and more recently has been found in 
low levels in brain stem neuronal cells59 and also in microglial cells of the 
central nervous system60.   
Like the CB1R, it is Gi/o coupled, and activation of the receptor causes 
inhibition of adenylyl cyclase, and activation of MAP kinase54.  Unlike the CB1 
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receptor, the CB2 receptor does not couple to calcium Q or inward rectifying 
potassium channels54.  The CB2 receptor has 68% amino acid homology with 
CB1 receptors within the transmembrane regions54, but only 44% overall61.   
1.4.3. GPR55 
For a number of years, evidence grew to suggest the presence of a third 
cannabinoid receptor, in addition to the CB1 and CB2 receptors.  Several groups 
have reported an orphan cannabinoid-like receptor in the brain,62, 63 vascular 
endothelium,64, 65 and the immune system66. The first suggestion of the 
existence of a novel third cannabinoid receptor came from studies of the effects 
of cannabinoids on vasodilation, in which  anandamide (19) and (R)-
methanandamide, possessed vasodilatatory ability; however )9-THC ((26) 
refer to Figure 1-14) and potent synthetic CB1 and CB2 cannabinoids had no 
effect67.  The vasodilatatory effect was inhibited by the CB1 antagonist 
SR141716 (41) but a higher concentration of SR141716 (41) than necessary to 
block CB1 receptors was needed64.  Parmitoylethanolamine (PEA) has been 
demonstrated to have potent antinociceptive effects peripherally which were 
blocked by the CB2 selective antagonist SR144528 (42)68.  As PEA does not 
activate the CB2 receptor, Calignano et al suggested that a third cannabinoid 
receptor may be responsible. 
 
19 
 
Figure 1-11- Structures of cannabidiol and abnormal cannabidiol 
 
The orphan receptor GPR55 was identified as potentially a novel cannabinoid 
receptor by Ryberg et al. in 199569.  Cells transfected with human cDNA for 
GPR55, were used, and radioligand binding assays showed that the receptor 
was activated by several endocannabinoids, as well as natural and synthetic 
cannabinoids.  Endogenous ligands active at the receptor include anandamide 
(19), 2-AG (20), noladin ether, PEA and virodhamine (22).  Virodhamine (22) 
had a particularly high efficacy that was double that of anandamide.  Other 
ligands which displayed activity at GPR55 included )9-THC (26), HU210 (29), 
and AM251 (44).  Cannabidiol (a low affinity CB1R and CB2R ligand (17)) 
and abnormal cannabidiol (18), which has no CB1 or CB2 activity, are active at 
GPR55, suggesting that their effects may be mediated by this receptor.   
Ryberg et al69 also reported the pattern of expression of GPR55 in mouse 
tissues, with the highest levels of GPR55 mRNA were located in the adrenal 
glands, parts of the gastrointestinal tract and the brain.  
GPR55 still remains to be reclassified as a cannabinoid receptor, as more 
recent evidence has suggested that it may be a receptor for endogenous 
phospholipids; lysophosphatidylinositols (LPI)70, with the arachidonic acid 
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containing species, 2-arachidonoyl-sn-glycero-3-phosphoinositol, having the 
highest affinity71.  Several groups have also reported that some cannabinoids, 
that have been previously described as ligands for GPR55, may not actually 
have affinity for the receptor70, 71. 
1.4.4. Ligands for Cannabinoid Receptors 
There are several different classes of ligands for the cannabinoid receptors, 
including the endocannabinoids, classical THC-like cannabinoids, non-
classical cannabinoids and the aminoalkylindoles. 
1.4.4.1. Endocannabinoids and the Endocannabinoid System 
There have been seven endogenous cannabinoid receptor ligands 
(endocannabinoids) identified to date, and they are thought to be involved in 
regulation of food intake,72 posture and movement,73 pain perception,68 and 
immune response74.  At nerve terminals endocannabinoids mediate 
neurotransmitter release by retrograde signalling across the synapse75. 
Endocannabinoids are synthesised on demand, not stored, and are metabolised 
in cells by enzymes, including fatty acid amide hydrolase (FAAH) and 
monoacylglycerol lipase.   
The first endocannabinoid identified was anandamide (19) 
(arachidonylethanolamide) in 1992.  It is a derivative of arachidonic acid (4) 
and was isolated from pig brain76. Anandamide (19) has a measureable affinity 
for both cannabinoid receptors 54 but only exerts a small agonist effect77.  
During the isolation of anandamide (19), two other compounds were found to 
bind to the CB1 receptor.  These two compounds (homo-γ- 
linolenoylethanolamide (24) and docosatetraenoylethanolamide (25)) were 
21 
later identified and synthesised by Hanus et al78 and were both found to bind to 
the CB1 receptor in a competitive binding experiment. 
During a study to find peripheral cannabinoid receptor ligands, a third 
endocannabinoid was reported.  It was named 2-arachidonoylglycerol (2-AG) 
(20), and was isolated from canine gut79 and rat brain80. It is synthesised from 
diacylglycerol and was shown to bind to CB1 and CB2 but demonstrates a 
higher affinity for CB1 79.  
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Figure 1-12-Endogenous Cannabinoids  
 
Between 2000 and 2002, three other endocannabinoids were characterised.  
These were N-arachidonyl dopamine (23), noladin ether, and virodhamine (22).  
(Figure 1-12).  
N-Arachidonoyl dopamine (23) (NADA) was isolated from rat brain in 200081.  
It is a selective CB1 receptor agonist82 and also displays agonist activity at the 
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vanilloid type 1 receptor (TRPV1)81.  In 2001, noladin ether (2-arachidonyl 
glycerol ether (21)) was isolated from porcine brain 83.  It is an agonist at both 
CB1 and CB2 but displays a higher affinity for the CB1 receptor84.  
Virodhamine (22), an analogue of anandamide (19), was the seventh 
endocannabinoid to be isolated85.  The ethanolamine moiety is connected via 
the oxygen, instead of the nitrogen, to form an ester.  It is an antagonist at the 
CB1 receptor and an agonist at the CB2 receptor.  
Two compounds that are structurally related to the endocannabinoids are the 
PPARα ligands; palmitoylethanolamine (PEA) and oleoylethanolamine (OEA).  
OEA has no activity at either cannabinoid receptor, but PEA has slight agonist 
activity at the CB2 receptor.  Both compounds activate the putative cannabinoid 
receptor GPR55 at nanomolar concentrations69. 
It has also been reported that several of the endocannabinoids have activity at 
PPARα.  In a study by Sun et al. they found that anandamide (19), noladin 
ether and virodhamine (22) bound to and activated PPARα5.   
1.4.4.2. Classical Cannabinoids 
The classical cannabinoids are natural or synthetic analogues of the 
psychoactive component of Cannabis sativa; )9-THC (26).  They consist of a 
tricyclic dibenzopyran-type core with a hydroxyl group at C1, and an alkyl 
group at C354 and varying substituents at C11.  
 
Figure 1-13 - Numbering system of classical cannabinoids 
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The first synthetic classical cannabinoid was 9-nor-9-
hydroxyhexahydrocannabinol (27)86.  It differs in structure from )9-THC (26) 
at C11 as a hydroxyl group has replaced the methyl group and the double bond 
between C9 and C10 is absent.  The effect of modification of the C3 alkyl 
substituent on cannabinoid receptor binding was then investigated, leading to 
the discovery of the high affinity cannabinoid dimethylheptyl-HHC (28)87 
where a dimethylheptyl group replaced the pentyl group.   
Later modifications to the )9-THC (26) structure led to HU210 (29)88.  In 
comparison to )9-THC (26), C11 is hydroxylated, and the C3 alkyl side chain 
is the dimethylheptyl group from dimethylheptyl-HHC (28).  HU210 (29) is 
more selective for CB1R than CB2R56, and has a 7-fold higher affinity for CB1 
receptors than )9-THC (26). The importance of the stereochemistry of HU210 
(29), at 6a and 10a, was investigated by Howlett et al.89, who found that the 
(6aR, 10aR) enantiomer had 1500 fold higher affinity for the CB1 receptor than 
the (6aS, 10aS) enantiomer (HU211 (30)).   
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Figure 1-14 Examples of classical cannabinoids  
 
Huffmann et al synthesised many synthetic cannabinoids, including the 
classical cannabinoids JWH-133 (32) and JWH-051 (31).90, 91  JWH-051 (31) is 
structurally related to HU-210, however the hydroxyl on C1 is not present.  
This change afforded an increased affinity for the CB2 receptor54. 
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 JWH-133 (32) also has increased selectivity for the CB2 receptor.  It differs 
from )9-THC (26) in that it has a double bond between C8 and C9, the 
hydroxyl on C1 is absent, and a dimethylbutyl group has also been 
incorporated into the structure54.  
1.4.4.3. Non Classical Cannabinoids 
The first non-classical cannabinoids were first reported by Pfizer in the 
1980’s92.  Melvin et al. found that when removing the dihydropyran ring 
present in the classical cannabinoids, cannabinoid activity was retained.92  This 
led to the development of the non-classical cannabinoid CP 47497 (33)93.   
The non-classical cannabinoids are based on AC bicyclic and ACD tricyclic 
cores.  
 
Figure 1-15- Non-classical cannabinoid lettering system 
 
 
Examples of compounds in this class are shown in Figure 1-16.  
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Figure 1-16 Examples of non-classical and classical/non-classical-hybrid cannabinoids 
 
CP55940 (35) is a high affinity non-selective cannabinoid receptor agonist, 
which differs from CP47497 (33) by the presence of a propyl alcohol group at 
C4 of the cyclohexanol ring.  The addition of this southern aliphatic hydroxyl 
(SAH) increased affinity for the CB1 receptor93.  Tritiated CP55940 is an 
important tool in determining activity of compounds at the cannabinoid 
receptors, and was used by Devane et al in 1988 to characterise the CB1 
receptor50.  
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CP55244 (34) is an ACD tricyclic non-classical cannabinoid, where the SAH 
of CP55940 (35) is conformationally restrained.  It has a high affinity for the 
CB1 receptor and behaves as a full agonist94  The restrained SAH of CP55244 
(34) was incorporated into classical cannabinoids to give non-classical/classical 
cannabinoid hybrids.  Examples of these include AM919 (36) and AM938 (37) 
which both have nanomolar affinity for both CB1R and CB2R95, 96.  AM919 
(36) is non-selective at the cannabinoid receptors, but AM938 (37) has a higher 
affinity for the CB2 receptor.  Selectivity was increased by rigidification of the 
SAH with an alkyne.    
1.4.4.4. Aminoalkylindoles 
The aminoalkylindoles were developed by structurally constraining analogues 
of the non-steroidal anti-inflammatory drug (NSAID) pravadoline.  The first 
compounds in this series displayed reduced prostaglandin synthase inhibitory 
activity, but retained antinociceptive activity via another mechanism97, which 
later proved to be activity at the cannabinoid receptors98.       
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Figure 1-17 Examples of aminoalkylindole cannabinoids 
 
R-(+)-WIN55212 (38) is a member of the aminoalkylindole series (Figure 
1-17), and is a high affinity agonist for both  the CB1 and CB2 receptors56 with 
a slight selectivity towards the CB2 receptor.  Since the synthesis of these first 
aminoalkylindoles, several others have been developed, such as the CB2 
selective ligands L-768242 (40) (GW405833)99 and JWH-015 (39)54.    
30 
1.4.4.5. Diarylpyrazoles 
The first 1,5-diarylpyrazole cannabinoid receptor ligands were reported by 
Sanofi Recherche in the 1990’s98.  They were a structurally novel class of 
ligands, which provided the first selective high affinity CB1 and CB2 receptor 
antagonists.  SR141716 (41) (Rimonabant) was reported in 1994 as a CB1 
antagonist100.  It has a high affinity at cloned human CB1 receptors and has 
1000 fold selectivity for CB1 over CB2.  A high affinity CB2 antagonist 
(SR144528 (42)) was reported four years later99,   with 700 fold lower affinity 
for the CB1 receptor.   
 
Figure 1-18 Examples of diarylpyrazole cannabinoids 
 
1.4.5. CB1 as a therapeutic target 
The CB1 receptor has potential as a target in several therapeutic areas, 
including appetite control, pain relief, and multiple sclerosis (MS). 
1.4.5.1. Analgesia 
Several studies in animal pain models have indicated a role for cannabinoid 
receptors as analgesics97. Richardson et al.101 found that anandamide (19) 
administered peripherally in rat paws reduced hyperalgesia and 
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inflammation101.  Reduction of hyperalgesia was prevented by the CB1 
selective inverse agonist SR141716 (41)101. 
Calignano et al.68 also found that in mice an analgesic effect was observed 
when anandamide (19), WIN55212 (38) or HU210 (29) were injected with 
formalin into paws68.  The analgesic effect was prevented by SR141716 (41) 
but not the CB2 selective antagonist SR144528 (42)68. 
In contrast to animal pain models, studies on the effect of cannabinoids on 
human pain have had varying results.  A systematic review of research carried 
out on human pain trials indicated that cannabinoids had little advantage over 
traditional pain relief medication in the treatment of post operative pain, with 
high incidences of adverse effects102. Buggy et al.103 also found that 5 mg of 
)9-THC (26) had no effect on post operative pain103.  The review however, 
indicated that cannabinoids may have an application in the treatment of MS, 
where )9-THC  (26) reduced spasticity and neuropathic pain102.  
1.4.5.2. Appetite 
The CB1 receptor was first implicated in appetite control when it was 
discovered that both anandamide (19) and )9-THC (26) induced appetite 
stimulation.104  
1.4.5.2.1. Appetite Suppression 
The CB1 receptor inverse agonist SR141716 (41) (rimonabant) was found to be 
effective in inducing weight loss, increasing HDL plasma concentrations and 
decreasing plasma triglycerides in humans105.  It is thought that the initial 
weight loss is due to the action of SR141716 (41) on CB1 receptors in the 
brain, by reducing appetite106.  However subsequent weight loss, after the 
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anoretic effect has diminished, is thought to be due to peripheral CB1 receptors 
found in adipocytes106, which can regulate adiponectin107and decrease 
lipoprotein lipase levels108.  
Rimonabant (41) was utilised as an aid to weight loss until 2008, when it was 
removed from the market, due to evidence of adverse effects in patients, such 
as depression and suicidal thoughts109.  This in turn led to several 
pharmaceutical companies abandoning projects researching potential CB1 
antagonists.  
1.4.5.2.2. Appetite Stimulation 
CB1 agonists are currently used in patients undergoing chemotherapy treatment 
and also patients with AIDS.  This is due to their ability to increase appetite 
(orexigenic effect) and relieve nausea (antiemetic effect)47.  Cannabinoids 
currently used are nabilone, a synthetic classical cannabinoid, and synthetic )9-
THC (26) which is also called dronabinol110. 
1.4.5.3.  Multiple Sclerosis 
Multiple sclerosis (MS) is an auto-immune disease where the myelin sheaths of 
axons are damaged.  This leads to demyelation that causes problems in the 
transmission of signals in nerve cells.  Symptoms include muscle spasticity, 
spasms, ataxia, tremor and lower urinary tract dysfunction.  
Cannabinoid compounds such as )9-THC (26) have shown potential in clinical 
trials as treatments for MS.  In a study carried out in 2003, 630 participants 
were given a cannabinoid extract, 5 mg of )9-THC (26) a day or placebo.73  In 
the group treated with 5 mg/day of )9-THC (26), an analgesic effect was 
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observed and the participants perceived an improvement in spasticity.73 
However there was no improvement when measured on the Ashworth scale.73 
In a smaller study with participants treated with 2.5 mg )9-THC (26) 
combined with 0.9 mg cannabidiol (17), a lower spasm frequency and 
increased mobility was observed in comparison to placebo111. 
Sativex® is a cannabinoid treatment that is used to relieve some of the 
symptoms associated with MS.  It was granted full approval for usage as a 
treatment for MS in the UK in June 2010.112  Sativex® is a Cannabis sativa 
extract containing )9-THC (26) and cannabidiol (17) and has been shown in 
clinical trials to reduce spasticity111.   
1.4.6. CB2 as a therapeutic target 
The therapeutic potential of the CB2 receptor has attracted less attention, as 
most studies have focused on the CB1 receptor.  More recently, interest has 
grown in investigating the ways in which the CB2 receptor can be exploited.  
Various studies have implicated the CB2 receptor in immune modulation and 
inflammation, the treatment of chronic pain and neuroprotection.  
1.4.6.1. Analgesia 
The CB2 receptor, in addition to the CB1 receptor, has the potential to be a 
target in pain relief.  Targeting the CB2 receptor may be advantageous in that 
central nervous system side effects, mediated by the central CB1 receptor, 
could be avoided.  Several studies have shown that acute pain induced by a 
thermal source can be alleviated by some CB2 agonists113.  
AM1241 has displayed an antinociceptive effect and this effect was blocked by 
AM630 (43), a CB2 receptor antagonist.  The CB1 receptor antagonist AM251 
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(44) has no effect on AM1241 antinociception suggesting the involvement of 
the CB2 receptors114.  
CB2 receptor agonists have also been shown to have an analgesic effect in 
models of persistent inflammatory pain.  Inflammation and pain induced by a 
carrageenan injection was blocked by the administration of AM1241.  This 
effect was inhibited by the CB2 receptor antagonist SR144528 (42) but not the 
CB1  receptor antagonist SR141716 (41).114  Antinociception was also 
observed in the capsaicin and the formalin pain models114. 
 
Figure 1-19 Examples of cannabinoids with antinociceptive effects 
 
The CB2 receptor could also be a target in the relief of neuropathic pain.  
Several studies have displayed the pain relieving effects of the CB2 agonists 
AM1241, JWH-133 (32) in behavioural and electrophysiological models114. 
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1.4.6.2. Immune modulation and inflammation   
CB2 receptors are mainly expressed in cells of the immune system, and could 
therefore be a target for immune modulation, and in the treatment of 
inflammatory diseases, such as Crohn’s disease, atherosclerosis and arthritis. 
It has been found that when tissues expressing CB2 receptors are stimulated 
with antigens, CB2 expression either increases or decreases, depending on the 
antigens or bioactive substance applied to the cells74. Treatment of immune 
cells also leads to the production and release of endocannabinoids such as 
anandamide (19) and 2-AG (20), which can induce migration of various cell 
types3.  
Steffens et al.115 found that when mice were treated with a low dose of )9-THC 
(26) (1 mg Kg-1), the progression of atherosclerosis was reduced115. They 
concluded that this reduction was mediated by the CB2 receptor, as it was 
found in atherosclerotic plaques, and that it exerts its effects by suppressing the 
TH1 response and inhibiting the migration of monocytes and macrophages to 
the site of inflammation115. 
1.5. Aims 
The aim of this project was to develop a compound with agonist activity at 
PPARα combined with antagonist activity at the CB1 receptor or agonist 
activity at the CB2 receptor.   
A CB1 antagonist could reduce appetite, whilst at the same time a PPARα 
agonist could decrease plasma triglyceride levels, increase HDL and lower 
LDL.  In addition a CB2 agonist could reduce inflammation.  A dual receptor 
ligand could offer the benefit of treating multiple syptoms of a disease such as 
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obesity without the side effects associated with taking multiple medications.  
To date a high affinity dual PPARα/cannabinoid receptor ligand has not been 
developed. 
1.5.1. Design of fenofibrate analogues 
Recent reports have suggested that some cannabinoids have activity at PPARα 
4, 5
.  Sun et al found that Win55212-2 (38), OEA, anandamide (19), noladin 
ether (21) and virodhamine (22) had micromolar affinity for PPARα with IC50 
values from 10 >M to 40 >M.  They also found that all of these ligands 
increased luciferase expression in a reporter gene assay and both noladin ether 
(21) and virodhamine (22) doubled luciferase transcription at a concentration 
of 10 >M. 
From this evidence it was hypothesised that the converse may be possible; that 
PPAR ligands may have activity at the cannabinoid receptors.  From initial 
screening, by Professor David Kendall, of 13 PPAR ligands, one was found to 
possess activity at both the cannabinoid receptors.  This compound was 
fenofibrate (10a).  It binds to the CB1 receptor with a Ki of 460 nM, and to CB2 
receptor with a Ki of 108 nM.  However, fenofibric acid (10b), the active 
metabolite at PPARα, was inactive at the CB1 and CB2 receptors.  It was 
envisaged that the functionalisation of the cannabinoid-inactive fenofibric acid 
(10b), with another group instead of the isopropyl ester, could result in activity 
at one or both of the cannabinoid receptors, whilst retaining activity at PPARα.  
It was decided to replace the ester with an ethanolamide group.  This group 
was chosen as the addition of an ethanolamide group, to the cannabinoid 
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receptor inactive compound arachidonic acid (4), gives the CB1 receptor 
agonist anandamide (19).  
 
Figure 1-20- Structures of arachidonic acid and anandamide 
 
It was thought that the metabolically more stable amide moiety, would give the 
fenofibric acid (10b) analogue a higher biological stability for interaction at 
both PPARα, and the cannabinoid receptors. 
Herein is described the synthesis of the fenofibrate (10a) derivatives, their 
pharmacology at PPARα and the cannabinoid receptors, and any structure 
activity relationships. 
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2. Amide derivatives of fenofibrate 
This chapter describes the synthesis and pharmacology of the first series of 
fenofibrate analogues.  
2.1. Synthesis  
From the range of PPAR ligands tested, the ability of fenofibrate (10a) to 
activate both cannabinoid receptors resulted in its selection as a lead 
compound.  As fenofibric acid (10b) is inactive at the cannabinoid receptors, 
and esters are rapidly hydrolysed in-vivo, potentially more metabolically stable 
amide derivatives were initially selected for synthesis. 
Compounds 48a to 48e were aminoalcohol or alkyl derivatives of fenofibrate, 
with varying chain lengths, based on the aminoethanol group of anandamide.  
Compounds 48f to 48n were aromatic or heterocyclic amine derivatives.  The 
larger aromatic and heterocyclic groups were selected to investigate whether 
affinity for the receptors could be improved relative to the smaller acyclic 
substituents.  
2.2. Synthetic Route 
Compounds 48a to 48k were synthesised by initial conversion of fenofibric 
acid (10b) to its corresponding N-hydroxysuccinimide (NHS) ester, which then 
underwent aminolysis with the desired amine to afford the required 
carboxamides (48a) to (48n).   
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Scheme 2-1- Synthesis of compounds 48a to 48n  
Reagents and conditions, i) N-hydroxysuccinimide, EDC, DCM, rt, 23hrs, yield 68%  ii) Selected amine, DCM, rt, 5 mins-24hrs, yields 42% - 97%  iii) SOCl2, 60°C 1 h,  iv) 
Selected amine, DCM, Et3N, rt, 2hrs to overnight,  yields 38% -68 % Syntheses of 48a to 48e carried out by Dr Barrie Kellam 
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The activated ester (47) of the commercially available fenofibric acid (10b) 
was synthesised using N-hydroxysuccinimide and 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC) in dichloromethane.  
The advantage of using EDC, rather than other peptide coupling reagents such 
as DCC, is that the resulting urea by-product is water soluble and therefore 
easily removed during aqueous work-up.  The yellow-white solid afforded 
from the reaction was triturated with methanol to afford the activated ester (47) 
with a yield of 68%.  Displacement of N-hydroxysuccinimide from the active 
ester, using a selection of commercially available amines, gave the target 
amides. 
Formation of 48a to 48e, by displacement of N-hydroxysuccinimide from 47, 
proceeded rapidly, with precipitation of the required product within 10 
minutes.  Compounds 48f to 48k were slower to form using the same method 
and required stirring from 1 hour to overnight, possibly due to steric 
hinderance of the amines used.   
 Subsequent compounds (48l to 48n) were prepared by converting fenofibric 
acid (10b) to its corresponding acid chloride with thionyl chloride, which then 
underwent direct aminolysis with the required amines in the presence of 
triethylamine.  This method was employed to overcome either the poor 
nucleophilicity of some of the amines, or possible steric hinderance which 
compromised amide formation using the NHS ester method.   
Structural determination, of the activated ester (47) and all the amides 
prepared, was carried out using NMR, FT-IR and high resolution mass 
spectrometry (HRMS).  With the exception of 48b, 48g, 48h, 48l and 48m, the 
remaining analogues were tested without further purification after work-up.  
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Compounds 48b, 48g, 48h, 48l and 48m were purified by column 
chromatography or preparative layer chromatography using solvent mixtures of 
either ethyl acetate and hexane or dichloromethane and methanol.  
HPLC analysis confirmed the purity of all analogues (98% or above) for 
pharmacological testing.   
2.3. Pharmacology results 
To assess the activity of the analogues synthesised, at PPARα and the 
cannabinoid receptors, several assays were employed.
2.3.1. Activity at the Cannabinoid Receptors 
Both affinity and efficacy at the cannabinoid receptors were determined in 
radioligand binding assays.  Binding affinity at CB1 receptors was measured by 
competitive displacement of 3H-CP55940 from whole rat brain homogenate.  
Meanwhile, binding at CB2 receptors was performed using CHO-K1 (Chinese 
Hamster Ovary) cells stably expressing the human-form of CB2 receptor.  In 
the absence of a cell line stably expressing the human-form of the CB1 
receptor, tissue containing rat CB1 receptors can provide a good approximation 
of activity at human receptors as they have 81% sequence identity61.   
3H-CP55940 has approximately the same affinity for both the cannabinoid
 
receptors (Ki = 0.58 ± 0.07 nM at CB1R and 0.69 ± 0.02 nM).  It is therefore 
important to use tissue or cells containing only the receptor to be investigated 
to avoid competitive binding to more than one target. 
The compounds were initially screened at a concentration of 10 >M and the 
level of binding that a compound displayed is expressed as the percentage of 
specific binding of the compound at the receptor (specific binding is calculated 
42 
by subtracting non-specific binding from total binding).  Ligands that displayed 
a high level of binding were then assayed at six further concentrations, ranging 
from 10 >M to 30 nM or 1 >M to 1 nM, to generate full dose-response curves.  
From these curves, in combination with the Cheng-Prussoff equation (Figure 
2-1), the IC50 and Ki values were calculated.  The IC50 is defined as the 
concentration of a ligand that inhibits the binding of the radioligand by 50 % 
and is experiment specific.  The Ki converts the IC50 into a value by which 
different experiments can be compared as the concentration of radioligand is 
taken into consideration116. 
 
Figure 2-1- Cheng-Prussoff equation 
Where IC50 is the experimentally determined inhibition constant, [L] is the concentration of 
radioligand and Kd is the dissociation constant of the radioligand. 
 
The level of activation of the cannabinoid receptors was measured in a 35S-
GTPγS binding assay58, also using whole rat brain homogenate, or CHO-K1   
cells stably expressing human CB2 receptors.  The assay uses a non-
hydrolysable radiolabelled analogue of GTP (35S-GTPγS) which binds to the 
Gα subunits on receptor activation.  As hydrolysis is prevented, the heterotrimer 
cannot reform, and the Gα subunits accumulate.  This allows the degree of 
activation to be calculated.  As the assay measures directly the level of 
activation at the earliest receptor mediated event, which is not subjected to 
signal amplification, it is a true functional assay and can be used to determine 
the degree of agonism and efficacy.  
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At a single concentration of 10 >M, agonists will increase the nucleotide 
binding above basal levels, and therefore display percentage activation above 
100%.  Inverse agonists will decrease nucleotide binding below basal levels 
and therefore give a percentage below 100%.  Finally, neutral antagonists, that 
do not affect nucleotide binding, display a percentage activation of 100%.  
EC50 values were calculated for compounds which displayed a high affinity 
combined with agonist activity, by measuring the level of receptor activation at 
six serial concentrations from 10 >M to 30 nM.  
As both of the radioligand binding and activation assays are able to generate a 
large amount of data, using small quantities of tissue within a short timeframe, 
they are both suited to high through-put screening. 
The affinity and efficacy at both cannabinoid receptors for the first series of 
analogues is illustrated in Tables 2-1 and 2-2.  
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No. R % Specific binding 
at CB1 (1x10-5M) Ki (nM) 
% Activation at 
CB1  (1x10-5M) 
EC50 
(nM) 
48a 
  
* * 112±7 * 
48b 
 
74±1 * 110±29 * 
48c 
 
72±1 * 125±8 * 
48d 
  
69±2 * 105±19 * 
48e 
  
93±2 * 87±13 * 
48f 
  
94±4 * 113±11 * 
48g 
  
96±4 102±30 137±6 93±2 
48h 
  
92±3 150±67 149±7 225±89 
48i 
  
81±4 * 101±20 * 
48j 
  
 
 
80±9 * 123±15 * 
48k 
  
81±9 * 108±9 * 
48l 
  
 
57±8 * 94±10 * 
48m 
  
67±7 * 101±8 * 
48n 
  
88±3 * 87±8 * 
Table 2-1 Results from binding and functional assays at the CB1 receptor for compounds 48a 
to 48n Binding at the CB1 receptor was calculated by measuring the displacement of 3H-
CP55940 from whole rat brain homogenate.  Ki values were determined from binding IC50 
values, based on the Cheng-Prussoff equation in which the Kd of 3H-CP55940 is 0.5nM and the 
concentration of 3H-CP55940 is 0.25nM.  Efficacy of compounds 48a to n at the CB1 receptor 
was calculated by measuring stimulation of 35S]-GTPγS binding in rat whole brain 
homogenate.* Not assayed.  Results are expressed as the percentage of stimulation of [35S]-
GTPγS binding.  Basal level of activation is 100%.  Data are the mean ± SD mean of three 
experiments performed in triplicate. 
45 
Apart from 48d, 48l, and 48m, the level of binding at the CB1 receptor of the 
remaining compounds was high, with percentage values 72% or above.   
The hexyl (48e), benzyl (48f), piperidinyl (48g) and morpholino (48h) 
derivatives had the highest level of binding at the CB1 receptor, with specific 
binding above 90% at a single concentration of 10 >M, indicating that an alkyl 
chain or large substituent may favour CB1 receptor binding.  The piperidinyl 
(48g) and morpholino (48h) derivatives also had the highest CB1 receptor 
activations of 137 ±6 nM and 149 ± 7 nM respectively.   
Due to time constraints, only compounds with the highest affinities, and 
agonist activity at 10 >M were selected for further pharmacological 
assessment.  As 48g and 48h showed a high affinity and agonist activity, CB1 
binding and affinity were measured at a series of six concentrations to generate 
dose-response curves.  This allowed determination of Ki and EC50 values.  48g 
and 48h had high nanomolar affinity for the CB1 receptor with Ki values of 150 
± 67 nM and 102 ± 30 nM respectively.  The error in the Ki value for 48g is 
quite high as although all the individual Ki values fell within the normal 
distribution one Ki value was higher than the other two.  This compound would 
need to be re-tested to improve the accuracy of the overall Ki value. 
In comparison to fenofibrate (10a) (Ki = 460 nM), 48g and 48h had a lower 
affinity for the CB1 receptor. 
48g (EC50 = 93 ± 2 nM) and 48h (EC50 = 225 ± 89 nM) are both agonists at the 
CB1 receptor and activated it to 37% and 49% above basal levels of activation 
respectively.  In comparison, Fenofibrate acts as a very weak partial agonist 
and is effectively a functional antagonist. 
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There is again a high error in the EC50 value for 48h so this compound would 
need to be retested in the CB1 activation assay to confim the EC50 value.   
Interestingly, when an ethylene linker was introduced between the amide and 
the morpholine moiety, affinity for the CB1 receptor decreased, as did agonist 
activity. 
The remaining analogues tested, that bound to the CB1 receptor, were 
antagonists (retain basal levels of activation), or were partial agonists that did 
not activate the receptor to maximal levels. 
When comparing the 1-hydroxyhexyl and n-hexyl derivatives, it appears that a 
terminal hydroxyl group reduced the level of binding, but resulted in agonist 
activity.  This could indicate that a hydrogen bond acceptor or donor may be 
important for agonist activation of the CB1 receptor.  
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No. R 
% Specific 
binding at CB2R 
(1x10-5M) 
Ki (nM) 
% Activation 
at CB2R 
(1x10-5M) 
EC50 
(M) 
48a 
  
- >10,000 93±9 * 
48b 
 
- 378 144±14 
* 
48c 
 
- 629 113±6 
* 
48d 
  
- 440 121±3 
* 
48e 
  
- 1200 84±2 
* 
48f 
  
99±4 219±10*** 84±23 
* 
48g 
  
98±4*** 15±4 152±10 * 
48h 
  
100±0 16±2 153±2 * 
48i 
  
60±2*** 
* 
89±15 
* 
48j 
  
 
87±7 
* 
87±8 
* 
48k 
  
88±1 
* 
69±10 
* 
48l 
  
 
83±4*** 
* 
78±10 
* 
48m 
  
99±1 
* 
73±7 
* 
48n 
  
100±0 146±64 104±3 
* 
Table 2-2 Results from binding and functional assays at the CB2 receptor for compounds 48a 
to 48n. 
 
Binding at the CB2 receptor was calculated by measuring the displacement of 3H-
CP55940 from CHO-K1 cells expressing hCB2.  Ki values were determined from binding IC50 
values, based on the Cheng-Prussoff equation in which the Kd of 3H-CP55940 is 0.5 and the 
concentration of 3H-CP55940 is 0.25nM.  Efficacy of compounds 48a to n at the CB1 receptor 
was calculated by measuring stimulation of 35S]-GTPγS binding in CHO-K1 cells expressing 
hCB2.  * Not assayed.  Results are expressed as the percentage of stimulation of [35S]-GTPγS 
binding.  Basal level of activation is 100%.  Data are the mean ± SD mean of three 
experiments performed in triplicate.  *** n=2.  Ki values for 48a to 48e were determined by 
Professor David Kendall.
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All of the compounds tested had a high level of binding at the CB2 receptor, at 
10>M, except for 48i and 48c.   
The aminoalkyl and aminoalcohol derivatives had higher Ki values for the CB2 
receptor than fenofibrate (Ki = 108 nM); however, as for the CB1 receptor, 48g 
and 48h both had lower Ki values than fenofibrate at the CB2 receptor.  These 
two compounds also had agonist activity, with activations 52% and 53% above 
basal levels at a single concentration of 10 >M respectively.  Compounds 48k, 
48l, 48m, 48e, 48f and 48j had inverse agonist activity as they had percentage 
activations that are below basal levels of activation. 
As for the CB1 receptor, introduction of an ethyl linker between the amide and 
morpholine resulted in a decrease in affinity and agonist activity. 
2.3.2. Activity of the analogues at PPARα 
After compounds 48a to 48n were assessed for activity at the cannabinoid 
receptors, they were tested in luciferase reporter gene assay and a Time 
Resolved Fluorescence Energy Transfer (TR-FRET) assay.  This was to 
determine whether PPAR α activity had been retained. 
2.3.2.1. PPAR Reporter Gene Assay 
The PPARα reporter gene assay employed in this study measures how a ligand 
affects regulation of the luciferase gene.  Cos-7 cells were transfected with two 
different plasmids, one containing the gene for expression of PPARα, and the 
other containing a reporter gene for the expression of luciferase.The reporter 
gene plasmid contains PPARα binding sites that are linked to a promoter which 
controls luciferase expression. 
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If a ligand activates PPARα then the expression of the luciferase gene will 
increase.  The level of activation can be measured by addition of luciferin to 
the assay.  Any luciferase that has been produced will oxidise the luciferin to 
oxyluciferin, causing measurable light emission. 
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Figure 2-1 Control experiment to establish basal level of luciferase expression and also the 
level of stimulation by a PPARα agonist.  
COS-7 cells were transiently co-transfected with PPARα and PPRE reporter gene plasmids.  
The cells were then exposed to either ligand or no ligand at 10 M overnight and the luciferase 
expression was then measured using luminometry.  Data are means ± SE mean of one 
experiment carried out in triplicate.  WY=WY14643, a PPARα agonist. 
 
A control experiment was carried out to show the basal level of PPARα 
activation, and also to ensure that when PPARα is stimulated with an agonist, 
the activation can be observed above basal levels (Figure 2-1).  The compound 
used to activate PPARα was WY14643 (13), a high affinity selective PPARα 
agonist, which caused a 1.6 fold increase in receptor activation.   
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Figure 2-2 - Effects of selected ligands on PPARα transcriptional activity.  
COS-7 cells were transiently co-transfected with PPARα and PPRE reporter gene plasmids.  
The cells were then exposed to either ligand or no ligand at 10 M overnight and the luciferase 
expression was then measured using luminometry.  Data are means ± SE mean of one 
experiment carried out in quadruplicate. 
 
In addition to WY14643, (13), fenofibric acid (10b) was used as a positive 
control when testing the fenofibrate analogues, and induced a 2 fold increase, 
in receptor activation, over basal levels.  
Compounds 48g, 48h, 48j and 48l had no affect on PPARα activation.  A 
binding assay was conducted to determine whether the lack of activation is due 
to the compounds binding and having no activity or whether they have no 
affinity for PPARα.  48k and 48m and 48f appeared to inhibit luciferase 
expression, however from this assay alone it is not evident whether this occurs 
by PPARα inhibition or not. 
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Figure 2-3 - Effects of selected ligands on PPARα transcriptional activity.  
COS-7 cells were transiently co-transfected with PPARα and PPRE reporter gene plasmids.  
The cells were then exposed to either ligand or no ligand at 10 M overnight and the luciferase 
expression was then measured using luminometry.  Data are means ± SE mean of one 
experiment carried out in triplicate. Data are means ± S E mean of one experiment carried out 
in quadruplicate. 
 
2.3.2.2. TR-FRET Assay 
As the results from the reporter gene assay are downstream of the ligand 
binding event, the experiment did not indicate whether compounds 48a to 48n 
were binding to PPARα or exerting their effect in an alternative way in the 
signalling cascade.  Therefore, whilst the functional assay provided some 
information about our novel compounds, a ligand binding experiment was 
undertaken.   
The assay used was a commercially available competitive binding assay kit 
which uses a human PPARα LBD, tagged with glutathione S-transferase 
(GST), a terbium-labelled anti-GST antibody, and a fluorescent ligand.   
When the fluorescent ligand binds there is energy transfer from the Terbium to 
the ligand and a high FRET ratio is observed.  If the fluorescent ligand is 
displaced by a competing compound then the FRET signal is lost.   
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Figure 2-4 - Schematic of the TR-FRET assay 
Image from Invitrogen LanthaScreen® Terbium Instrument Control Application Note 
 
By plotting the TR-FRET ratio versus a series of test compound 
concentrations, and in conjunction with the Cheng-Prusoff equation, the Ki can 
be calculated.   
GW7647 (15), a PPARα selective agonist, and fenofibric acid (10b) were used 
as positive controls in the assay.  They displayed affinities of 1.67 nM and 1.16 
>M respectively.
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Figure 2-5 - Dose response curves for the positive controls fenofibric acid (10b) and 
GW7647. 
Ki values were determined from binding IC50 values, based on the Cheng-Prussoff equation in 
which the Kd of Fluormone Pan-PPAR Green is 12nM and the concentration of Fluormone 
Pan-PPAR Green is 20nM.  Data are means ± SE mean of one experiment carried out in 
duplicate and were analysed using Graphpad prism 3. 
 
Of the 14 compounds tested (48a to 48n) none displayed any measurable 
affinity for PPARα.  Example graphs are shown below in Figure 2-6.  
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Figure 2-6 - Example dose-response curves from TR-FRET PPARα competitive binding 
assay.  Data are means ± SE mean of one experiment carried out in duplicate and were 
analysed using Graphpad prism 3. 
2.4. Conclusions 
All the compounds described in this chapter have affinity at one or both of the 
cannabinoid receptors.  However, none of these compounds displayed affinity 
for PPARα.  The lack of binding to PPARα for analogues 48a to 48n could be 
due to the loss of the carboxylic head group of fenofibric acid (10b) which is 
known to interact with residues in the ligand binding domain19.  However, this 
functional group is not critical since anandamide ((19), which also contains 
amide functionality) has been shown to possess agonist activity at PPARα.  It 
was therefore disappointing that analogue 48a did not exhibit any activity at 
PPARα.  However, the structural differences between anandamide (19) and 
fenofibric acid (10b) could mean that the two compounds display very 
different binding poses, or even bind at different locations on the receptor.  
Computer modelling, in combination with x-ray crystal structures of 
anandamide (19) and fenofibric acid (10b) in complex with PPARα, could 
provide an insight into how both these ligands bind to and activate PPARα. 
Although the compounds described in this chapter failed to bind to PPARα, 
they do show promise as cannabinoid receptor ligands at both CB1 and CB2. 
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At both of the cannabinoid receptors, the piperidinyl (48g) and morpholino 
(48h) analogues have the highest affinity and agonist activity.  Compounds 48g 
and 48h have micromolar affinity for the CB1 receptor (102 ± 30 nM (48g) and 
150 ± 67 nM (48h)) and and low micromolar EC50 values (0.92 ± 0.02 >M 
(48g) and 2.25 ± 0.88 >M (48h)).  At the CB2 receptor they have nanomolar Ki 
values (15 ± 4 nM (48g) and 16 ± 2 nM (48h)).  Although compounds 48g and 
48h have shown agonist activity at 10 >M, EC50 values for the CB2 receptor 
still remain to be determined.  
Due to the lack of binding of 48a to 48n at PPARα, it was decided to focus on 
improving affinity for the cannabinoid receptors.  The compounds selected for 
development were the benzyl (48f), phenyl (48n), piperidinyl (48g) and 
morpholino (48h) derivatives.  The benzyl (48f) and phenyl (48n) derivatives 
were selected as they bind well to the CB2 receptor, and the benzyl and phenyl 
groups are also easily substituted.  The piperidine (48g) and morpholine (48h) 
derivatives were selected, as they have the highest affinities for both the 
cannabinoid receptors, as well as the highest agonist activities. 
The synthesis and pharmacological activity of derivatives of these four lead 
structures is described in the following two chapters. 
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3. Substituted benzyl and phenyl derivatives  
As described in Chapter 2 benzyl (48f) and phenyl (48n) analogues of 
fenofibric acid (10b) were selected for further development.  The following 
chapter describes the synthesis and pharmacology of these substituted 
compounds.  
 
3.1. Synthesis of derivatives  
Taking 48f and 48n as lead compounds, N-benzyl and N-phenyl analogues 
were synthesised, to investigate steric, positional, and electronic effects of 
substitution.  The analogues comprised of ortho-, meta-, and para- fluoro and 
methyl substituted benzylamines and anilines.  A fluoro substituent was 
selected as it is small, with a similar size to hydrogen, but allows the 
investigation of electronic effects of substitution and also hydrogen bonding as 
it is a hydrogen bond acceptor.  A methyl substituent was also selected to 
investigate how a bulky, electron donating substituent affects cannabinoid 
receptor binding and activation.    
3.1.1. Synthetic route 
The synthetic route employed, required 2-[4-(4’-chlorobenzoyl)-2-methyl 
propanoic acid (fenofibric acid (10b)) (Scheme 1) as a starting material.  This 
was synthesised using a method developed at GlaxoSmithKline by Fitzgerald 
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et al.117, where 4-chloro-4’-hydroxybenzophenone was alkylated with α-
bromoisobutyric acid.  The yield afforded from this reaction was 68% after 
purification.  
The fenofibric acid (10b) was converted to the acid chloride (46) by heating in 
thionyl chloride.  Acid chloride (46) was then condensed with selected 
commercially available amines, in the presence of triethylamine to afford the 
corresponding amides.  The formation of the analogues proceeded with 
reaction times of 1 hour (analogues 51a to 51d) or overnight (analogues 50a to 
50f and 51e) and with yields between 26% and 59%.  All of the analogues were 
purified by preparative layer chromatography (PLC) and characterised using 
NMR, FT-IR and HRMS.  The purity of all analogues was confirmed by HPLC 
at 98% or above. 
 
 
57 
 
Scheme 3-1 - Synthesis of compounds 50a to 51c  
Reagents and conditions: i) α-bromoisobutyric acid, NaOH, butan-2-one, 60°C, 68% ii) Thionyl chloride, 60°C, 1hr. iii) Selected amine, anhydrous 
dichloromethane, 0°C to room temperature, 1 hr or overnight, yields 26% - 59%. 
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3.2. Pharmacology  
3.2.1. Activity at the cannabinoid receptors 
The affinity and efficacy of the analogues at the cannabinoid receptors, was 
assessed using the 3H-CP55940 and 35S-GTPγS radioligand binding assays, 
with whole rat brain homogenate and CHO cells expressing CB2 receptors. 
3.2.1.1. Substituted benzyl derivatives 
 
No R 
% Specific 
binding at CB1 
(1x10-5M) 
% Activation at 
CB1  (1x10-5M) 
48f H 94±4 104±18 
50a o-F 89±10 83±21 
50b m-F 96±5 87±11 
50c p-F 89±7 100±17 
50d o-Me 79±5 61±18 
50e m-Me 55±3 85±14 
50f p-Me 59±12 76±15 
 
Table 3-1 - Affinity and efficacy of the unsubstituted and substituted benzyl analogues at 
CB1R 
Binding and affinity were evaluated using whole rat brain homogenate, and 3H-CP55940 or 
[35S]-GTPγS.  Ki values were determined from binding IC50 values, based on the Cheng-
Prussoff equation in which the Kd of 3H-CP55940 is 0.5nM and the concentration of 3H-
CP55940 is 0.25nM. Results are expressed as the percentage of stimulation of binding.  Basal 
level of activation is 100%.  Data are the mean ± SD mean of three experiments performed in 
triplicate (n=3) and were analysed using Graphpad prism 3. 
 
Compounds 50a to 50c with a fluoro substituent, at either the ortho, meta or 
para position, have a high a level of binding at the CB1 receptor; however 
compounds with a methyl substituent have a lower level of binding.  This could 
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indicate that smaller substituents are preferred for binding, or that electron 
withdrawing substituents are preferred over electron donating substituents.  
More analogues, with various electron donating and withdrawing substituents 
of differing sizes, would need to be synthesised to establish whether the size or 
electronic property of a substituent has the greater effect.    
Between the positions of the substituents there is not a large difference in the 
level of binding at the CB1 receptor, apart from the ortho-methyl analogue, 
which has a higher level of binding than the meta- or para- analogues.   
The unsubstituted and the 4-fluoro substituted analogues are antagonists at 
CB1; whereas the other fluoro and methyl substituted analogues appear to have 
a degree of inverse agonist activity.  The analogues with activations around 
85% could probably be considered as antagonists as the level of activation 
probably returns to basal levels (100%) very quickly as the concentration of 
ligand is decreased. 
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No R 
% Specific 
binding at CB2 
(1x10-5M) 
Ki (nM) % Activation at CB2  (1x10-5M) 
48f H 99±2 2190±1010 84±23 
50a o-F 99±3 583±170 75±6 
50b m-F 94±10 428±89 69±10 
50c p-F 100±0 242±32 80±2 
50d o-Me 99±2 1140±110 68±9 
50e m-Me 90* 2340±689 39±5 
50f p-Me 93±12 1320±482 40±2 
 
Table 3-2 - Affinity and efficacy of the unsubstituted and substituted benzyl analogues at the 
CB2R 
Binding and affinity were evaluated using CHO cells expressing CB2 receptors and 3H-
CP55940 or [35S]-GTPγS Ki values were determined from binding IC50 values, based on the 
Cheng-Prussoff equation in which the Kd of 3H-CP55940 is 0.5nM and the concentration of 
3H-CP55940 is 0.25nM.  * n=1.  Results are expressed as the percentage of stimulation of 
[35S]-GTPγS binding.  Basal level of activation is 100%.  Data are the mean ± SD mean of 
three experiments performed in triplicate (n=3) and were analysed using Graphpad prism 3. 
 
All of the substituted benzylamine analogues have a high level of specific 
binding at the CB2 receptor (90-100%), at 1x10-5 M.  This is in contrast to the 
affinities at the CB1 receptor where the methyl substituted analogues have 
lower affinities than the unsubstituted and fluoro substituted compounds.   
On comparing the Ki values for the benzylamine analogues, there is an increase 
in affinity for the CB2 receptor, when the substituent is fluorine and no 
improvement when the substituent is a methyl group.  Additionally the 
unsubstituted analogue (48f) has a lower affinity for the CB2 receptor than the 
fluorine analogues.  Taking this into account, the electronic properties of the 
substituent may be more important for CB2 receptor affinity than the size of the 
substituent.  The position of the substituent may also influence affinity at the 
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CB2 receptor, as there is a slight increase in affinity in the order para > meta > 
ortho, for the fluorine substituted analogues.  For the methyl substituted 
analogues, there is little difference in the Ki values when the position of the 
methyl group on the ring is changed.  This indicates that the position of the 
substituent probably has little effect.   
In the 35S-GTPγS assay, all the analogues tested displayed inverse agonism.  
The meta- and para- methyl substituents exhibit a high level of binding and 
good inverse agonism, in comparison to the other analogues, which may 
indicate that this area of the compound may be important for CB2 receptor 
activity. 
3.2.1.2. Substituted phenyl compounds 
 
No R 
% Specific 
binding at CB1 
(1x10-5M) 
% Activation 
at CB1     
(1x10-5M) 
48n H 88±3 87±8 
51a o-F 82±1 69±16 
51b m-F 71±8 111±11 
51c p-F 76±19 91±2 
51d o-Me 42±25 100±8 
51e m-Me 59±5 114±8 
 
Table 3-3 Affinity and efficacy of the unsubstituted and substituted phenyl analogues at the 
CB1R 
Binding and affinity were evaluated using whole rat brain homogenate and 3H-CP55940 or 
[35S]-GTPγS Ki values were determined from binding IC50 values, based on the Cheng-Prussoff 
equation in which the Kd of 3H-CP55940 is 0.5nM and the concentration of 3H-CP55940 is 
0.25nM.  Results are expressed as the percentage of stimulation of [35S]-GTPγS binding.  Basal 
level of activation is 100%.  Data are the mean ± SD mean of three experiments performed in 
triplicate (n=3) and were analysed using Graphpad prism 3. 
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All of the substituted phenyl analogues have a high level of specific binding at 
the at CB1 receptor, apart from ortho and meta-methyl substituted compounds.   
They also display antagonist activity, except 51a; which has inverse agonist 
activity and 51d and 51e; which considering their low affinity for the CB1 
receptor, probably have little effect.  Further testing is needed to confirm the 
inverse agonist activity of 51a. 
 
No R 
% Specific 
binding at CB2 
(1x10-5M) 
Ki (nM) 
% Activation 
at CB2     
(1x10-5M) 
48n H 99±2 395±191 86±17 
51a o-F 99±3 1160±566 90±4 
51b m-F 100±0 3340±80 97±10 
51c p-F 96±4 1350±485 89±6 
51d o-Me 95±16 1560±113 89±15 
51e m-Me 97±5 762±294 87±4 
 
Table 3-4 - Affinity and efficacy of the unsubstituted and substituted phenyl analogues at the 
CB2R 
Binding and affinity were evaluated using CHO cells expressing CB2 receptors and 3H-
CP55940 or [35S]-GTPγS Ki values were determined from binding IC50 values, based on the 
Cheng-Prussoff equation in which the Kd of 3H-CP55940 is 0.5nM and the concentration of 
3H-CP55940 is 0.25nM.  Results are expressed as the percentage of stimulation of [35S]-GTPγS 
binding.  Basal level of activation is 100%.  Data are the mean ± SD mean of three 
experiments performed in triplicate (n=3 )and were analysed using Graphpad prism 3. 
 
All of the compounds tested display a high specific binding at the CB2 receptor, 
with binding above 95% for all compounds.  The analogues had Ki values in 
the micromolar range and they all had antagonist activity.  When comparing 
the substituted phenyl compounds with the unsubstituted phenyl analogue there 
is an obvious reduction in affinity at the CB2 receptor. 
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3.2.2. Activity at PPARα 
The compounds were screened for activity at PPARα using the TR-FRET assay 
previously described in Chapter 2. 
As for the compounds described in Chapter 2, the substituted benzylamine 
analogues had no activity at PPARα.  The substituted phenyl analogues also do 
not display activity at PPARα. 
3.3. Conclusions 
Early exploration, of the effects of substitution at the phenyl and benzylamine 
moieties, has been described in this chapter.  The analogues were assessed in 
three different assays to determine their affinity for PPARα and both their 
affinity and efficacy at the cannabinoid receptors.  
The phenyl analogues (51a to 51e) were found to be antagonists, or inverse 
agonists, at the CB1 receptor, and antagonists at the CB2 receptor.  Meanwhile, 
the benzylamine (50a to 50f) analogues displayed antagonist or inverse agonist 
activity at CB1, and inverse agonist activity at CB2.  Again, both phenyl and 
benzyl analogues display no activity at PPARα.  
At the CB1 receptor, when comparing corresponding benzyl and phenyl 
analogues, the methyl substituted phenyl (50a to 50c) and benzyl analogues 
(51d and 51e) all have a low level of specific binding at the CB1 receptor, 
indicating that the benzylic CH2 has little effect on binding of these analogues 
at 10 >M.  However for the unsubstituted (48f and 48n) and fluoro–substituted 
(50a to 50c and 51a to 51c) analogues, the benzyl derivatives appear to have a 
slightly higher level of binding.  When compared directly to their 
corresponding phenyl derivatives, the benzylic methylene was shown to have a 
positive influence on the affinity of fluoro substituted benzyl analogues at the 
64 
CB2 receptor.  Conversely it has a negative effect on the unsubstituted benzyl 
derivative (48f).  When comparing the effect of the benzylic methylene on CB2 
receptor activation, it was observed that the benzyl (51a to 51e) analogues are 
inverse agonists whereas the phenyl (50a to 50f) derivatives are antagonists.  
This effect on activation of the receptor could be due to the shift in position of 
the substituent in the receptor binding site, or perhaps the ability of the benzyl 
derivatives to form a greater number of conformers, due to the extra rotatable 
bond. 
Although there was little or no improvement in affinity or efficacy at the 
cannabinoid receptors, with the range of substituted N-phenyl or N-benzyl 
compounds synthesised so far, some structure activity relationships have been 
explored.  These relationships indicate that the synthesis of a wider range of 
substituted benzyl or phenyl analogues may offer the opportunity to tune 
activity at the cannabinoid receptors.  
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4.  N-Morpholino-2-(4-(4-chlorobenzoyl)-phenoxy)-2-
methylpropanamide (48h) and N-piperidinyl-2-(4-(4-
chlorobenzoyl)-phenoxy)-2-methylpropanamide (48g) 
derivatives 
 
The morpholino (48h) and piperidinyl (48g) derivatives described in Chapter 
2 displayed a high affinity, in comparison to fenofibrate and analogues 
displayed in Table 2-1 and Table 2-2, at both cannabinoid receptors.  They 
also display a high level of CB1 and CB2 receptor activation indicating that 
both 48g and 48h are agonists at both receptors.  They were therefore selected 
as lead compounds and a library of derivatives were synthesised.   
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4.1. Synthesis of derivatives  
In an attempt to explore the steric, electronic and positional effects of 
substituents on the lead molecules (48g and 48h), a library comprising of 
derivatives bearing various electron donating and withdrawing groups in the 
ortho-, meta-, or para positions on the left hand side of the pharmacophore 
were synthesised. 
 
 
Figure 4-1- Basic benzophenone pharmacophore  
(R = o-, m- or p CH3, CN, NO2, F or Cl, R1= 1-aminopiperidine or 4-aminomorpholine)  
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4.1.1. Synthetic route 
Since the majority of the substituted 4-hydroxybenzophenones were not 
commercially available, they required synthesis.  The first step of the synthesis 
involved conversion of the substituted benzoic acids (52a to 52i) to their 
corresponding acid chlorides (53a to 53i).  The acid chlorides (53a to 53i) were 
then condensed with anisole, under Friedel-crafts conditions, in the presence of 
AlCl3, affording substituted 4-methoxybenzophenones (54a to 54i), (Scheme 
1).  As the methoxy group of anisole is ortho/para directing, a mixture of 2-
methoxy and 4-methoxy isomers were obtained.  Separation of these two 
products was achieved by column chromatography using a mixture of either 
TBME and PE 40-60 or EtOAc and PE 40-60, with yields ranging from 15% to 
71% of the desired isomer.   
The next step of the synthesis required O-demethylation of the aromatic methyl 
ether to relinquish the free phenol for subsequent alkylation.  Established 
conditions (BBr3 in DCM) proved unsuccessful, so a method developed by 
Kulkarni et al118 using pyridine hydrochloride with microwave heating, was 
attempted. This proved successful as the substituted 4-hydroxybenzophenones 
(55a to 55l) were prepared in yields between 8 and 99%.  
For compound 55a where R is an ortho-methyl group the O-demethylation 
occurred simultaneously during the Friedel crafts acylation with anisole.  This 
may be due to the ability of aluminium chloride to coordinate to the methoxy 
group, which then allows removal of the O-methyl group by a chloride ion 
from the aluminium chloride.  The aluminate ester formed is then broken down 
on aqueous work up.   
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Alkylation of these phenols was possible via either Williamson ether synthesis 
or Mitsunobu chemistry.  The Williamson ether synthesis, described previously 
in Chapter 3, utilised butan-2-one as the solvent.  The reaction mixture 
became difficult to stir when butan-2-one was used, in the synthesis of 
fenofibric acid (10b), so the solvent was changed to acetonitrile for the 
syntheses described in this chapter. 
In situations where the Williamson ether synthesis proved unsuccessful I 
reverted to standard Mitsunobu chemistry (DIAD and triphenyl phosphine) to 
effect the required phenolic alkylation.  Compounds synthesised in this manner 
were 56b, 56d and 56e in yields of 51%, 42% and 64% respectively after 
purification by column chromatography.  It could be argued that in the case of 
the compounds that failed to react under Williamson ether conditions, the 
electron withdrawing groups present within the molecules may have reduced 
the nucleophilicity of the respective phenolate anions.  In the cases where 
alkylations were carried out with methyl-2-bromo-2-methylpropanoate (56a, 
56c and 56f), the methyl esters obtained were subsequently saponified to their 
corresponding carboxylic acids, using lithium hydroxide in a mixture of THF 
and water in yields from 50% to 92% They were deemed to be pure enough, by 
1H and 13C NMR, to be used used directly in the next step after work-up, and 
were therefore coupled to 1-aminopiperidine or 4-aminomorpholine using 
HBTU in the presence of triethylamine. This afforded the desired amides (58a 
to 58l and 59a to 59h), which were purified by preparative layer 
chromatography (PLC) or column chromatography, in yields from 8% to 89%.  
The analogues were characterised using NMR, FT-IR and HRMS, and purity 
was confirmed by HPLC at 98% or above. 
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Scheme 4-1- Synthesis of analogues 58a to 58l and 59a to 59j  
 Reagents and conditions: a) SOCl2, 60°C, N2 1 h, b) Anisole, DCM, AlCl3, N2, overnight, 15-71% c) Py.HCl, microwave irradiation, 215W, 2-20 mins, 8%-
99% d) methyl-2-hydroxyisobutyrate, DIAD, triphenylphosphine, toluene, 80°C, 2 h, 42% -62% e) ethyl-2-bromo-2-methylpropanoate,  K2CO3, MeCN, 
reflux, 43%-84%  f) α-bromoisobutyric acid, MeCN, NaOH, 2.5 h, 11%-76% g) LiOH.H2O, THF/water (1:1), N2, 2 h, 50%-92%  h) 4-aminomorpholine or 
1-aminopiperidine, HBTU, dichloromethane, Et3N,  2-18 h, 8%-89%.  
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4.1.2. Pharmacology 
 
The affinity of compounds at the cannabinoid receptors was assessed by 
competitive displacement of 3H-CP55940, from CHO cells expressing hCB2 
receptors, and whole rat brain homogenate.  The efficacies of the analogues at 
both receptors were examined in the 35S-GTPγS radioligand binding assays, 
again utilising CHO cells expressing hCB2 receptors, and whole rat brain 
homogenate.  EC50 values at the CB2 receptor were not obtained as when a test 
assay was carried out there was no displacement of radioligand.  When the 
problem was investigated further by PCR, no CB2 receptor transcript was 
found.  This indicated that the batch of cells had failed to express the CB2 
receptors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
70 
4.1.2.1. N-Morpholino-2-(4-(4-chlorobenzoyl)phenoxy)-2-
methylpropanamide (48h) derivatives  
4.1.2.1.1. Affinity and efficacy at the CB1 receptor 
 
 
No. R 
% Specific 
binding at CB1 
(1x10-5M) 
Ki (nM) % Activation at CB1  (1x10-5M) ** 
 
EC50 
(M) 
58a o-CH3 95±4 * 99±10 * 
58b m-CH3 94±2 * 99±7 * 
58c p-CH3 93±3 * 103±18 * 
58d m-CN 39±1 * 107±11 * 
58e p-CN * * * * 
58f m-Cl 94±1 * 101±6 * 
48h p-Cl 92±3 150±67 149±7 2.25±0.89 
58g o-F 92±4 92±14 130±19 1.24±0.97 
58h m-F 89±7 * 89±9 * 
58i p-F 89±12 * 89±7 * 
58j m-NO2 79±6 * 92±14 * 
58k p-NO2 * * * * 
58l H 93±4 * 97±18 * 
 
Table 4-1- Binding and efficacy of 58a to 58l at the CB1 receptor 
Binding and affinity were evaluated using whole rat brain homogenate, and 3H-CP55940 or 
[35S]-GTPγS Ki values were determined from binding IC50 values, based on the Cheng-Prussoff 
equation in which the Kd of 3H-CP55940 is 0.5 nM and the concentration of 3H-CP55940 is 
0.25 nM.  * Not assayed **Results are expressed as the percentage of stimulation of [35S]-
GTPγS binding.  Basal level of activation is 100%.  Data are the mean ± SD mean of three 
experiments performed in triplicate.  
 
All of the analogues assayed displayed good levels of specific binding at the 
CB1 receptor at a 10 >M concentration apart from the meta-cyano 58d and 
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meta-nitro 58j substituted analogues.  This could indicate that electron 
withdrawing groups are unfavourable for CB1 binding; however the ortho- and 
para- nitro and cyano derivatives would need to be assayed to confirm that it is 
an electronic rather than a positional effect. 
The results from the 35S-GTPγS binding assay demonstrated that two of the 
analogues (48h and 58g) are agonists at the CB1 receptor, with activations of 
49 ± 7% and 30 ± 19% above basal levels.  The rest of the analogues were 
neutral antagonists or displayed slight inverse agonist activity, as they showed 
high level of binding at the CB1 receptor, but the level of receptor activation 
remains at basal levels (approximately 100%) or just below.   
Since compounds 58g and 48h had a high affinity and a good efficacy, they 
were further tested at six serial concentrations, in both the binding and 
activation assays, to give full dose-response curves.  This allowed the 
determination of Ki and EC50 values.  The Ki values were in the nanomolar 
range at 150 ± 67 nM and 92 ± 14 nM respectively, and the EC50 values for 
both compounds were in the micromolar range at 2.25 ± 0.89 >M and 1.24 ± 
0.97 >M respectively. 
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Figure 4-1 – Percentage activation of the CB1 receptor by compounds 58a to 58l.   
Results are expressed as the percentages of stimulation of [35S]-GTPγS binding.  Data are the 
mean ± SD mean of three experiments performed in triplicate   Dotted line indicates basal level 
of receptor activation  
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4.1.2.1.2. Affinity and efficacy at the CB2 receptor 
 
No. R 
% Specific 
binding at CB2 
(1x10-5M) 
Ki (nM) 
% Activation 
at CB2  (1x10-
5M) 
58a o-CH3 92±3 56.8±16.8  148±24 
58b m-CH3 90±5 * 104±5 
58c p-CH3 96±6 310±16.5 160±9 
58d m-CN 42±10 * 98±1 
58e p-CN * * * 
58f m-Cl 94±5 * 82±4 
48h p-Cl 100±0 12.8±3.5 153±2 
58g o-F 100±0 146±25.2 119±19 
58h m-F 89±6 * 116±5 
58i p-F 99±3 231±90.2 135±7 
58j m-NO2 80±5 * 106±14 
58k p-NO2 * * * 
58l H 96±9 299±3.5 137±8 
 
Table 4-2 - Binding and efficacy of 58a to 58l at the CB2 receptor 
Binding and affinity were evaluated using CHO-K1 cells expressing hCB2, and 3H-CP55940 or 
[35S]-GTPγS.  Ki values were determined from binding IC50 values, based on the Cheng-
Prussoff equation in which the Kd of 3H-CP55940 is 0.5 nM and the concentration of 3H-
CP55940 is 0.25nM.  * Not assayed **Results are expressed as the percentage of stimulation 
of [35S]-GTPγS binding.  Basal level of activation is 100%.  Data are the mean ± SD mean of 
three experiments performed in triplicate.  
 
 
Analogous with the results at the CB1 receptor, compounds 58l to 58k 
displayed a high level of specific binding at the CB2 receptor at a 10 >M 
concentration, with the exception of the meta-nitro (58j) and meta-cyano (58d) 
substituted analogues, which display less than maximal binding at this 
concentration (42 ± 10% and 80 ± 5% respectively).  
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The meta- substituted analogues mostly demonstrated antagonist or slight 
inverse agonist activity at the CB2 receptor.  The exception was the ortho-
fluoro-substituted analogue (58g), which possibly displayed partial agonist 
activity.  Compound 58f, which displayed inverse agonist activity at 10 >M, 
can possibly be considered as an antagonist, but further testing is needed to 
confirm this. 
These results could indicate that steric, rather than electronic, factors play a 
role in activation of the CB2 receptor, as the fluorine substituent is only slightly 
larger than hydrogen whereas the other substituents are considerably larger.  
The para- substituted analogues all display agonist activity, with percentage 
activations between 35 ± 7% and 60 ± 9% above basal levels of receptor 
activation. 
Compounds 58g and 58a with ortho substituents are possibly partial agonists, 
although they have large standard deviations, so further testing needs to be 
carried out to determine whether this is actually the case.   
Ki values were determined only for compounds that have a high level of 
binding, combined with a good efficacy at the CB2 receptor.  All the analogues 
tested have a range of nanomolar Ki values.  The para-chloro analogue has the 
highest affinity at 12.8 nM.  The apparent agonist activity imparted by para-
substituents and the deleterious effect of meta substitution may indicate that 
substituents in the meta position may interact unfavourably with residues in the 
binding pocket.  As the results for the ortho substituted compounds are mixed, 
a larger range of ortho substituted compounds needs to be synthesised.  
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Figure 4-2 - Percentage activation of the CB1 receptor by compounds 58a to 58l.   
Results are expressed as the percentages of stimulation of [35S]-GTPγS binding.  Data are the 
mean ± SD mean of three experiments performed in triplicate   Dotted line indicates basal level 
of receptor activation 
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4.1.2.2. 1-Piperidinyl-2-(4-(4-chlorobenzoyl)phenoxy)-2-
methylpropanamide (48g) derivatives 
4.1.2.2.1. Affinity and efficacy at the CB1 receptor 
 
No. R 
% Specific 
binding at 
CB1 (1x10-5M) 
Ki (nM) % Activation at CB1  (1x10-5M) 
EC50 
(nM) 
59a o-CH3 92±1 * 105±9 * 
59b m-CH3 96±0 * 102±14 * 
59c p-CH3 94±3 26±10 174±20 367±193 
59d m-CN 71±3 * 112±12 * 
59e p-CN 94±3 * 104±4 * 
59f m-Cl 94±2 * 97±8 * 
48g p-Cl 96±4 102±30 137±6 92.6±2 
59g o-F 94±4 * 119±13 * 
59h m-F 93±3 * 87±15 * 
59i p-F 82±11 46±19 140±22 362±32 
59j H 96±2 * 127±6 * 
 
Table 4-3 - Binding and efficacy of 59a to 59j at the CB1 receptor  
Ki values were determined from binding IC50 values, based on the Cheng-Prussoff equation in 
which the Kd of 3H-CP55940 is 0.5 nM and the concentration of 3H-CP55940 is 0.25nM.  * Not 
assayed **Results are expressed as the percentage of stimulation of [35S]-GTPγS binding.  
Basal level of activation is 100%.  Data are the mean ± SD mean of three experiments 
performed in triplicate.  
 
All of the compounds display a high level of specific binding at the CB1 
receptor at the tested concentration of 10 >M, except the meta-cyano derivative 
(59d) (Table 4-3).  The cyano group is polar, and linear in shape, which may 
cause unfavourable interactions with the receptor and reduce affinity, or the 
observed pharmacology could be due to the electron withdrawing nature of the 
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group.  The comparison of the meta-methyl (59b) with the corresponding meta-
trifluoromethyl analogue could reveal whether it is a steric or electronic effect 
which reduces affinity. 
Table 4-3 and figure 4-3 show that para substituted compounds are once again 
agonists at the CB1 receptor, except the cyano derivative which displays 
antagonist activity.  The remaining meta and ortho substituted derivatives are 
antagonists with activations between 97 ± 8% and 112 ± 12%.  The only 
exception is the ortho-fluoro (59g) analogue which has agonist activity.  
Compounds 59i, 59c and 48g displayed the highest affinities at the CB1 
receptor as well as corresponding high activations, so Ki and EC50 values were 
calculated.  All three of these compounds have nanomolar affinities and good 
efficacies with Ki values at 102 ± 30 nM, 26 ± 10 nM, 46 ± 19 nM and EC50 
values at 92.6 ± 1.6 nM and 369 ± 42.4 nM respectively.  These results may 
indicate the importance of both positional and electronic effects in agonist 
activation of the CB1 receptor, with para electron donating substituents 
favoured.
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Figure 4-3 - Percentage activation of the CB1 receptor by compounds 59a to 59j.    
Results are expressed as the percentages of stimulation of [35S]-GTPγS binding.  Data are the 
mean ± SD mean of three experiments performed in triplicate.  Dotted line indicates basal level 
of receptor activation  
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4.1.2.2.2. Affinity and Efficacy at the CB2 Receptor 
 
 
No. R 
% Specific 
binding at CB2 
(1x10-5M) 
Ki (nM) % Activation at CB2 (1x10-5M) 
59a o-CH3 91±1 * 102±23 
59b m-CH3 90±4 * 77±14 
59c p-CH3 93±2 29±11 155±4 
59d m-CN 71±6 * 108±1 
59e p-CN 90±4 * 114±19 
59f m-Cl 91±3 * 82±18 
48g p-Cl 100 15±4 152±10 
59g o-F 91±6 * 134±4 
59h m-F 89±4 * 110±9 
59i p-F 100±0 14±3 129±9 
59j H 94±6 * 124±3 
 
Table 4-4 - Binding and efficacy of 59a to 59j at the CB2 receptor  
Ki values were determined from binding IC50 values, based on the Cheng-Prussoff equation in 
which the Kd of 3H-CP55940 is 0.5 nM and the concentration of 3H-CP55940 is 0.25nM.* Not 
assayed **Results are expressed as the percentage of stimulation of [35S]-GTPγS binding.  
Basal level of activation is 100%.  Data are the mean ± SD mean of three experiments 
performed in triplicate.  
 
All of the analogues displayed a high level of specific binding at the CB2 
receptor, at the single concentration of 10 >M tested, apart from the meta-
cyano substituted compound (59d) (Table 4-4).  The lower level of binding of 
the meta-cyano analogue (59d) could be again due to the linearity of the nitrile, 
or its electron withdrawing properties.  Other analogues with electron 
withdrawing substituents, such as a trifluoromethyl group, would need to be 
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assayed so that a direct comparison, of the effect of electron withdrawing and 
electron donating substituents, could be made.  The para- substituted analogues 
displayed agonist activity at 10 >M; however the cyano derivative (59e) has a 
large standard deviation value, so further testing needs to be carried out to 
determine its efficacy at the receptor.  The meta-substituted derivatives were 
antagonists or inverse agonists at the CB2 receptor, although the meta-chloro 
(59f) and methyl (59b) analogues could be antagonists as the standard 
deviations are quite large.  Of the two ortho substituted analogues tested, the 
fluoro (59g) substituted is an agonist and the methyl (59a) substituted is an 
antagonist, which could indicate that sterics play an important role in activation 
of the receptor, as the methyl group is larger than the fluoro group.  Other 
possibilities are that it is an electronic effect or that the fluoro substituent is 
acting as a hydrogen bond acceptor for a residue in the binding pocket.  
As compounds 48g, 59c, 59i have a high level of binding and agonist activity, 
their Ki values were calculated.  All of the Ki values are in the nanomolar range 
indicating high affinity at low concentrations; however (59c) has a high 
standard deviation so further testing is required to confirm this observation.  
These results indicate that, for the substituted analogues, substituent position 
appears to be important for agonist activity at the CB2 receptor, with para 
substituents favoured.  The ortho fluoro analogue may also be an agonist due to 
the fluorine being a similar size to hydrogen, and therefore having less steric 
bulk which avoids clashes with residues in the binding pocket of the receptor.  
Conversely an electronic or hydrogen bonding interaction may be occurring.  
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Figure 4-4 - Percentage activation of the CB2 receptor by compounds 59a to 59j.   
Results are expressed as the percentages of stimulation of [35S]-GTPγS binding.  Data are the 
mean ± SD mean of three experiments performed in triplicate.  Dotted line indicates basal level 
of receptor activation. 
 
4.2. Unbranched and Tertiary Amide Derivatives  
As several of the piperidinyl and morpholino analogues displayed a high 
affinity at both of the cannabinoid receptors, other alterations were made to the 
structures of 48g and 48h to investigate any further structure activity 
relationships.  Analogues were synthesised omitting the gem-dimethyl groups 
to investigate their importance.  Also, morpholine and piperidine were coupled 
directly to fenofibric acid (10b), affording tertiary amide products, to 
investigate the relevance of the NH of 48g and 48h on receptor binding. 
4.2.1. Synthetic routes 
The synthesis of compounds 62a and 62b started with alkylation of 4-chloro-
(4’-hydroxy)-benzophenone, via a Williamson ether synthesis, as described in 
Chapter 3.  However ethyl-2-bromoacetate was used instead of α-
bromoisobutyric acid.  The ethyl ester was saponified using lithium hydroxide 
in a mixture of THF and water, which afforded the corresponding carboxylic 
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acid in a yield of 87%.  It was deemed pure by 1H and 13C NMR and mass 
spectrometry after work-up, and was used without further purification in the 
coupling to 4-amino morpholine and 1-amino piperidine, using HBTU in the 
presence of triethylamine.  This afforded 62a and 62b in crude yields of 25% 
and 23% respectively.  62a and 62b were determined to be a mixture of 
compounds by NMR, and due to time constraints they were not purified or 
tested.    
Compounds 63a and 63b were synthesised by coupling fenofibric acid (10b) to 
piperidine and morpholine using HBTU, in the presence of triethylamine, in 
yields of 50% and 62% respectively.  The analogues were characterised using 
NMR, FT-IR and HRMS, and purity was confirmed by HPLC at 98% or above. 
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Scheme 4-2 Reagents and conditions: a) Ethyl bromoacetate, MeCN, NaOH, 3hrs, b) LiOH.H2O, THF/water (1:1), N2, 3.75 hrs, 87 %  c) 4-
aminomorpholine or 1-aminopiperidine, HBTU, dichloromethane, Et3N, overnight, 23% and 25% crude 
 
 
 
 
Scheme 4-3 Reagents and conditions: a) 4-aminomorpholine or 1-aminopiperidine, HBTU, dichloromethane, Et3N, 3hrs, 50% and 62% 
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4.2.2. Pharmacology 
 
The affinities, and efficacies of 63a and 63b, at the cannabinoid receptors, 
were assessed using the 3H-CP55940 and 35S-GTPγS radioligand binding 
assays.  The effect of 62a and 62b on cannabinoid receptor binding and 
activation still remains to be carried out as they were below the necessary 
purity (approximately 50%) to allow testing.  
4.2.2.1. Activity at the cannabinoid receptors 
 
 
No R 
% Specific 
binding at 
CB1 (1x10-5M) 
Ki (nM) % Activation at CB1 (1x10-5M) 
EC50 
(M) 
48g 1-aminopiperidine 96±4 102±30 137±6 92.6±1.6 
48h 4-aminomorpholine 92±3 150±67 149±7 2.25±0.89 
63a morpholine 65±5 * 94±11 * 
63b piperidine 94±2 * 72±6 * 
 
Table 4-5 - Binding and efficacy of compounds 48g to 63b at the CB1 receptor 
Ki values were determined from binding IC50 values, based on the Cheng-Prussoff equation in 
which the Kd of 3H-CP55940 is 0.5 nM and the concentration of 3H-CP55940 is 0.25nM.  * Not 
assayed **Results are expressed as the percentage of stimulation of [35S]-GTPγS binding.  
Basal level of activation is 100%.  Data are the mean ± SD mean of three experiments 
performed in triplicate.  
 
 
On comparing the analogues in Table 4-5, 63a had a lower level of binding at 
the CB1 receptor than the other compounds.  In contrast to 48g and 48h, the 
piperidine and morpholine analogues had no agonist activity; 63b had inverse 
agonist activity and 63a was an antagonist.  This indicates that the NH of the 
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amide, in 48h and 48g, is probably important for binding to the CB1 receptor, 
and it appears to be necessary for agonist activity.  
 
 
 
No R 
% Specific 
binding at CB2 
(1x10-5M) 
Ki (nM) % Activation at CB2  (1x10-5M) 
48g 1-aminopiperidine  100 ± 0 14.8 ± 4.3 152 ± 10 
48h 4-aminomorpholine  100 ± 0 12.8 ± 3.5 153 ± 2 
63a morpholine  73 ± 2 * 72 ± 2 
63b piperidine  81 ± 2 * 57 ± 13 
 
Table 4-6 - Binding and efficacy of 48g to 63b at the CB2 receptor 
Ki values were determined from binding IC50 values, based on the Cheng-Prussoff equation in 
which the Kd of 3H-CP55940 is 0.5 nM and the concentration of 3H-CP55940 is 0.25nM.* Not 
assayed **Results are expressed as the percentage of stimulation of [35S]-GTPγS binding.  
Basal level of activation is 100%.  Data are the mean ± SD mean of three experiments 
performed in triplicate.  
 
 
Compounds 63a and 63b also displayed a lower level of affinity at the CB2 
receptor than 48g and 48h.  The morpholine and piperidine derivatives also 
possessed inverse agonist activity.  These results indicated that the NH of the 
amide in both 48g and 48h is important for both binding and agonist activation 
of the CB2 receptor. 
4.3. Conclusions 
A series of 24 analogues derived from 48g and 48h have been synthesised and 
their pharmacological activity has been assessed.  Several compounds have 
been identified as having a high affinity and efficacy at the cannabinoid 
receptors.  
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Of the 48h derivatives, 58g has micromolar agonist activity combined with 
nanomolar affinity at the CB1 receptor.  The remaining analogues, excluding 
the meta-cyano (58d) and meta-nitro (58j) analogues show a high level of 
binding and antagonist activity at 10>M.  The Ki values of these antagonists 
still remain to be determined.  At the CB2 receptor the 48h derivatives have a 
high level of binding apart from the meta-cyano (58d) and meta-nitro (58j) 
analogues.  All of the analogues displayed agonist activity apart from the meta-
cyano (59d), methyl (59b) and chloro (59f) substituted analogues.  The para 
substituted analogues possessed nanomolar affinity combined with nanomolar 
agonist activity.   
The 48g derived analogues have a high level of binding at the CB1 receptor 
except the meta-cyano (59d) analogue.  The unsubstituted (59j), para-
substituted and ortho-fluoro (59g) analogues displayed agonist profiles 
whereas the rest of the analogues were antagonists at 10 >M.  Compounds 59i, 
59c and 48g had both nanomolar agonist activity and affinity.  At the CB2 
receptor all of the 48g derived analogues have a high affinity except the meta-
cyano analogue.  The unsubstituted, para-substituted and ortho-fluoro 
analogues had nanomolar agonist activity whereas the rest of the analogues 
displayed antagonist activity.  
The importance of the amide NH on affinity and efficacy at the cannabinoid 
receptors was investigated by the synthesis and testing of 63a and 63b (tertiary 
amide analogues).  These two analogues show that the NH of the amide is 
important for agonist activity at the CB1 receptor as 63a and 63b have inverse 
agonist and antagonist activity respectively.  
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The amide NH is also important for affinity and agonist activity at the CB2 
receptor as both 63a and 63b have reduced affinity and inverse agonist activity. 
In general, all the analogues have a high level of binding at the CB1 and CB2 
receptors apart from meta-substituted analogues with electron withdrawing 
substituents.  Additionally, the stark difference, in both the level of binding and 
activation, between compounds with and without the amide NH, underline the 
importance of the NH bond in both receptor binding and activation.  N-
methylated derivatives of 48g and 48h could be used to further probe this 
apparent structure activity relationship. 
Ideas for the further development of this novel class of cannabinoid receptor 
ligands are discussed in Chapter 5.   
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5. Conclusions and future work 
5.1. Conclusions  
An initial screen, of a library of PPARα ligands, revealed that one compound 
(fenofibrate (10a)), displayed activity at the cannabinoid receptors.   
Considering this, a series of amide derivatives of fenofibrate have been 
designed, synthesised and evaluated for their activity at PPARα and both 
cannabinoid receptors. 
5.1.1. Amide derivatives of fenofibrate  
The first library of ligands synthesised, was a broad structural exploration into 
the type of compound which may confer PPARα and cannabinoid receptor 
activity.  A range of alkyl, alcohol, aromatic, and heterocyclic amide 
derivatives were synthesised (Table 5-1), and two of the heterocyclic 
analogues (48g and 48h) possessed the highest affinity for the two cannabinoid 
receptors combined with agonist activity.  Unfortunately none of the analogues 
assayed in the first series had affinity for PPARα. 
The piperidinyl (48g) and morpholino (48h) derived analogues have 
micromolar affinity for the CB1 receptor (150 ± 67 nM (48h) and 102 ± 30 nM 
(48g), and low micromolar EC50 values (0.92 ± 0.02 >M (48g) and 2.25 ± 0.88 
>M (48h)).  At the CB2 receptor they have nanomolar Ki values (15 ± 4 nM 
(48g) and 16 ± 2 nM (48h).  These two derivatives, together with 48f and 48n, 
showed promise as cannabinoid receptor ligands, and therefore were selected 
for further development, to investigate whether affinity and efficacy at the 
cannabinoid receptors could be augmented. 
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No. R % Specific Binding at 
CB1 (1x10-5 M) 
Ki (nM) 
at CB1 
% Activation at CB1 
(1x10-5 M) 
EC50 
at
 
CB1 
% Specific Binding at 
CB2 (1x10-5 M) 
Ki(nM) 
at CB2 
% Activation at 
CB2 (1x10-5 M) 
 
 
48a 
 
* * 112±7 * * >10,000 93±9 
48b 
 
74±1 * 110±29 * * 378 144±14 
48c 
 
72±1 * 125±8 * * 629 113±6 
48d 
 
69±2 * 105±19 * * 440 121±3 
48e 
 
93±2 * 87±13 * * 1200 84±2 
48f 
 
94±4 * 113±11 * 99±4 219±10*** 84±23 
48g 
 
96±4 102±30 137±6 93±2 98±4*** 15±4 152±10 
48h 
 
92±3 150±67 149±7 225±89 100±0 16±2 153±2 
48i 
 
81±4 * 101±20 * 60±2*** * 89±15 
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No. R % Specific Binding at 
CB1 (1x10-5 M) 
Ki (nM) 
at CB1 
% Activation at CB1 
(1x10-5 M) 
EC50 
at
 
CB1 
% Specific Binding at 
CB2 (1x10-5 M) 
Ki(nM) 
at CB2 
% Activation at 
CB2 (1x10-5 M) 
 
48j 
 
 
80±9 * 123±15 * 87±7 * 87±8 
48k 
 
81±9 * 108±9 * 88±1 * 69±10 
48l 
 
 
57±8 * 94±10 * 83±4*** * 78±10 
48m 
 
67±7 * 101±8 * 99±1 * 73±7 
48n 
 
88±3 * 87±8 * 100±0 146±64 104±3 
 
Table 5-1 –Results of all binding and functional assays at CB1 and CB2 receptors for compounds 48a to 48n  
Binding at the CB1 and CB2 receptors was calculated by measuring the displacement of 3H-CP55940 from CHO-K1 cells expressing hCB2 or whole rat brain homogenate .  Ki 
values were determined from binding IC50 values, based on the Cheng-Prussoff equation in which the Kd of 3H-CP55940 is 0.5 and the concentration of 3H-CP55940 is 
0.25nM.  Efficacy of compounds 48a to n at the CB1 and CB2 receptors was calculated by measuring stimulation of 35S]-GTPγS binding in CHO-K1 cells expressing hCB2 or 
whole rat brain homogenate.  * Not assayed.  Results are expressed as the percentage of stimulation of [35S]-GTPγS binding.  Basal level of activation is 100%.  Data are the 
mean ± SD mean of three experiments performed in triplicate.  *** n=2.  Ki values for 48a to 48e were determined by Professor David Kendall. 
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5.1.2. Substituted N-benzyl and N-phenyl analogues 
The second series of compounds were substituted benzyl and phenyl analogues 
of fenofibrate derived from 48f and 48n (Table 5-2).  The phenyl and benzyl 
moieties were substituted with fluoro and methyl groups at the ortho, meta and 
para positions.  These modifications did not offer an increase in affinity at the 
cannabinoid receptors in comparison to fenofibrate, however; they did provide 
some structure activity relationship data.  
At the CB1 receptor, the level of binding is lowered, in comparison to 48f when 
the benzyl ring bears a methyl substituent.  However; the level of binding 
remains high with the fluoro substituted analogues.  This may indicate that the 
size or electronic properties of a substituent are important for binding at the 
CB1 receptor.  At the CB2 receptor the level of binding is high and there is an 
improvement in affinity when comparing the fluoro substituted analogues with 
48f.  However; the affinity of these compounds for the CB1 receptor is still 
lower relative to that of fenofibrate (10a).  
When comparing the substituted phenyl analogues (51a to 51e), they had a 
lower level of binding compared to the parent compound (48n).  At the CB2 
receptor the level of binding was high for all of the substituted phenyl 
analogues; however affinity was lower than for the parent compound (48n).   
These analogues were not developed any further, as although they are 
antagonists at the CB1 receptor they are also antagonists or inverse agonists at 
the CB2 receptor (which is undesirable). 
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No. R % Specific Binding at 
CB1 (1x10-5 M) 
% Activation at CB1 
(1x10-5 M) 
% Specific Binding at 
CB2 (1x10-5 M) 
Ki(nM) 
at CB2 
% Activation at 
CB2 (1x10-5 M) 
 
48f 
 
94±4 104±18 99±2 2190±1010 84±23 
50a 
 
89±10 83±21 99±3 583±170 75±6 
50b 
 
96±5 87±11 94±10 428±89 69±10 
50c 
 
89±7 100±17 100±0 242±32 80±2 
50d 
 
79±5 61±18 99±2 1140±110 68±9 
50e 
 
55±3 85±14 90* 2340±689 39±5 
50f 
 
59±12 76±15 93±12 1320±482 40±2 
48n 
 
88±3 87±8 99±2 395±191 86±17 
51a 
 
82±1 69±16 99±3 1160±566 90±4 
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No. R % Specific Binding at 
CB1 (1x10-5 M 
% Activation at CB1 
(1x10-5 M) 
% Specific Binding at 
CB2 (1x10-5 M 
Ki(nM) 
at CB2 
% Activation at 
CB2 (1x10-5 M) 
 
51b 
 
71±8 111±11 100±0 3340±80 97±10 
51c 
 
76±19 91±2 96±4 1350±485 89±6 
51d 
 
42±25 100±8 95±16 1560±113 89±15 
51e 
 
59±5 114±8 97±5 762±294 87±4 
 
Table 5-2 - Affinity and efficacy of the unsubstituted and substituted phenyl and benzyl analogues at the CB1 and CB2 receptors 
Binding and affinity were evaluated using CHO cells expressing CB2 receptors or whole rat brain homogenate and 3H-CP55940 or [35S]-GTPγS Ki values were determined 
from binding IC50 values, based on the Cheng-Prussoff equation in which the Kd of 3H-CP55940 is 0.5nM and the concentration of 3H-CP55940 is 0.25nM.  Results are 
expressed as the percentage of stimulation of [35S]-GTPγS binding.  Basal level of activation is 100%.  Data are the mean ± SD mean of three experiments performed in 
triplicate (n=3) and were analysed using Graphpad prism 3. 
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5.1.3. Substituted benzophenone derivatives 
The next series of analogues investigated were derivatives of 48g and 48h 
(Table 5-3 and Table 5-4).  Substitution of the benzophenone with electron 
donating and withdrawing groups at the ortho, meta and para positions 
provided several compounds with high affinity and efficacy at both 
cannabinoid receptors.  
All of the morpholino derived analogues had a high level of binding at the CB1 
receptor apart from analogues with meta electron withdrawing substituents.    
This may indicate that the position of the substituent is important for binding 
although ortho- and para- nitro and cyano derivatives would need to be 
assayed to confirm that it is an electronic rather than a positional effect.  The 
morpholino analogues were all antagonists at the CB1 receptor apart from the 
para chloro (48h) and ortho fluoro (58g) derivatives which were agonists.  
This may indicate that positional and electronic effects are not the only factors 
to affect CB1 receptor binding.    
At the CB2 receptor the 48h derivatives had a high level of binding with the 
exception of the meta - nitro and meta - cyano derivatives.  In general the para 
and meta substituted analogues had agonist activity whereas the ortho 
substituted analogues were antagonists.  This indicated that position of the 
substituent is important for agonist activity at the CB2 receptor.  Ortho 
substituents may cause a conformational restriction in the rotation of the 
benzophenone rings, relative to each other, which may disrupt the interaction 
required for activation of the receptor. 
All the 48g derivatives displayed a high level of binding at the CB1 receptor 
apart from the meta cyano analogue (59d).  In general, para electron donating 
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substituents are favoured for agonist activity, whereas other substituents at the 
ortho and meta positions give compounds which are antagonists at the CB1 
receptor.  Affinity for the CB1 receptor was determined for two compounds in 
the series (59c and 59i), and they displayed a higher affinity than fenofibrate 
(10a) and also the parent compound 48g. 
At the CB2 receptor, the 48g analogues displayed a high level of binding apart 
from the meta-cyano substituted analogue (59d).  The para substituted 
analogues showed agonist activity at the CB2 receptor and the meta substituted 
analogues were antagonists or inverse agonists.  The ortho fluoro analogue 
(59g) displayed agonist activity whereas the ortho methyl analogue (59a) 
displayed antagonist activity.  This may indicate that for ortho substituted 
analogues the size and electronic properties of a substituent are important, and 
in this case the fluorine atom in 59g may be acting as a hydrogen bond 
acceptor.  To establish whether this is indeed the case, the corresponding ortho 
OH and OMe analogues could be synthesised.  When comparing the 48g 
analogues there is no improvement in affinity or efficacy in comparison to 48g, 
however they are improved in comparison with fenofibrate (10a). 
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No. R % Specific Binding at 
CB1 (1x10-5 M) 
Ki (nM) 
at CB1 
% Activation at CB1 
(1x10-5 M) 
EC50 
at
 
CB1 
% Specific Binding at 
CB2 (1x10-5 M) 
Ki(nM) 
at CB2 
% Activation at 
CB2 (1x10-5 M) 
 
 
58a o-CH3 95±4 * 99±10 * 92±3 56.8±16.8  148±24 
58b m-CH3 94±2 * 99±7 * 90±5 * 104±5 
58c p-CH3 93±3 * 103±18 * 96±6 310±16.5 160±9 
58d m-CN 39±1 * 107±11 * 42±10 * 98±1 
58e p-CN * * * * * * * 
58f m-Cl 94±1 * 101±6 * 94±5 * 82±4 
48h p-Cl 92±3 150±67 149±7 2.25±0.89 100±0 12.8±3.5 153±2 
58g o-F 92±4 92±14 130±19 1.24±0.97 100±0 146±25.2 119±19 
58h m-F 89±7 * 89±9 * 89±6 * 116±5 
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No. R % Specific Binding at 
CB1 (1x10-5 M) 
Ki (nM) 
at CB1 
% Activation at CB1 
(1x10-5 M) 
EC50 
at
 
CB1 
% Specific Binding at 
CB2 (1x10-5 M) 
Ki(nM) 
at CB2 
% Activation at 
CB2 (1x10-5 M) 
 
58i p-F 89±12 * 89±7 * 99±3 231±90.2 135±7 
58j m-NO2 79±6 * 92±14 * 80±5 * 106±14 
58k p-NO2 * * * * * * * 
58l H 93±4 * 97±18 * 96±9 299±3.5 137±8 
Table 5-3 - Binding and efficacy of 58a to 58l at the CB1 and CB2 receptors 
Binding and affinity were evaluated using CHO-K1 cells expressing hCB2 or whole rat brain homogenate, and 3H-CP55940 or [35S]-GTPγS.  Ki values were determined from 
binding IC50 values, based on the Cheng-Prussoff equation in which the Kd of 3H-CP55940 is 0.5 nM and the concentration of 3H-CP55940 is 0.25nM.  * Not assayed 
**Results are expressed as the percentage of stimulation of [35S]-GTPγS binding.  Basal level of activation is 100%.  Data are the mean ± SD mean of three experiments 
performed in triplicate.  
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No. R % Specific Binding at 
CB1 (1x10-5 M) 
Ki (nM) 
at CB1 
% Activation at CB1 
(1x10-5 M) 
EC50 
at
 
CB1 
% Specific Binding at 
CB2 (1x10-5 M) 
Ki(nM) 
at CB2 
% Activation at 
CB2 (1x10-5 M) 
 
 
 
59a o-CH3 92±1 * 105±9 * 91±1 * 102±23 
59b m-CH3 96±0 * 102±14 * 90±4 * 77±14 
59c p-CH3 94±3 26±10 174±20 367±193 93±2 29±11 155±4 
59d m-CN 71±3 * 112±12 * 71±6 * 108±1 
59e p-CN 94±3 * 104±4 * 90±4 * 114±19 
59f m-Cl 94±2 * 97±8 * 91±3 * 82±18 
48g p-Cl 96±4 102±30 137±6 92.6±2 100 15±4 152±10 
59g o-F 94±4 * 119±13 * 91±6 * 134±4 
59h m-F 93±3 * 87±15 * 89±4 * 110±9 
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No. R % Specific Binding at 
CB1 (1x10-5 M) 
Ki (nM) 
at CB1 
% Activation at CB1 
(1x10-5 M) 
EC50 
at
 
CB1 
% Specific Binding at 
CB2 (1x10-5 M) 
Ki(nM) 
at CB2 
% Activation at 
CB2 (1x10-5 M) 
 
59i p-F 82±11 46±19 140±22 362±32 100±0 14±3 129±9 
59j H 96±2 * 127±6 * 94±6 * 124±3 
Table 5-4 - Binding and efficacy of 59a to 59j at the CB1 and CB2 receptors 
Binding and affinity were evaluated using CHO-K1 cells expressing hCB2 or whole rat brain homogenate, and 3H-CP55940 or [35S]-GTPγS.  Ki values were determined from 
binding IC50 values, based on the Cheng-Prussoff equation in which the Kd of 3H-CP55940 is 0.5 nM and the concentration of 3H-CP55940 is 0.25nM.  * Not assayed 
**Results are expressed as the percentage of stimulation of [35S]-GTPγS binding.  Basal level of activation is 100%.  Data are the mean ± SD mean of three experiments 
performed in triplicate.  
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5.1.4. Tertiary Amide Derivatives  
Another modification to the structures of the morpholino and piperidinyl 
derivatives was to couple morpholine and piperidine directly to fenofibric acid 
(10b) which afforded the tertiary amide products 63a and 63b.   
The morpholine derivative (63a) exhibited a lower level of binding at the CB1 
receptor compared to 48h, and both 63a and 63b lost their agonist activity.  
This would indicate that the amide NH is important for agonist activity at the 
CB1 receptor. 
For both 63a and 63b the level of binding was quite high at the CB2 receptor. 
Additionally, these compounds were inverse agonists.  In comparison to 48g 
and 48h the removal of the amide NH diminished the level of binding at the 
receptor and also switched the activity from agonism to inverse agonism. 
5.2. Future work 
So far, a series of fenofibrate analogues have been developed that displayed 
activity at the cannabinoid receptors.   
The substituted benzyl and phenyl derivatives showed a high affinity for the 
CB2 receptor; however they did not have a higher affinity than fenofibrate 
(10a) or the desirable agonist activity.  The fluoro and methyl derivatives 
synthesised indicated that activity can be tuned by varying the substituent, and 
potentially affinity and possible efficacy could be altered.  A larger library of 
compounds with differing substituents needs to be synthesised to investigate 
further whether it is a positional, steric or electronic effect.  Some of these 
substituents could be; hydroxyl, trifluoromethyl, methoxy, nitro and cyano 
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groups.  At the CB1 receptor, the benzyl and phenyl derivatives had antagonist 
or inverse agonist activity, and a high level of binding at 10>M apart from the 
methyl derivatives.  Therefore it would be valuable to investigate further 
whether this is a positional, steric or electronic effect by again synthesising a 
larger library of compounds as described above.   
Considering the pharmacological data obtained to date, the series of 23 
morpholino and piperidinyl derivatives, described in Chapter 4, appear to be 
the best candidates to use as leads for further development. 
All of the morpholino and piperidinyl analogues displayed a high level of 
binding at the cannabinoid receptors, apart from meta cyano and nitro 
derivatives.  Of these, selected analogues that were assayed, displayed a high 
affinity.  They have displayed varying activities at the cannabinoid receptors, 
which appears to be substituent dependent, and therefore varying the type of 
substituent and its position could potentially allow tuning of their activity.  As 
only a few examples of various substituents have been exemplified so far, a 
wider range may offer this possibility.  Examples are shown in Figure 5-1.  
A larger library of substituted compounds with differing electronic and steric 
properties could also help clarify whether size, position or electronic effects are 
responsible for the mixed results at the CB2 receptor for ortho-substituted 
compounds in the series 58a to 58l.  
Other alterations to the pharmacophore, to further explore structure activity 
relationships, could be the rigidification of the benzophenone by tethering the 
two phenyl rings together to form either an anthracenone or a fluorenone.  
Morpholino and piperidinyl derivatives (48g and 48h) with the geminal 
dimethyl groups omitted, may also give an indication of the components of the 
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pharmacophore that are important for affinity and activity at the cannabinoid 
receptors.  These two compounds have been synthesised but remain to be re-
purified and then tested, due to time constraints, as they were below the 
necessary purity for testing (approximately 50% from NMR).    
 
Figure 5-1 Potential pharmacophore modifications  
As PPARα activity of fenofibric acid (10b) was lost with substitution of the 
carboxylic acid with various amides, molecular modelling may indicate which 
interactions are unfavourable for binding and activation of the receptor.  
PPARα has previously been crystallised with both agonists and antagonists11, 17, 
19
, and so docking studies may indicate the reasons for fenofibric acid (10b) 
and anandamide possessing activity at PPARα whereas compounds described 
in this thesis do not.   
Although a ligand with dual PPARα / cannabinoid receptor activity has not 
been discovered with the amide derivatives synthesised to date, this scaffold 
could provide a platform for the further development of novel cannabinoid 
receptor ligands.  
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The possibility of developing a sub-type selective cannabinoid receptor ligand, 
or one combining antagonist/inverse-agonist activity at the CB1 receptor with 
agonist activity at the CB2 receptor is still of therapeutic interest.  Such an 
activity profile has the potential to target a variety of disorders, such as pain, 
MS and obesity. 
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6. Experimental 
6.1. Pharmacology 
6.1.1. Molecular cloning 
The competent E.Coli (xl-blue) was obtained from Promega.  The PPARα 
pcDNA plasmid was prepared by Yan Sun, the 3xPPRE plasmid was a gift 
from Walter Wahli at the Université de Lausanne and the RXR plasmid was a 
gift from David Mangelsdorf at UT Southwestern Medical Centre. 
6.1.1.1. Preparation of LB Media 
The solutes were added together and either 400 ml or 250 ml deionised water 
was then added.  The mixture was shaken until the solutes dissolved and the 
pH was adjusted with 1M NaOH.  The solution was then autoclaved. 
 With Agar (400ml) Without Agar (250ml) 
Tryptone (Oxoid) 4g 2.5g 
Yeast Extract (Oxoid) 2g 1.25g 
NaCl (Fisher Scientific) 2g 1.25g 
1M NaOH (Fisher Scientific) 0.4ml 0.25ml 
Agar (MP Biomedicals) 6g - 
 
6.1.1.2. Preparation of LB plates 
LB media with agar was prepared as described above, melted and ampicillin 
(100 >g ml-1) was added.  The media was poured onto 10 cm diameter petri 
dishes and left to set a room temperature.  The plates were then stored at 4 °C. 
6.1.1.3. Transformation of bacterial cells 
The bacterial cells were removed from the freezer and were defrosted on ice 
over 30 minutes.  In three separate vials 50ng of DNA (either PPARα, PPRE or 
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RXR) was added 100 >l of competent cells were then added to each vial.  The 
mixtures were then stored on ice for 30 minutes.  
LB medium (800 >l) was added to each tube and they were incubated at 37°C 
with shaking for 1 hour.  After this time the cells were spread onto LB agar 
plates containing ampicillin (100 >g ml-1) and were then incubated at 37°C 
until the transformed colonies appeared (18 hours).  
A single colony of bacteria was inoculated into 10ml of LB medium containing 
ampicillin (100 >g ml-1) and was incubated with shaking for 4 hours.  After this 
time 1 ml of each of the plasmid containing competent cells, were transferred 
into 100 ml each of LB medium containing ampicillin (100 >g ml-1).  The three 
suspensions were then incubated overnight.  
6.1.1.4. Plasmid DNA Preparation 
The Maxi-prep of the plasmid DNA was carried out using the Qiagen Plasmid 
Maxi Kit following the manufacturer’s protocol. 
6.1.1.4.1. Maxi-preparation 
In summary 100 ml of the transformed bacterial culture was pelleted (4000g 
for 10 minutes).  10 ml of lysis buffer was added, and the lysate was incubated 
at room temperature for 5 minutes, and then centrifuged at >15,000g for 10 
minutes at room temperature.  The supernatant was removed and loaded onto 
the equilibrated column.  The solution was allowed to drain by gravity flow 
and the flow through was discarded.  The column was washed once with wash 
buffer and the solution was allowed to drain by gravity.  The flow through was 
discarded. 
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15 ml of elution buffer (E4) was added to the column to elute the DNA.  The 
solution in the column was allowed to drain by gravity flow.  150 ml 
isopropanol was then added to the elution tube to precipitate the plasmid DNA.  
This was mixed well and was centrifuged at >15000xg for 30 minutes at 4°C.  
The supernatant was discarded.  
5 ml 70 % ethanol was added to the pellet and was centrifuged at >15000xg for 
5 minutes at 4°C.  The supernatant was removed and the pellet was air dried 
for 10 minutes.  The pellet was then resuspended in 200-500 >l of sterile HPLC 
water and was stored at -20°C.
6.1.1.4.2. Plasmid DNA Concentration 
The plasmid DNA concentrations for PPARα, RXR and PPRE were 
determined using a Nanodrop ND1000 spectrophotometer.
6.1.2. Cell culture 
All reagents were obtained from Sigma Aldrich unless otherwise stated.  All 
culture flasks and 6-well plates were obtained from Grenier Bio-one GmbH 
and Nunc respectively.The cells used throughout this study were; COS-7cells, 
and were obtained from the American Type Culture Collection (ATCC).  
E.Coli (Promega) was used to carry out the transformation of the three 
different plasmids for PPARα, PPRE and RXR.  The cells were cultured in 
Dulbecco’s Minimum Essential Medium D6546 (DMEM), which was 
supplemented with L-glutamine (0.5%), non-essential amino acids (0.5 %), 
sodium pyruvate (0.5 %) and fetal bovine serum (10 %).  The COS-7 cells 
were incubated at 37°C, 5 % CO2.  All cell culture was carried out in a sterile 
hood using sterile techniques  
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6.1.2.1. Passage of cells
The COS-7 cells were passaged when they had reached ~60 % confluence.  
Firstly the DMEM was aspirated and the cells were then washed with PBS (10 
ml) at 37°C.  Trypsin/EDTA (4 ml, 37 °C) was added and the cells were 
incubated at 37 °C, 5 % CO2 for 2 minutes.  After this time the trypsin/EDTA 
was neutralised with DMEM (15ml) and the cell suspension was centrifuged at 
1000 rpm for 5 minutes.  The resulting pellet was resuspended in DMEM (3 
ml) and 1 ml of the suspension was added to two new 400 ml flasks containing 
DMEM (35 ml, 37°C).
6.1.2.2. Seeding of cells  
COS-7 cells that were at ~70 % confluence were removed from the flask and 
centrifuged as described above.  The cell pellet was resuspended in DMEM (3 
ml) and the cells were counted using a haemocytometer.  Further DMEM was 
then added to achieve a density of 1.0x105 cells when 1 ml of the suspension 
was added to 1 well of a six well plate.  The plates were then returned to the 
incubator at 37 °C, 5 % CO2.  
 COS-7 cells used for the luciferase assay were seeded into 6-well plates 24 
hours before transfection was carried out. 
6.1.2.3. Transient transfections 
All transfections were carried out in a sterile hood using sterile techniques.  
The pCDNA 3.1/zeo + and the transfection reagent TransFast was obtained 
from Promega.  All other reagents were from Sigma Aldrich. 
6.1.2.3.1. Transfection with TransFast transfection reagent 
• All plasmids were diluted to 500 ng / >l. 
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• 1 ml of combined DNA/TransFast/serum free DMEM mixture was used per 
well. 
Day 1 – COS-7 cells were seeded into 6-well plates, at a density of 5x104 cells 
well-1 in 10% FBS DMEM 
Day 2 – To serum free DMEM the DNA, and then TransFast were added.  A 
1:1 ratio of DNA to TransFast was used (3 >l of TransFast per >g of DNA).  
The mixture was briefly vortexed and was left to incubate for 15 minutes.
The medium was removed from the cells (~60 % confluent) and 1 ml of the 
DNA/TransFast mixture was added to each of the wells.  The cells were 
returned to the incubator (37 °C, 5 % CO2) for 1 hour after which time 1 ml of 
1 % FBS DMEM with or without ligands was added.  The cells were then 
returned to the incubator for 24 hours.  
6.1.3. Assays 
6.1.3.1. Luciferase Assay 
24 hours after transfection, the media was aspirated from each of the wells, and 
the cells were washed with 1ml PBS.  The cells were lysed with passive lysis 
buffer (400 >l 5x diluted) and the cells were scraped from the plates.  The 
lysates were pipetted into eppendorf vials and were stored at -20 °C for 24 
hours. After storage at -20 °C, the lysates were defrosted and centrifuged at 
13000 rpm for 2 minutes.  10 >l of each of the samples were tested for 
luciferase activity by adding 100 >l of luciferase assay buffer (Promega).  The 
light emitted was measured with a luminometer (TD-20/20 luminometer, 
Turner Designs). 

109 
6.1.3.2. TR-FRET assay 
The assay was carried out as described in the manufacturer’s protocol. 
In summary 20 >l of test compound, control competitor, or test compound 
solvent were pipetted into a 384 well black assay plate.  10 >l of Fluormone 
Pan-PPAR Green was then added to the plate followed by a 10 >l mixture of 
PPARα/Tb-Anti-GST Ab.  The plate was gently mixed on an orbital shaker for 
30 seconds, covered and then incubated at room temperature.  After 2 hours 
incubation the fluorescent emission signal of each well was measured at 495 
nM and 520 nM on a Perkin Elmer EnVision plate reader.  The plate was read 
again after a further 2 hours incubation to ensure than equilibration had been 
reached.  
6.1.4. Radioligand binding assays 
6.1.4.1. Preparation of CHO-K1 cells expressing hCB2 receptors 
CHO-K1 cells expressing hCB2 receptors were grown to confluence, harvested, 
pelleted and frozen down.  This work was kindly carried out by Liaque Latif. 
The pellet was defrosted and resuspended in Tris buffer (50 mM Tris, 5 mM  
MgCl2, 2 nM EDTA, pH 7.0).  The suspension was homogenised and 
centrifuged (40, 000g for 20 minutes) and the supernatant was discarded.  This 
process was repeated twice.  The final pellet was resuspended in Tris buffer 
and divided into 1 ml aliquots to a protein concentration of 5 mg/ml. 
6.1.4.2. Preparation of rat brain homogenate 
The tissue was weighed and excess fluid was removed.  It was then 
homogenised on ice, in Tris buffer, using a Polytron homogeniser in three, ten 
second bursts.  The tissue was then diluted (1 g in 40mls of Tris buffer) and 
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centrifuged at 40,000 g for ten minutes, and the supernatant was discarded.  
This process was repeated twice.  The pellet was resuspended in Tris buffer, (1 
g of the original tissue in 10mls), and divided into 1 ml aliquots.  
6.1.4.2.1.  [3H] CP55940 Radioligand Competition Binding Assay 
Tubes containing of CHO-K1 membranes expressing human CB2 receptors or 
whole rat brain were incubated at 30°C for 1hour 30 minutes in 850 >l assay 
buffer (50mM Tris.HCl, 2mM EDTA, 5 mM MgCl2 and 0.2 mg ml-1 bovine 
serum albumin (BSA) pH 7.0 at 30 °C) with 50 >l 3H CP55940 (Perkin-Elmer 
Life Sciences Inc.), and 50 >l competing drug (Tris.HCl, 2mM EDTA, 5mM 
MgCl2 and 5.0 mg ml-1 bovine serum albumin (BSA) pH 7.0 at 30 °C) giving a 
final assay volume of 1 ml.  Specific binding was calculated by subtracting non 
specific binding (NSB) from the total binding.  The NSB was determined in the 
presence of 1 >M SR144528.  A Brandel cell harvester (Brandel Inc., 
Gaitherburg, MD, U.S.A) was used to harvest the membranes and separate the 
bound from unbound radioligand.  The membranes were collected on filters pre 
soaked with assay buffer, and the bound radioligand was quantified using a 
liquid scintillation counter (Packard, Tri-Carb 2100TR).  Nonlinear regression 
analysis was carried out using GraphPad Prism 3, and Ki values were 
determined from IC50 values using the Cheng-Prusoff equation where the 
concentration of [3H] CP 55940 was 0.25 nM and KD was 0.5 nM.  Results are 
mean values ± SD mean.       
6.1.4.2.2. [35S]GTPγS Radioligand Binding Assay   
The assay was carried out as described previously by G Griffin et al 58. 
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CHO-K1 cells homogenate expressing human CB2 membranes, or whole rat 
brain, was incubated at 30 °C for 20 minutes in 30 ml assay buffer with added 
GDP (100 µM) and theophylline (1 µM).  0.5 ml of this membrane solution 
was added to assay tubes containing the desired concentration of drug, and 0.5 
ml of [35S]-GTP-γ-S solution (0.05 nM).  The tubes were then incubated at 30 
°C for 1 hour 30 minutes.  The NSB was determined using non-radiolabelled 
GTP-γ-S (10 µM).  The membranes were harvested under vacuum onto filter 
mats, and the tubes were washed twice with approximately 2 ml of cold wash 
buffer.  The level of bound radioligand was quantified using liquid scintillation 
spectrophotometry (Packard liquid scintillation analyser, Tri-Carb 2100TR).  
Nonlinear regression analysis was carried out using GraphPad Prism 3. 
The stimulation of the [35S]-GTP γS binding was defined as the percentage 
increase above basal levels ((dpm (agonist)-dpm (no agonist)/dpm no agonist) 
x100).  Results are mean ± S E mean. 
6.2. General Chemistry 
Chemicals and solvents were purchased from standard suppliers and used 
without further purification.  Merck Kieselgel 60, 230-400 mesh, for flash 
column chromatography was supplied by Merck KgaA (Darmstadt, Germany) 
and deuterated solvents were purchased from Goss International Limited 
(England) and Sigma-Aldrich Company Ltd (England). 
Unless otherwise stated, reactions were carried out at ambient temperature.  
Reactions were monitored by thin layer chromatography on commercially 
available precoated aluminium backed plates (Merck Kieselgel 60 F254).  
Visualisation was by examination under UV light (254 and 366 nm).  General 
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staining carried out with Ninhydrin and potassium permanganate.  All organic 
extracts after aqueous work-up procedures were dried over MgSO4 or Na2SO4 
before gravity filtering and then evaporated under reduced pressure at ≤ 40°C 
(water bath temperature).  Purification using preparative layer chromatography 
was carried out using Fluka silica gel 60 PF254 containing gypsum (200 mm x 
200 mm x 1 mm).  Flash chromatography was performed using Merck 
Kieselgel 60 (0.040-0.063 mm) on either a Flashmaster 2 or Isolera 4. 
Melting points were recorded on a Reichert 7905 apparatus.  FT-IR spectra 
were recorded as thin films or KBr discs in the range of 4000 – 500 cm-1 using 
and Avatar 360 Nicolet FT-IR spectrophotometer. 
Mass spectra (TOF ES +/- or API) were recorded on a Waters 2795 separation 
module/micromass LCT platform, or Applied Biosystems API2000. 
1H NMR spectra were recorded on a Bruker-AV 400 at 400.13 MHz.  13C 
NMR spectra were recorded at 101.62 MHz. Chemical shifts (δ) are recorded 
in ppm with reference to the chemical shift of the deuterated solvent/an internal 
TMS standard.  Coupling constants (J) are recorded in Hz and the significant 
multiplicities described by singlet (s), doublet (d), triplet (t), quadruplet (q), 
broad (br), multiplet (m), doublet of doublets (d of d), doublet of doublet of 
doublets (ddd), doublet of doublet of doublet of doublets(dddd), or doublet of 
triplets (d of t).  Unless otherwise stated all spectra were recorded in CDCl3. 
Microwave synthesis was carried out in a CEM Explorer series microwave 
reactor.  
Analytical HPLC was performed using systems 1 to 4 to confirm purity.  All 
retention times are quoted in minutes.   
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System 1: Waters millennium 995 LC system.  Phenomenex Onyx Monolithic 
reverse phase C18 column (100 x 4.6 mm).  
Flow rate: 3.00 mL/min and UV detection at 254 nm.  
Gradient 5% - 95% solvent B over 10 minutes.  
Solvent A: 0.1% formic acid in water; solvent B: 0.1% formic acid in MeCN. 
System 2: Waters millennium 995 LC system.  Waters symmetry reverse phase 
C18 column (75 x 4.6 mm). 
Flow rate: 1.00 mL/min. UV detection at 254 and 220 nm.   
Gradient: 5% - 95% solvent B over 20 minutes.   
Solvent A: 0.1% formic acid in water; solvent B: 0.1% formic acid in MeOH. 
System 3: Shimadzu UFLCXR system coupled to an Applied Biosystems 
API2000. Gemini-NX 3u-110A, 50x2mm column which was thermostated at 
40oC.  
Flow rate: 0.5ml/min. UV detection at 220 and 254nm. 
Gradient: Pre-equilibration run for one min at 10% B, 10 to 98% solvent B in 
2min, 98% for 2min, 98 to 10% B in 0.5min then 10% for one min. 
Solvent A: 0.1% Formic Acid in water; solvent B: 0.1% Formic Acid in 
MeCN. 
System 4: Shimadzu UFLCXR system coupled to an Applied Biosystems 
API2000.  Luna 3u (PFP2) 110A, 50x2 mm. column which was thermostated at 
40oC. 
Flow rate: 0.5ml/min. UV detection at 220 and 254 nm. 
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Gradient: Pre-equilibration run for one min at 10% B, 10 to 98% solvent B in 
2min, 98% for2min, 98 to 10% B in 0.5min then 10% for one min. 
Solvent A: 0.1% Formic Acid in water; solvent B: 0.1% Formic Acid in 
MeCN. 
 
All HPLC and LC-MS traces, of compounds for screening, confirmed purity of 
98% or above at both 220 nm and 254 nm.  
 
Compounds were synthesised by the general methods described below unless 
otherwise stated. 
General Method A: To a stirred solution of Fenofibrate-OSu (1.0 eq) in 
anhydrous dichloromethane (20 ml) the selected amine (1.0 eq) was added.  An 
instantaneous precipitate of N-hydroxysuccinimide was formed, and the 
reaction was stirred for between 5 minutes and 24 hours.  Water was added to 
the reaction, and the organic layer was then washed firstly with potassium 
hydrogen sulfate, then saturated sodium bicarbonate, water and brine.  The 
organic layer was dried with magnesium sulfate and then filtered.  The solvent 
was evaporated under vacuum.  
General Method B: To fenofibric acid (10b) (1eq) thionyl chloride was added 
as the solvent.  The mixture was heated at 60°C for between 1 hour and 1hour 
45 minutes.  The thionyl chloride was removed under vacuum and the solid or 
oil afforded was used directly in the next step. The selected amine (1eq) was 
dissolved in anhydrous dichloromethane and triethylamine (2eq) was added. 
The mixture was cooled to 0°C and the acid chloride (1eq) was slowly added. 
After addition the ice bath was removed and the reaction was stirred for 
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between 1 hour and overnight. The reaction mixture was then washed  twice 
with hydrochloric acid (2M), sodium hydroxide (2M), and then water. The 
organic phase was dried with sodium sulfate, filtered, and the solvent was 
removed under vacuum. 
General Method C: To the methyl or ethyl ester (1eq), water and THF (1:1) 
were added.  Lithium hydroxide (5eq) was then added under nitrogen.  The 
reaction was stirred between for 2 hours and 24 hours.  The THF was removed 
under vacuum, water was added, and the resulting aqueous solution was 
acidified to pH 4 with concentrated HCl.  The product was then extracted into 
dichloromethane and the combined organic layers were dried with sodium 
sulfate.  The solvent was then removed under vacuum.   
General Method D: To benzoic acid (1eq) thionyl chloride was added as the 
solvent.  The mixture was heated at 60°C for between 1 hour and 2 hours 30 
minutes.  The thionyl chloride was removed under vacuum and the solid or oil 
afforded was used directly in the next step.  Anisole (1eq) in anhydrous 
dichloromethane was cooled to 0°C and aluminium chloride (1.5eq) was 
slowly added.  The benzoyl chloride (1eq) was dissolved in dichloromethane 
and then slowly added to the mixture.  After 30 minutes at 0°C, the ice bath 
was removed and the reaction was stirred at room temperature overnight.  The 
reaction mixture was poured onto a mixture of ice and concentrated HCl and 
was then extracted with dichloromethane, and the organic were washed with 
water (x 3) and then brine. The organic layer was dried over magnesium sulfate 
and the solvent was removed under vacuum.  
General Method E: To the 4-hydroxybenzophenone (1eq) dissolved in MeCN, 
sodium hydroxide or potassium carbonate was added (5.5eq).  The mixture was 
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heated to 50°C and stirred for 1 hour.  α-Bromoisobutyric acid (1.5eq) 
dissolved in acetonitrile was then added and the mixture was heated for a 
further 2 hours 30 minutes.  The solvent was removed under vacuum and the 
resulting solid was dissolved in dichloromethane.  This was then washed with 
HCl (2M) and water.  The organic layer was dried with sodium sulfate and the 
solvent was removed under vacuum.  
General Method F: A mixture of the 4-methoxybenzophenone (1eq) and 
pyridine hydrochloride (5eq) were placed in a microwave vial and irradiated at 
215 W and 150°C, 200°C or 250°C and for between 2 and 14 minutes.  Ice 
water was then added to quench the reaction and it was extracted with ethyl 
acetate.  The organic layer was washed with sodium hydroxide (1M), and then 
discarded.  The aqueous layer was acidified to ~pH5 with concentrated HCl 
and the resulting precipitate was extracted into ethyl acetate.  The organic layer 
was dried with magnesium sulfate and the solvent was removed under vacuum.  
General Method G: To the carboxylic acid in dichloromethane (1eq), 
triethylamine was added.  HBTU was then added and the mixture was stirred 
for 5 minutes.  The selected amine was then added and the reaction was stirred 
for 1 hour 15 minutes to overnight.  The reaction was then diluted with 
dichloromethane and was washed with HCl (1M), NaOH (1M), and water.  The 
organic layer was dried over sodium sulfate and the solvent was removed under 
vacuum.  
General Method H: To the benzophenone (1eq), and PPh3 (1.2) in toluene at 
80°C, a solution of DIAD (1.2) and methyl-2-hydroxyisobutyrate (1.1eq) and 
toluene were slowly added via a dropping funnel.  The reaction was stirred for 
2 hours to 3 hours and was then diluted with toluene.  The mixture was washed 
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with NaOH (1M), and water and then dried over magnesium sulfate.  The 
solvent was then removed under vacuum.   
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2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid (10b) 
To 4-chloro-4’-hydroxybenzophenone 
(6.917 g, 2.97 mmol), butan-2-one (40ml) 
and then NaOH (6.397 g, 0.15 mol) were 
added.  The mixture was heated at 50°C for 1 hour 45 minutes, and α-
bromoisobutyric acid (7.520 g, 4.50 mmol) dissolved in butan-2-one (10 ml) 
was added.  A further 300 ml of butan-2-one was then added to the suspension 
and was stirred at 50°C for 21 hours.  Water (100 ml) was added to the reaction 
and the organic layer was collected.  Ethyl acetate was added to the organic 
layer and was then washed with HCl (300 ml, 0.5 M) and water (300 ml).  The 
organic layer was reduced in volume under vacuum and petroleum ether 40-
60°C was added to precipitate the product.  This was collected by vacuum 
filtration and then recrystallised from toluene. 
 Yield:  68 % 
Appearance: White needle-like crystals 
Purification: Recrystallised from toluene 
1H NMR (CDCl3): 1.59 (s, 6H, C(CH3)2), 6.93 (d, 3J = 8.8 Hz, 2H, phenoxy 
2-H and 6-H), 7.61 (d, 3J = 8.6 Hz, 2H, benzoyl 3-H and 5-H), 7.68-7.74 (m, 
4H, phenoxy 3-H and 5-H and benzoyl 2-H and 6-H), 13.08 (broad s, OH, 1H).  
13C NMR (CDCl3): 25.11 (C(CH3)2), 78.93 (C(CH3)2), 117.08 (phenoxy 2-C 
and 6-C), 128.60 (benzoyl 3-C and 5-C), 129.32 (phenoxy 3-C and 5-C), 
131.19 (phenoxy 4-C), 136.30 (benzoyl 1-C), 137.02 (benzoyl 4-C), 159.54 
(phenoxy 1-C), 174.42 (carboxylic acid C=O), 193.26 (ketone C=O). 
Melting point: 181 - 183 °C 
m/z:  HRMS (ES-TOF-) C17H14ClO4 [MH]- calculated 317.0586; found 
317.0593.  
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FT-IR (KBr): 2948 (amide NH), 2608, 2495 (CH3 stretch), 1742 (carboxylic 
acid C=O), 1632 (ketone C=O), 1598 (aryl CH stretch), 893, 834 (para 
disubtituted aromatic ring).) 
2,5-Dioxopyrrolidin-1-yl 2-(4-(4-chlorobenzoyl)phenoxy)-2-
methylpropanoate (47) 
2-(4-(4-Chlorobenzoyl)phenoxy)-2-
methylpropanoic acid (10b) (1.142 g, 3.58 
mmol), was dissolved in anhydrous 
dichloromethane (50 ml).   
N-Hydroxysuccinimide (1.031 g, 8.95 mmol) followed by EDC (1.03 g, 5.37 
mmol) were then added to the flask.  The reaction was stirred for 12 hours, and 
saturated sodium bicarbonate (30 ml) was then added to the reaction flask. The 
aqueous layer was extracted with ether (50 ml), and the organic layer was 
washed with water (50 ml) and brine (50 ml), and then dried with magnesium 
sulphate.  The solvent was removed under reduced pressure, and the white 
solid dried under high vacuum for 1 hr to give 2,5-dioxopyrrolidin-1-yl 2-(4-
(4-chlorobenzoyl)phenoxy)-2-methylpropanoate (Fenofibrate-OSu).  
Yield: 68% 
Appearance: White Solid 
Purification: Used without further purification 
 Melting Point: 100 - 101 °C  
1H NMR (CDCl3): 1.81 (s, 6H, C(CH3)2, 2.86 (m, 3J = 4.1 Hz, 2H, 
succinimide CH2,), 7.07 (d, 3J = 8.6 Hz, 2H, phenoxy 2-H and 6-H), 7.45 (d, 3J 
= 8.6 Hz, 2H, benzoyl 3-H and 5-H) 7.71 (d, 3J = 8.6 Hz, 2H, phenoxy 3-H and 
5-H), 7.78 (d, 3J = 8.9 Hz, 2H, benzoyl 2-H and 6-H).   
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13C NMR (CDCl3):  25.63 (C(CH3)2), 30.95 (succinimidyl CH2,), 78.56 
(C(CH3)2), 118.52 (phenoxy 2-C and 6-C ), 128.58 (benzoyl 3-C and 5-C), 
131.24 (phenoxy 3-C and 5-C), 131.42 (phenoxy C-4), 132.06 (benzoyl 2-C 
and 6-C), 136.28 (benzoyl C-1) 138.51 (benzoyl C-4), 158.48 (phenoxy C-1), 
168.74 (succinimidyl C=O), 169.38 (ester C=O), 194.50 (ketone C=O).    
m/z:  HRMS (ES-TOF+)  C21H18ClNO6 [MH]+ calculated 416.0895; found 
416.1038.  
N-(2-Hydroxyethyl)-2-(4-(4-chlorobenzoyl)phenoxy-2-methylpropanamide 
(48a)* 
 Following General Method A, Fenofibrate-OSu (0.416 g, 1 mmol), and 
ethanolamine (0.060 ml, 1.000 mmol) in DCM (20 ml) were reacted for 5 
minutes to afford 48a (0.350 g, 
0.967 mmol). 
Yield: 97%  
Appearance: Colourless Oil 
Purification: Used without further purification 
1H NMR (CDCl3): 1.56 (s, 6H, C(CH3)2), 3.17 (broad s, OH, 1H), 3.42 (d of t, 
3J = 5.8 Hz, 3J = 4.8 Hz 2H, CH2 next to OH), 3.64 (t, 3J = 5.0 Hz, 2H, CH2 
next to NH), 6.93 (d, 3J = 8.9 Hz, 2H, phenoxy 2H and 6H), 7.08 (t, 3J = 6.1 
Hz, 1H, NH), 7.41 (d, 3J = 8.6 Hz, 2H, benzoyl 3-H
 
and 5-H,) 7.65 (d, 3J = 8.6 
Hz, 2H, phenoxy 3-H and 5-H), 7.68 (d, 3J = 8.6 Hz, 2H, benzoyl 2-H and 6-
H).   
13C NMR (CDCl3): 25.22 (C(CH3)2), 42.18 (CH2NH), 61.75 (CH2OH), 81.89 
(C(CH3)2), 119.62 (phenoxy 2-C and 6-C), 128.62 (benzoyl 3-C and 5-C), 
131.23 (phenoxy 3-C and 5-C), 131.50 (phenoxy C-4), 131.87 (benzoyl 2-C 
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and 6-C), 135.99 (benzoyl C-1) 138.71 (benzoyl C-4), 158.57 (phenoxy C-1), 
175.06 (ester C=O), 194.40 (ketone C=O).    
m/z:  HRMS (ES-TOF+)  C19H20ClNO4 [MH]+ calculated 362.1154; found 
362.1143. 
HPLC: System 3, Rt = 2.65 minutes 
    System 4, Rt = 2.67 minutes  
*Synthesised by Dr Barrie Kellam 
N-(2-Hydroxybutyl)-2-(4-(4-chlorobenzoyl)phenoxy-2-
methylpropanamide (48b)* 
 Following General Method A, Fenofibrate-OSu (0.208 g, 0.5 mmol), and 4-
amino-1-butanol (0.055 ml, 0.600 mmol) in DCM (20 ml) were reacted for 5 
minutes to afford 48b 
(0.175g, 0.449 mmol). 
Yield: 90% 
Appearance: Colourless Oil. 
Purification: Used without further purification. 
1H NMR (CDCl3): 1.47-1.63 (m, 4H, CH2CH2NH, CH2CH2OH), 1.61 (s, 6H, 
C(CH3)2), 2.19 (broad s, 1H, OH), 3.33 (d of t, 3J = 5.9 Hz, 3J = 5.9 Hz, 2H, 
CH2NH) 3.61 (t, 2H, CH2OH 3J = 5.9 Hz), 6.75 (t, 3J = 5.9 Hz, 1H, NH) 6.96 
(d, 3J = 9.0 Hz, 2H, phenoxy 2-H and 6-H), 7.45 (d, 3J = 9.1 Hz, 2H, benzoyl 
3-H and 5-H), 7.72 (d, 3J = 9.1 Hz, 2H,  phenoxy 3-H and 5-H), 7.74 (d, 3J = 
9.1 Hz, 2H, benzoyl 2-H and 6-H). 
 
13C NMR (CDCl3): 25.30 (C(CH3)2), 26.09 (CH2CH2OH), 29.74 
(CH2CH2NH), 39.26 (CH2NH), 62.20 (CH2OH), 81.88 (C(CH3)2), 119. 31 
(phenoxy 2-C and 6-C), 131.23 (phenoxy 3-C and 5-C) 131.40 (phenoxy C-4), 
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131.88 (benzoyl 2-C and 6-C), 136.04 (benzoyl C-1), 138.66 (benzoyl C-4), 
158.63 (phenoxy C-1), 174.03 (amide C=O), 194.32 (ketone C=O).  
m/z:  HRMS (ES-TOF+)  C21H24ClNO4 [MH]+ calculated 390.1467; found 
390.150 
HPLC: System 3, Rt = 2.70 minutes 
    System 4, Rt = 2.73 minutes  
*Synthesised by Dr Barrie Kellam 
N-(2-Hydroxyhexyl)-2-(4-(4-chlorobenzoyl)phenoxy-2-
methylpropanamide (48c)* 
Following General Method A, 
Fenofibrate-OSu (0.208 g, 0.5 
mmol), and 6-amino-1-hexanol 
(0.070 g, 0.600 mmol) in DCM (20 ml) were reacted for 5 minutes to afford 
48c (0.167 g, 0.400 mmol). 
Yield: 80% 
Appearance: Colourless Oil. 
Purification: Used without further purification.  
1H NMR (CDCl3) 1.20-1.31 (m, 2H, CH2-(CH2)2-NH). 1.32-1.41 (m, 2H, 
CH2-(CH2)2-OH) 1.44-1.57 (m, 4H, CH2-(CH2)2CH2-OH), 1.63 (s, 6H, 
C(CH3)2), 3.31 (d of t, 3J = 6.8 Hz, 3J = 6.2 Hz, 2H, CH2-NH) 3.61 (t, 3J = 6.2 
Hz, 2H, CH2OH,), 6.50 (t, 3J = 5.6 Hz 1H, NH,), 6.95 (d, 3J = 9.0 Hz, 2H, 
phenoxy 2H and 6H), 7.48 (d, 3J = 8.5 Hz, 2H, benzoyl 3H and 5H), 7.74 (d,  
3J = 8.5 Hz, 2H, phenoxy 3H and 5H), 7.76 (d, 3J = 9.0Hz, 2H, benzoyl 2H and 
6H).  
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13C NMR (CDCl3): 25.44 (C(CH3)2), 25.47 (CH2CH2CH2OH), 26.71 
(CH2CH2CH2NH), 29.61 (CH2CH2NH) 32.76 (CH2CH2NH), 39.48 (CH2NH), 
62.83 (CH2OH), 82.06 (C(CH3)2), 119.44 (phenoxy 2-C and 6-C), 128.85 
(benzoyl 3-C and 5-C), 131.43 (phenoxy 3-C and 5-C), 131.58 (phenoxy C-4), 
132.07 (benzoyl 2-C and 6-C), 136.23 (benzoyl C-1), 138.88 (benzoyl C-4), 
158.79 (phenoxy C-1), 174.05 (amide C=O), 194.53 (ketone C=O). 
m/z:  HRMS (ES-TOF+) C23H28ClNO4 [MH]+ calculated 418.1780; found 
418.1783.  
HPLC: System 3, Rt = 2.84 minutes 
    System 4, Rt = 2.83 minutes  
*Synthesised by Dr Barrie Kellam 
N-Isopropyl-2-(4-(4-chlorobenzoyl)phenoxy-2-methylpropanamide (48d)* 
Following General Method A, Fenofibrate-OSu (0.208 g, 0.5 mmol) and 
Isopropylamine (0.086 ml, 1.0 mmol) in DCM (20 ml) were reacted for 5 
minutes to afford 48d (0.171 g, 0.475 mmol). 
Yield: 95% 
Appearance: Colourless Oil 
1H NMR (CDCl3): 1.09 (d, 3J = 6.3 Hz, 6H, 
isopropyl 2 x CH3,), 1.56 (s, 6H, C(CH3)2), 
4.01-4.14 (m, 1H, isopropyl CH), 6.21 (d, 3J = 7.2 Hz, 1H, NH,), 6.93 (d, 3J = 
8.8 Hz, 2H, phenoxy 2-H and 6-H), 7.44 (d, 3J = 8.8 Hz, 2H, benzoyl 3-H and 
5-H), 7.68 (d, 3J = 8.8 Hz, 2H, phenoxy 3-H and 5-H), 7.71 (d, 3J = 8.8 Hz, 2H, 
benzoyl 2-H and 6-H).  
13C NMR (CDCl3): 22.72 (isopropyl 2xCH3), 25.40 (C(CH3)2), 41.61 
(isopropyl CH), 82.01 (C(CH3)2), 119.53 (phenoxy 2-C and 6-C), 128.81 
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(benzoyl 3-C and 5-C), 131.40 (phenoxy 3-C and 5-C), 131.59 (phenoxy C-4), 
132.05 (benzoyl 2-C and 6-C), 136.33 (benzoyl C-1), 138.79 (benzoyl C-4), 
158.80 (phenoxy C-1), 173.12 (amide C=O, 194.43 (ketone C=O).  
m/z:  HRMS (ES-TOF+)  C20H22ClNO3 [MH]+ calculated 360.1361; found 
360.1398.  
HPLC: System 3, Rt = 3.00 minutes 
    System 4, Rt = 2.99 minutes 
*Synthesised by Dr Barrie Kellam  
N-Hexyl-2-(4-(4-chlorobenzoyl)phenoxy-2-methylpropanamide (48e)* 
Following General Method A, Fenofibrate-OSu (0.208 g, 0.500 mmol) and 
hexylamine (0.132 ml, 1.0 mmol) in DCM (20 ml)were reacted for 5 minutes 
to afford 48e.  
Appearance: White Solid 
1H NMR (CDCl3) 0.81 (t, 3J = 
6.3 Hz, 3H, CH3-(CH2)5-NH), 1.21 (m, 6H, CH3-(CH2)3-(CH2)2-NH), 1.39-1.49 
(m, 2H, CH2-CH2-NH), 1.57 (s, 6H, C(CH3)2), 3.25 (d of t, 3J = 6.4 Hz, 3J = 
7.1 Hz, 2H, CH2-NH), 6.47 (t, 3J = 7.1 Hz, 1H, NH), 6.93 (d, 3J = 8.7 Hz, 2H, 
phenoxy 2-H and 6-H), 7.41 (d, 2H, 3J = 8.6 Hz,  benzoyl 3H and 5H), 7.67 (d, 
3J = 8.4 Hz, 2H, phenoxy 3-H and 5-H), 7.71 (d, 3J = 8.7 Hz, 2H, benzoyl 2-H 
and 6-H).  
13C NMR (CDCl3): 13.99 (hexyl CH3), 22.51 (CH2CH3), 25.28 (C(CH3)2), 
26.50 (CH2CH2CH2NH), 29.38 (CH2CH2NH), 31.39 (CH2CH2CH3), 39.49 
(CH2NH), 82.05 (C(CH3)2), 119.29 (phenoxy 2-C and 6-C), 128.60 (benzoyl 3-
C and 5-C), 131.18 (phenoxy 3-C and 5-C), 131.36 (phenoxy C-4), 131.86 
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(benzoyl 2-C and 6-C), 136.12 (benzoyl C-1), 138.59 (benzoyl 4-C), 158.65 
(phenoxy 1-C), 173.77 (amide C=O), 194.16 (ketone C=O).   
HPLC: System 3, Rt = 3.23 minutes 
   System 4, Rt = 3.16 minutes  
m/z: MS (API) C23H29O3NCl [MH]+ calculated 402.2, found 402.5 
*Synthesised by Dr Barrie Kellam 
N-Benzyl-2-[4-(4-chloro-benzoyl)-phenoxy]-2-methyl-propionamide (48f) 
Following General Method A, Fenofibrate-OSu (0.201 g, 0.483 mmol) and 
benzylamine (0.104 ml, 0.967 mmol) in DCM (20 ml)were reacted for 1 hour 
to afford 48f (0.138 g, 0.339 mmol).  
Yield: 70% 
Appearance: White Solid 
1H NMR (CDCl3) 1.63 (s, 6H, 
C(CH3)2), 4.48 (d, 3J = 5.9 Hz, 2H, benzyl CH2), 6.77 (t, 3J = 5.9 Hz, 1H, NH), 
6.92 (d, 3J = 8.7 Hz, 2H, phenoxy 2-H and 6-H), 7.21-7.24 (m, 3H, benzyl 2-H, 
6-H and 4-H ), 7.26-7.32 (m, 2H, benzyl 2-H and 6-H and benzyl 4-H), 7.45 (d, 
3J = 8.5 Hz, 2H, benzoyl 3-H and 5-H), 7.68-7.72 (m,  4H, phenoxy 2-H and 6-
H, and benzoyl 3-H and 5-H). 
13C NMR (CDCl3) 25.47 (C(CH3)2),  43.74 (benzyl CH2,), 82.14 (C(CH3)2), 
119.66 (phenoxy 2-C and 6-C), 127.8 (benzyl 6-C), 127.96 (benzyl 2-C and 6-
C), 128.82 (benzyl 3-C and 5-C),
 
128.92 (benzoyl 3-C and 5-C), 131.41 
(phenoxy 3-C and 5-C), 131.72 (phenoxy C-4), 132.05 (benzoyl 2-C and 6-C), 
136.28 (benzoyl 1-C), 138.05 (benzyl 1-C), 138.85 (benzoyl 4-C), 158.62 
(phenoxy 1-C), 174.06 (amide C=O), 194.39 (ketone C=O).                                                        
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Melting point: 131.2 - 132.9°
HPLC: System 1,  Rt = 7.15 minutes. 
 System 2, Rt = 19.08 minutes. 
m/z:  HRMS (ES-TOF+)  C24H22O3NCl [MH]+ calculated 408.1361; found 
408.1647.  
FT-IR (KBr): 1503 (Arene), 1599 (Arene), 1658 C=O (amide), 2938 alkane, 
3359 N-H (amide).  
1-Piperidinyl-2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanamide (48g) 
Following General Method A, Fenofibrate-OSu (0.200 g, 0.481 mmol)and 1-
aminopiperidine (0.130 ml, 1.202 mmol) in DCM (10 ml)were reacted for 2 
hours 45 minutes to afford 48g (0.082 g, 0.204 mmol).  
Yield: 42%  
Appearance: Yellow-white solid 
1H NMR (CDCl3): 1.23-1.27 (m, 2H 
piperidinyl 4-CH2,), 1.61 (s, 6H, C(CH3)2), 1.66-1.71 (m, 4H, piperidinyl 3-
CH2 and 5-CH2), 2.68-2.70 (m, 4H, piperidinyl 2-CH2 and 6-CH2), 6.97 (d, 3J = 
8.8 Hz, 2H, phenoxy 2-H and 6-H) 7.11 (s, NH, 1H), 7.45 (d, 3J = 8.6 Hz, 2H, 
benzoyl 3-H and 5-H), 7.71 (d, 3J = 8.6 Hz, 2H, phenoxy 2-H and 6-H), 7.75 
(d, 3J = 8.6 Hz, 2H, benzoyl 2-H and 6-H).  
13C NMR (CDCl3): 23.22 (C(CH3)2,), 25.28 (CH2, piperidinyl C-4), 25.39 
(CH2, piperidinyl 3-C and 5-C), 56.82 (CH2, piperidinyl C-2 and C-6), 81.64 
(C(CH3)2), 119.16 (phenoxy 2-C and 6-C), 128.68 (benzoyl 3-C and 5-C), 
131.26 (phenoxy 3-C and 5-C), 131.50 (phenoxy C-4), 131.93 (benzoyl 2-C 
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and 6-C), 136.13 (benzoyl C-1), 138.71 (benzoyl C-4), 158.48 (phenoxy C-1), 
170.74 (amide C=O), 194.27 (ketone C=O).                                                              
Melting point: 152.9 - 153.8°
HPLC: System 1, Rt = 5.97 minutes. 
 System 2, Rt = 18.22 minutes 
m/z:  HRMS (ES-TOF+)  C22H25ClN2O3 [MH]+ calculated 401.1626; found 
401.1643.  
FT-IR (KBr): 1504 (Arene), 1598 (Arene), 1684 C=O (amide), 2856 (alkane), 
2941 (alkane), 3278 N-H (amide). 
N-Morpholino-2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanamide 
(48h) 
Following General Method A, Fenofibrate-OSu (0.208 g, 0.499 mmol)and 4-
aminomorpholine (0.097 ml, 0.998 mmol) in DCM (10 ml)were reacted for 31 
hours and 25 minutes to afford 48h (0.091 g, 0.227 mmol).  
Yield: 45% 
Appearance: White solid 
Purification: Column 
chromatography using 80 % EtOAc / 20 % hexane, and by preparative HPLC.  
1H NMR (CDCl3)  1.61 (s, 6H, C(CH3)2), 2.80 (t, 3J = 4.6 Hz, 4H, morpholino 
3-CH2 and 5-CH2), 3.80  (t, 3J = 4.6 Hz, 4H, morpholino 2-CH2 and 6-CH2), 
6.98 (d, 3J = 8.6 Hz, 2H, phenoxy 2-H and 6-H) 7.21 (s, NH, 1H), 7.46 (d, 3J = 
8.6 Hz, 2H, benzoyl 3-H and 5-H), 7.71(d, 3J = 8.6 Hz, 2H, phenoxy 3-H and 
5-H), 7.75 (d, 3J = 8.8 Hz, 2H, benzoyl 2-H and 6-H)   
13C NMR (CDCl3) 25.32 (C(CH3)2), 55.71 (morpholino 3-C and 5-C), 66.38 
(morpholino 2-C and 6-C) 81.72 (C(CH3)2), 119.39 (phenoxy 2-C and 6-C) 
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128.70 (benzoyl 3-C and 5-C), 131.25 (phenoxy 3-C and 5-C), 131.76 
(phenoxy C-4), 131.95 (benzoyl 2-C and 6-C), 136.06 (benzoyl C-1), 138.77 
(benzoyl C-4), 158.26 (phenoxy C-1), 171.22 (amide C=O) 194.21 (ketone 
C=O). 
Melting point: 145.6 - 146.1° 
HPLC: System 1, Rt = 5.27 minutes. 
 System 2, Rt=17.03 minutes 
m/z:  HRMS (ES-TOF+)  C21H23ClN2O4 [MH]+ calculated 403.1419; found 
403.1430.  
FT-IR (KBr): 1504 (Arene), 1598 (Arene), 1659 C=O (amide), 1681 (aryl 
ketone), 2844 alkane, 3207 N-H (amide), 3359 N-H (amide).  
N-(2-Pyrrolidino)ethyl-2-(4-(4-chlorobenzoyl)phenoxy)-2-
methylpropanamide (48i) 
Following General Method A, Fenofibrate-OSu (0.214 g, 0.516 mmol)and 1-
(2-aminoethyl) pyrrolidine (0.130 ml, 1.029 mmol) in DCM (10 ml) were 
reacted for 24 hours to afford 48h (0.091 g, 0.227 mmol).  
Yield: 75% 
Appearance: Yellow-white 
solid.  
Purification: Used without further purification. 
1H NMR (CDCl3)  1.62 (s, 6H, dimethyl CH3), 1.68 (broad s, 4H, pyrrolidine 
CH2), 2.42 (broad s, 2H, pyrrolidine CH2), 2.58 (broad s, 2H, ethylene CH2), 
3.39-3.40 (m, 2H, ethylene CH2), 6.97(d, 3J = 8.5 Hz, 2H, phenoxy 2H and 
6H), 7.46 (d, 3J = 8.5 Hz 2H, benzoyl 3H and 5H), 7.71 (d, 3J = 8.5 Hz, 2H, 
phenoxy 2H and 6H), 7.73 (d, 3J = 8.5 Hz, 2H, benzoyl 2H and 6H). 
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13C NMR (CDCl3)  23.76 (pyrrolidine C-3 and C-4), 25.64 (C(CH3)2), 38.11 
(ethyl CH2NH), 54.09 (pyrrolidine C-2 and C-5), 54.61 (ethyl CH2-N), 82.05 
(C(CH3)2), 119.32 (phenoxy 2-C and 6-C), 128.92 (benzoyl 3-C and 5-C),  
131.46 (phenoxy 3-C and 5-C) 131.50 (phenoxy C-4), 132.15 (benzoyl C-2 and 
C-6),  136.49 (benzoyl C-1) 138.89 (benzoyl C-4) 159.22 (phenoxy C-1) 
174.41 (amide C=O) 194.53 (ketone C=O). 
Melting point: 100.2-101.5° 
HPLC: System 1, Rt = 4.03 minutes 
 System 2, Rt = 12.00 minutes 
m/z:  HRMS (ES-TOF+)  C23H27ClN2O3 [MH]+ calculated 415.1783; found 
415.1762.  
FT-IR (KBr): 1511 (Arene), 1599 (Arene), 1679 C=O (amide), 2803 (alkane), 
2828 (alkane), 2873 (alkane), 2931 (alkane), 2961 (alkane), 2978 (alkane), 
3389 N-H (amide). 
N-(2-Morpholino)-ethyl-2-(4-(4-chlorobenzoyl)phenoxy)-2-
methylpropanamide (48j) 
Following General Method A, Fenofibrate-OSu (0.1019 g, 0.245 mmol)and 4-
(2-aminoethyl)-morpholine (0.064 ml, 0.490 mmol) in DCM (10 ml) were 
reacted for 2 hours and 40 minutes to afford 48j (0.064 g, 0.147 mmol).  
Yield: 60% 
Appearance: Yellow-white 
solid. 
Purification: Used without further purification. 
1H NMR (CDCl3) 1.63 (s, 6H, dimethyl CH3), 2.36-2.48 (m, 4H, morpholino 
CH2), 3.41-3.54 (m, 4H, morpholino CH2), 6.97 (d, 3J = 8.5 Hz, 2H, phenoxy 
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2-H and 6-H), 7.46 (d, 3J = 8.5 Hz, 2H, benzoyl 3-H and 5-H), 7.70 (d, 3J = 
8.5 Hz, 2H, phenoxy 2-H and 6-H), 7.74 (d, 3J = 8.5 Hz, 2H, benzoyl 2-H and 
6-H). 
13C NMR (CDCl3)  25.58 (C(CH3)2), 35.56 (ethyl CH2NH), 53.34 (morpholino 
3-C and 5-C) 57.05 (ethyl CH2NH) 66.50 (morpholino 2-C and 6-C) 81.98 
(C(CH3)2) 119.17 (phenoxy 2-C and 6-C), 128.94 (benzoyl 3-C and 5-C) 
131.47 (phenoxy 3-C and 5-C), 132.15 (benzoyl 2-C and 6-C) 136.36 (benzoyl 
1-C) 138.95 (benzoyl 4-C), 159.15 (phenoxy 1-C), 174.42 (amide C=O), 
194.42 (ketone C=O).                                                             
Melting point: 93.8-94.7°C 
HPLC: System 1, Rt = 3.93 minutes 
 System 2, Rt = 12.03 minutes 
m/z:  HRMS (ES-TOF+)  C23H27ClN2O4 [MH]+ calculated 431.1732; found 
431.1778.          
FT-IR (KBr): 1511 (Arene), 1600 (Arene), 1677 C=O (amide), 2815 (alkane), 
2854 (alkane), 2937 (alkane), 2952 (alkane), 2968 (alkane), 2978 (alkane), 
3397 N-H (amide).  
N-tert-Butyl-2-(4-(chlorobenzoyl)phenoxy)-methylpropanamide (48k) 
Following General Method A, Fenofibrate-OSu (0.127 g, 0.304 mmol) and 
tert-butylamine (0.045 ml, 0.608 mmol) in DCM (10 ml)were reacted for 22 
hours 40 minutes to afford 48k (0.089 g, 
0.238 mmol).  
Yield: 78% 
131 
Appearance: Pale orange-yellow solid. 
Purification: Used without further purification. 
1H NMR (CDCl3) 1.34 (s, 9H, tert-butyl CH3), 1.57 (s, 6H, dimethyl CH3), 
6.96 (d, 3J = 8.8 Hz, 2H, phenoxy 2H and 6H), 7.46 (d, 3J = 8.8 Hz, 2H, 
benzoyl 3-H and 5H), 7.72 (d, 3J = 8.8 Hz, 2H, phenoxy 2H and 6H) 7.76 (d, 
3J = 8.8 Hz, 2H, benzoyl 2H and 6H). 
13C NMR (CDCl3) 25.10 (C(CH3)2), 28.45 (C(CH3)3), 51.04 (C(CH3)3) 81.95 
(C(CH3)2), 119.06 (phenoxy 2-C and 6-C) 128.56 (benzoyl 3-C and 5-C) 
131.14 (phenoxy 3-C and 5-C), 131.26 (phenoxy C-4), 131.80 (benzoyl 2-C 
and 6-C) 136.13 (benzoyl 1-C) 138.54 (benzoyl 4-C), 158.64 (phenoxy 1-C), 
173.01 (amide C=O), 194.18 (ketone C=O). 
Melting point: 128.1 - 129.0 °C 
HPLC: System 1, Rt =7.20  minutes 
 System 2, Rt = 19.49 minutes 
m/z:  HRMS (ES-TOF+)  [MH]+ C23H27ClN2O4 calculated 374.1517; found 
374.1512.  
FT-IR (KBr): 1503 (Arene), 1599 (Arene), 1672 C=O (amide), 2933 (alkane), 
2976 (alkane), 3371 N-H (amide), 3359 N-H (amide). 
N-(4-Methylpiperazinyl)-2-(4-(4-chlorobenzoyl)phenoxy)-2-
methylpropanamide (48l) 
To a suspension of fenofibric 
acid (10b) (0.0507g, 
0.157mmol) in toluene (7ml), 
thionyl chloride (0.037g, 0.314mmol) was added. The mixture was heated to 
95°C for 1 hour 15 minutes. The solvent and excess thionyl chloride were 
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removed under high vacuum which gave an off white solid. This was used 
directly in the next step to form the amide. The acid chloride was redissolved 
in dry dichloromethane (7ml) and 1-amino-4-methyl-piperazine was added. 
The flask was covered in foil to prevent light entering and the reaction was left 
stirring for 1 hour 25 minutes. The solvent was then removed under vacuum. 
Yield: 64% 
Appearance: Yellow-white solid 
Purification: Column chromatography 95 % DCM / 5 % MeOH to 80 % 
DCM / 20 % MeOH over 25 minutes. 
1H NMR (CDCl3): 1.61 (s, 6H, C(CH3)2), 2.29 (s, 3H,  4-methylpiperazine 
CH3), 2.57 (broad s, 4H, 4-methylpiperazine CH2), 2.79 ( broad s, 4H, 4-
methylpiperazine CH2), 6.98 (d, 3J = 8.8 Hz, 2H, phenoxy 2-H and 6-H), 7.11 
(s, 1H, NH), 7.46 (d, 3J = 8.8 Hz, 2H, benzoyl 3-H and 5-H), 7.71 (d, 3J = 8.8 
Hz, 2H, phenoxy 3-H and 5-H), 7.75 (d, 3J = 8.8 Hz, 2H, 2-H and 6-H).  
13C NMR (CDCl3): 25.64 (C(CH3)2), 46.00 (piperazine CH3), 54.50 
(piperazine 2-C and 6-C), 55.50 (piperazine 3-C and 5-C), 81.99 (C(CH3)2), 
119.62 (phenoxy 2-C- and 6-C), 128.97 (benzoyl 3-C and 5-C), 131.54 
(phenoxy 3-C and 5-C), 131.95 (phenoxy 4-C), 132.23 (benzoyl 2-C and 6-C), 
136.39 (benzoyl 1-C), 139.01 (benzoyl 1-C), 158.64 (phenoxy 4-C), 171.34 
(amide C=O) 194.18 (ketone C=O). 
Melting point: 149.7-150.8 °C
HPLC: System 1, Rt =3.82  minutes.
 System 2, Rt = 11.92 minutes. 
m/z:  HRMS (ES-TOF+)  C22H26ClN3O3 [MH]+ calculated 416.1735; found 
416.1759.  
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FT-IR (KBr): 1505 (Arene), 1597 (Arene), 1692 C=O (amide), 2767 (alkane), 
2794 (alkane), 2842 (alkane), 2874 (alkane) 2938 (alkane), 3359 N-H (amide). 
N-(4-(2-Hydroxyethyl)phenyl)-2-(4-(4-chlorobenzoyl)phenoxy)-2-
methylpropanamide (48m) 
To a suspension of fenofibric acid (10b) (0.0507, 0.162mmol) an excess of 
thionyl chloride (5ml) was  
added. The mixture was 
heated at 60°C for 1 hour 
15 minutes. The thionyl 
chloride was removed under high vacuum which gave an off white solid 
(0.0413g, 0.122mmol). This was used directly in the next step to form the 
amide. The acid chloride was redissolved in dry dichloromethane (3ml), and 
cooled to 0°C. 2-(-4-aminophenyl)ethanol and triethylamine (0.016ml) were 
dissolved in dichloromethane (4ml) and DMF (0.2ml) was added as the amine 
was insoluble. The mixture of 2-(-4-aminophenyl)ethanol and triethylamine 
was then slowly added to the acid chloride and the mixture was stirred for 1 
hour 15 minutes. The reaction mixture was washed with 2M HCl (5ml) and the 
solvent was removed under vacuum. 
Yield: 38% 
Appearance: Yellow-white solid 
Purification: Column chromatography 10 % MeOH : 90 % DCM 
1H NMR (CDCl3): 1.62 (s, 6H, C(CH3)2), 2.84 (t, 3J = 6.7 Hz, 2H, ethylene 
CH2 next to phenyl), 3.50 (s, 1H, OH) 3.86 (d of t, 3J = 5.2 Hz, 3J = 6.6 Hz, 
2H, ethylene CH2 next to NH), 7.04 (d, 3J = 8.2 Hz, phenoxy 2-H and 6-H), 
7.21 (d, 3J = 8.2 Hz, phenyl 2-H and 6-H), 7.46 (d, 3J = 8.2 Hz, benzoyl 3-H 

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and 5-H ), 7.48 (d, 3J = 8.2 Hz, phenyl 3-H and 5-H), 7.71 (d, 3J = 8.2 Hz, 
phenoxy 3-H and 5-H), 7.77 (d, 3J = 8.2 Hz, benzoyl 2-H and 6-H), 8.25 (s, 
1H, NH). 
13C NMR (CDCl3): 25.11(C(CH3)2), 38.59 (CH2CH2OH), 63.61 
(CH2CH2OH), 82.37 (C(CH3)2), 119.93 (phenoxy 2-C and 6-C), 120.20 
(phenyl 3-C and 5-C), 128.65 (benzoyl 3-C and 5-C), 129.64 (phenyl 2-C and 
6-C), 131.22 (phenoxy 3-C and 5-C), 132.00 (phenoxy 4-C), 132.07 (benzoyl 
2-C and 6-C), 135.07 (phenyl 1-C), 135.67 (phenyl 4-C), 136.00 (benzoyl 1-C), 
138.72 (benzoyl 4-C), 158.72 (phenoxy 1-C),  172.16 (amide C=O, 194.18 
(ketone C=O). 
Melting point: 61.0 - 62.3 °C
HPLC: System 1, Rt = 6.24 minutes.
 System 2, Rt = 18.02 minutes. 
m/z:  HRMS (ES-TOF+)  C25H24ClNO4 [MH]+ calculated 438.1467; found 
438.1483.  
FT-IR (KBr): 1505 (Arene), 1598 (Arene), 1669 C=O (amide), 2936 (alkane), 
3395 N-H (amide). 
N-(Phenyl)-2-(4-(4-chlorobenzoyl) phenoxy)-2-methylpropanamide (48n) 
Following General Method B, Fenofibric acid (0.200 g, 0.627 mmol)and an 
excess of thionyl chloride (7ml)were reacted for 1 hours and 30 minutes to 
afford the corresponding acid chloride (0.211 g, 0.625 mmol).  The acid 
chloride was then reacted directly with 
aniline (0.117g, 0.625 mmol) and 
triethylamine (0.118 ml, 0.625 mmol) 
in DCM (10 ml) to afford 49n. 
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Yield: 66%  
Appearance: Yellow-orange solid 
1H NMR (CDCl3): 1.69 (s, 6H, C(CH3)2,), 7.05 (d, 3J = 8.8 Hz, 2H, phenoxy 
2-H and 6-H), 7.14 (dd, 3J = 7.4 Hz, 4J = 7.4 Hz, 1H, phenyl 4-H), 7.34 (dd, 3J 
= 7.4 Hz and 4J = 7.4 Hz, 2H, phenyl 3-H and 5-H), 7.45 (d, 3J = 8.6 Hz, 2H, 
benzoyl 3-H and 5-H), 7.52-7.56 (m, 2H, phenyl 2-H and 6-H), 7.72 (d, 3J = 
8.6 Hz, 2H, phenoxy 3-H and 5-H), 7.77 (d, 3J = 8.8 Hz, 2H, benzoyl 2-H and 
6-H), 8.28 (s, 1H, NH).  
13C NMR (CDCl3): 25.45 (C(CH3)2), 82.75 (C(CH3)2), 120.22 (phenoxy 2-C 
and 6-C), 120.36 (pheny1 2-C and 6-C) 125.07 (phenyl 4-C), 128.99 (benzoyl 
3-C and 5-C), 129.46 (phenoxy 3-C and 5-C), 131.57 (phenoxy 4-C), 132.35 
(benzoyl 2-C and 6-C), 132.45 (phenoxy 4-C) 136.32 (benzoyl 1-C), 137.56 
(benzoyl 4-C), 139.06 (phenyl 1-C), 158.51 (phenoxy 1-C), 172.51 (amide 
C=O), 194.52 (ketone C=O).  
Melting point: 144 – 146 °C 
HPLC: System 1, Rt = 7.15 minutes
 System 2, Rt = 19.30 minutes 
   System 3, Rt = 3.12 minutes 
    System 4, Rt = 3.11 minutes  
m/z:  HRMS (ES-TOF+) C23H20ClNO3 [MH]+ calculated 394.1204; found 
394.1299.  
N-(2-Fluorobenzyl)-2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanamide 
(50a) 
 
Following General Method B, Fenofibric acid (0.112 g, 0.350 mmol)and an 
excess of thionyl chloride (5ml)were reluxed for 1 hours and 30 minutes to 
afford the corresponding acid chloride (0.118 g, 0.350 mmol).  The acid 
136 
chloride was then reacted directly with 2-fluorobenzylamine (0.04 ml, 0.350 
mmol) and triethylamine (0.054 ml, 0.385 mmol) in DCM (6 ml) to afford 50a. 
Yield: 47% 
Appearance: Yellow-white solid 
Purification: PLC, 3% EtOH/ 97% 
DCM 
1H NMR (CDCl3): 1.60 (s, C(CH3)2, 6H), 4.51 (d, 3J =  6.1 Hz, 2H, benzylic 
CH2), 6.83 (t, 3J = 5.9 Hz, 1H, NH), 6.88 (d, 3J = 8.8 Hz, 2H, phenoxy 2-H and 
6-H), 6.97 (ddd, 3J = 9.9 Hz, 3J = 8.5 Hz, 1H, 2-fluorobenzyl 5-H), 7.08 (ddd, 
3J = 7.5 Hz, 3JHF = 7.5 Hz, 4J = 1.1 Hz, 2-fluorobenzyl 6-H), 7.21 – 7.28 (m, 
1H, 2-fluorobenzyl 3-H), 7.30 (ddd, 1H 3J = 7.5 Hz, 3J = 7.5 Hz, 4JHF = 1.7 Hz, 
2-fluorobenzyl 4-H), 7.45 (d, 3J = 8.6 Hz, 2H, benzoyl 3-H and 5-H), 7.67 (d, 
3J = 8.8 Hz 2H, phenoxy 3-H and 5-H) 7.69 (d, 3J = 8.6 Hz, 2H, benzoyl 2-H 
and 6-H).  
13C NMR (CDCl3): 25.22 (C(CH3)2), 37.70 (benzyl CH2), 81.86 (C(CH3)2, 
115.42 (d, 2JCF = 21Hz, 2-fluorobenzyl 3-C), 119.27 (phenoxy 2-C and 6-C), 
124.29 (d, 4JCF = 4Hz, 2-fluorobenzyl 5-C), 124.78 (d, 2JCF=15 Hz, 2-
fluorobenzyl 4-C), 128.61 (benzoyl 3-C and 5-C),  129.48 (d, 3JCF=8 Hz, 2-
fluorobenzyl 5-C), 130.35 (d, 4JCF = 4 Hz, 2-fluorobenzyl), 131.22 (phenoxy 3-
C and 5-C), 131.33 (d, 2JCF = 22 Hz, 2-fluorobenzyl 1-C), 131.82 (benzoyl 2-C 
and 6-C), 136.12 (benzoyl 1-C), 138.63 (benzoyl 4-C), 158.42 (phenoxy 1-C), 
161.03 (d,1JCF = 246Hz, 2-fluorobenzyl 2-C), 173.95 (amide C=O), 194.18 
(ketone C=O).    
Melting point: 110-112 °C
HPLC: System 1, Rt = 7.00  minutes.
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 System 2, Rt = 19.15  minutes. 
m/z:  HRMS (ES-TOF+) C24H21ClFNO3 [MH]+ calculated 426.1261; found 
426.1318.       
FT-IR (KBr): 3367 (amide NH), 2973, 2942 (CH3 stretch), 1689 (amide 
C=O), 1645 (ketone C=O), 1534 (aryl CH stretch), 856 (para disubstituted 
ring). 
N-(3-Fluorobenzyl)-2-(4-(4-chlorobenzoyl)phenoxy)-2methylpropanamide 
(50b) 
Following General Method B, Fenofibric acid (0.112 g, 0.350 mmol)and an 
excess of thionyl chloride (5ml)were refluxed for 1 hours and 30 minutes to 
afford the corresponding acid chloride (0.118 g, 0.350 mmol).  The acid 
chloride was then reacted directly with 3-fluorobenzylamine (0.04 ml, 0.350 
mmol) and triethylamine (0.054 ml, 0.350 mmol) in DCM (6 ml) to afford 50b. 
Yield: 47% 
Appearance: Yellow-white solid 
Purification: PLC 5% EtOH / 95% DCM 
1H NMR (CDCl3): 1.64 (s, 6H, C(CH3)2), 4.48 (d, 3J = 6.0 Hz, 2H, benzylic 
CH2), 6.84 (t, NH, 1H, 3J = 5.6 Hz), 6.87-7.13 (m, 5H, phenoxy 2-H and 6-H, 
3-fluorobenzyl 2-H/4-H/6-H), 7.22 – 7.29 (m, 1H, 3-fluorobenzyl 5-H), 7.46 
(d, 3J = 8.6 Hz, 2H benzoyl 3-H and 5-H), 7.71 (d, 3J = 8.5 Hz, 2H, phenoxy 3-
H and 5-H), 7.72 (d, 3J = 8.8 Hz, 2H, benzoyl 2-H and 6-H). 
13C NMR (CDCl3): 25.27 (C(CH3)2), 42.94 (benzyl CH2), 81.91 (C(CH3)2), 
114.51 (d, 2J = 21.0 Hz, 3-fluorobenzyl 4-C), 119.44 (phenoxy 2-C and 6-C), 
123.25 (d, 4J = 2.0 Hz, 3-fluorobenzyl 6-C), 128.64 (benzoyl 3-C and 5-C), 
131.76 (d, 2JCF = 26.0 Hz, 3-fluorobenzyl 2-C), 136.06 (benzoyl 1-C), 140.49 
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(d, 3J = 8.0 Hz, 3-fluorobenzyl 5-C), 158.34 (phenoxy 1-C), 162.94 (d, 1JCF = 
246 Hz, 3-fluorobenzyl 3-C).  
Melting point: 99-102 °C
HPLC: System 1, Rt = 9.99  minutes.
 System 2, Rt = 19.17  minutes. 
m/z:  HRMS (ES-TOF+) C24H21ClFNO3 [MH]+ calculated 426.1261; found 
426.1345. 
FT-IR (KBr): 3377 (amide NH), 2973, 2934 (CH3 stretch), 1683 (amide 
C=O), 1650 (ketone C=O), 1535 (aryl CH stretch), 838 (para disubstituted 
ring). 
N-(4-Fluorobenzyl)-2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanamide 
(50c) 
Following General Method B, Fenofibric acid (0.112 g, 0.350 mmol)and an 
excess of thionyl chloride (5ml)were refluxed for 1 hours and 30 minutes to 
afford the corresponding acid chloride (0.118 g, 0.350 mmol).  The acid 
chloride was then reacted directly with 4-fluorobenzylamine (0.04 ml, 0.350 
mmol) and triethylamine (0.054 ml, 0.350 mmol) in DCM (6 ml) to afford 50c. 
Yield: 48% 
Appearance: Yellow-white solid 
Purification: PLC, 3.5% EtOH / 96.5 % DCM. 
1H NMR (CDCl3): 1.62 (s, 6H, C(CH3)2), 4.44 (d, 3J = 6.0 Hz, 2H, benzylic 
CH2), 6.79 (t, 3J = 5.8 Hz, 1H, NH), 6.92 (d, 3J = 8.8 Hz, 2H, phenoxy 2-H and 
6-H), 6.98 (dd, 2H, 3J = 8.6 Hz, 3JHF = 8.6 Hz, 4-fluorobenzyl 3-H and 5-H), 
7.19 (dd, 2H, 3J = 8.8 Hz, 4JHF = 5.3 Hz, 4-fluorobenzyl 2-H and 6-H), 7.46 (d, 
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3J = 8.6 Hz, 2H, benzoyl 3-H and 5-H), 7.69 (d, 3J = 8.6 Hz, 2H, phenoxy 3-H 
and 5-H)  7.71 (d, 2H, 3J = 8.8 Hz, benzoyl 2-H and 6-H).      
13C NMR (CDCl3): 25.24 (C(CH3)2), 42.80 (benzylic CH2), 81.93 (C(CH3)2), 
115.58 (d, 2JCF = 21Hz, 4-fluorobenzyl 3-C and 5-C), 119.49 (phenoxy 2-C and 
6-C), 128.65 (benzoyl 3-C and 5-C), 129.48 (d, 3JCF = 8Hz, 4-fluorobenzyl 2-C 
and 6-C), 131.20 (phenoxy 3-C and 5-C), 131.61 (phenoxy 4-C), 131.85 
(benzoyl 2-C and 6-C), 133.76 (d, 4JCF = 3Hz, 4-fluorobenzyl 1-C), 136.04 
(benzoyl 4-C), 138.70 (benzoyl 4-C), 158.36 (amide C=O), 162.21 (d, 1JCF =  
246Hz, 4-fluorobenzyl 4-C), 194.16 (ketone C=O). 
Melting point: 105-107 °C
HPLC: System 1, Rt = 6.95 minutes.
 System 2, Rt = 19.22  minutes. 
m/z:  HRMS (ES-TOF+) C24H21ClFNO3 [MH]+ calculated 426.1261; found 
426.1329.  
FT-IR (KBr): 3370 (amide NH), 2973, 2926 (CH3 stretch), 1684 (amide 
C=O), 1648 (ketone C=O), 1536 (aryl CH stretch). 
N-(2-Methylbenzyl)-2-(4-(4-chlorobenzoyl)phenoxy)-2-
methylpropanamide (50d) 
Following General Method B, Fenofibric acid (0.112 g, 0.350 mmol)and an 
excess of thionyl chloride (5ml)were refluxed for 1 hours and 30 minutes to 
afford the corresponding acid chloride (0.118 g, 0.350 mmol).  The acid 
chloride was then reacted directly with 2-methylbenzylamine (0.04 ml, 0.350 
mmol) and triethylamine (0.054 ml, 0.350 mmol) in DCM (6 ml) to afford 50d. 
Yield: 34% 
Appearance: White semi solid 
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Purification: PLC, 6% EtOH / 94 % DCM. 
1H NMR (CDCl3): 1.63 (s, 6H, C(CH3)2), 2.25 (s, 3H,  2-methylbenzyl CH3), 
4.47 (d, 3J =  5.6 Hz, 2H, benzylic, CH2), 6.66 (t, 3J = 4.9 Hz, 1H, NH), 6.93 
(d, 3J = 8.8 Hz, 2H, phenoxy 2H and 6H), 7.10-7.21 (m, 4H, 2-methylbenzyl 
3-H 4-H 5-H and 6-H), 7.45 (d, 3J = 8.6 Hz, 2H, benzoyl 3H and 5H), 7.66-
7.71 (m, 4H, phenoxy 3-H and 5-H and benzoyl 2-H and 6-H)  
13C NMR (CDCl3): 19.09 (2-methyl benzyl CH3), 25.43 (C(CH3)2), 41.92 
(benzylic CH2), 82.13 (C(CH3)2), 119.62 (phenoxy 2-C and 6-C), 126.36 (2-
methyl benzyl 6-C), 128.04 (2-methyl benzyl 5-C), 128.74 (2-methyl benzyl 4-
C), 128.77 (benzoyl 3-C and 5-C), 130.72 (phenoxy 4-C), 131.36 (phenoxy 3-
C and 5-C), 131.71 (2-methyl benzyl 3-C), 132.01 (benzoyl 2-C and 6-C), 
135.52 (2-methyl benzyl 2-C), 136.24 (benzoyl 1-C), 136.54 (2-methyl benzyl 
1-C), 138.80 (benzoyl 4-C), 158.57 (phenoxy 1-C), 173.85 (amide C=O), 
194.33 (ketone C=O).  
Melting point: N/A
HPLC: System 1, Rt = 7.22 minutes.
 System 2, Rt = 19.75  minutes. 
m/z:  HRMS (ES-TOF+) C25H24ClNO3 [MH]+ calculated 422.1512; found 
422.1487.  
FT-IR (KBr): 3345 (amide NH), 2980, 2934 (CH3 stretch), 1665 (amide 
C=O), 1603 (ketone C=O), 1525 (aryl CH stretch), 854 (para disubstituted 
aromatic ring). 
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N-(3-Methylbenzyl)-2-(4-(4-chlorobenzoyl)phenoxy)-2-
methylpropanamide (50e) 
Following General Method B, Fenofibric acid (0.112 g, 0.350 mmol)and an 
excess of thionyl chloride (5ml)were refluxed for 1 hours and 30 minutes to 
afford the corresponding acid chloride (0.118 g, 0.350 mmol).  The acid 
chloride was then reacted directly with 3-methylbenzylamine (0.04 ml, 0.350 
mmol) and triethylamine (0.054 ml, 0.350 mmol) in DCM (6 ml) to afford 50e. 
Yield: 59% 
Appearance: Yellow-white solid 
Purification: PLC, 6% EtOH / 94 % DCM 
1H NMR (CDCl3): 1.63 (s, 6H, C(CH3)2), 2.27 (s, 3H, 3-methylbenzyl CH3), 
4.44 (d, 3J = 5.9 Hz, 2H, benzylic CH2), 6.81 (t, 3J = 5.3 Hz, 1H, NH), 6.93 (d, 
3J = 8.8 Hz, 2H, phenoxy 2-H and 6-H), 6.97-7.08 (m, 3H, 3-methylbenzyl 2-
H, 4-H and 6-H), 7.17 (dd, 3J = 7.9 Hz, 3-methylbenzyl 5-H), 7.44 (d, 3J =  8.5 
Hz, 2H, benzoyl 3-H and 5-H), 7.68 (d, 3J = 8.5 Hz, 2H, phenoxy 3-H and 5-
H), 7.70 (d, 3J = 8.8 Hz, 2H, benzoyl 2H and 6H). 
13C NMR (CDCl3): 21.41 (3-methylbenzyl CH3), 25.35 (C(CH3)2), 43.58 
(benzylic CH2), 81.96 (C(CH3)2), 119.44 (phenoxy 2-C and 6-C), 124.82 (3-
methylbenzyl 6-C), 128.37 (3-methylbenzyl 5-C), 128.56 (3-methylbenzyl C-
5), 128.67 (benzoyl 3-C and 5-C), 131.25 (), 131.49 (phenoxy 3-C and 5-C), 
131.92 (phenoxy C-4), 136.19 (benzoyl 1-C), 137.87 (3-methylbenzyl 1-C), 
138.46 (3-methylbenzyl 3-C), 138.67 (benzoyl 4-C), 158.59 (phenoxy 1-C), 
194.86 (ketone C=O) 
Melting point: 67-70 °C
HPLC: System 1, Rt = 7.22 minutes.
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 System 2, Rt = 19.72  minutes. 
m/z:  HRMS (ES-TOF+) C25H24ClNO3 [MH]+ calculated 422.1512; found 
422.1556.  
FT-IR (KBr): 3345 (amide NH), 2988, 2926 (CH3 stretch), 1683 (amide 
C=O), 1648 (ketone C=O), 855 (para disubstituted aromatic ring).  
N-(4-Methylbenzyl)-2-(4-(4-chlorobenzoyl)phenoxy)-2-
methylpropanamide (50f) 
Following General Method B, Fenofibric acid (0.112 g, 0.350 mmol)and an 
excess of thionyl chloride (5ml)were refluxed for 1 hours and 30 minutes to 
afford the corresponding acid chloride (0.118 g, 0.350 mmol).  The acid 
chloride was then reacted directly with 4-methylbenzylamine (0.04 ml, 0.350 
mmol) and triethylamine (0.054 ml, 0.350 mmol) in DCM (6 ml) to afford 50f. 
Yield: 59% 
Appearance: Yellow-white solid 
Purification: PLC, 6 % MeOH / 94 % DCM 
1H NMR (CDCl3): 1.63 (s, 6H, C(CH3)2), 2.31 (s, 3H, 4-methylbenzyl CH3), 
4.44 (d, 3J = 5.8 Hz, 2H, benzylic CH2), 6.72 (t, 3J = 5.4 Hz, 1H, NH), 6.92 (d, 
3J = 8.8 Hz, 2H, phenoxy 2-H and 6-H), 7.10 (s, 4H, 4-methylbenzyl aromatic 
CH), 7.45 (d, 3J = 8.6 Hz, 2H, benzoyl 3H and 5H), 7.65-7.75 (m, 4H, 
phenoxy 3H and 5H and 2H and 6H).  
13C NMR (CDCl3): 21.09 (4-methylbenzyl CH3), 25.28 (C(CH3)2), 43.33 
(benzylic CH2), 81.94 (C(CH3)2), 119.46 (phenoxy 2-C and 6-C), 127.77 (4-
methylbenzyl 2-C and 6-C), 128.63 (benzoyl 3-C and 5-C), 129.39 (4-
methylbenzyl 3-C and 5-C), 131.22 (phenoxy 3-C and 5-C), 131.49 (phenoxy 
4-C), 131.86 (benzoyl 2-C and 6-C), 134.81 (4-methylbenzyl 1-C), 136.12 
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(benzoyl 1-C), 137.36 (4-methylbenzyl 4-C), 138.64 (benzoyl 4-C), 158.48 
(phenoxy 1-C), 173.79 (amide C=O), 194.21 (ketone C=O). 
Melting point: 115-118 °C 
HPLC: System 1, Rt = 7.22 minutes.
 System 2, Rt = 19.72  minutes. 
m/z:  HRMS (ES-TOF+) C25H24ClNO3 [MH]+ calculated 422.1512; found 
422.1555.  
FT-IR (KBr): 3351 (amide NH), 3004, 2919 (CH3 stretch), 1671 (amide 
C=O), 1650 (ketone C=O), 1540 (aryl CH stretch), 853, 830 (para 
disubstituted aromatic ring) 
N-(2-Fluorophenyl)-2-(4-(4-chlorobenzoyl)phenoxy)-2-
methylpropanamide (51a) 
Following General Method B, Fenofibric acid (0.1008 g, 0.314 mmol)and an 
excess of thionyl chloride (5ml)were refluxed for 1 hours and 30 minutes to 
afford the corresponding acid chloride (0.107 g, 0.317 mmol).  The acid 
chloride was then reacted directly with 2-fluoroaniline (0.03 ml, 0.317 mmol) 
and triethylamine (0.05 ml, 0.317 mmol) in DCM (6 ml) to afford 51a. 
Yield: 50% 
Appearance: Yellow-white solid 
Purification: PLC, 70 % EtOAc : 30% 
hexane. 
1H NMR (CDCl3): 1.70  (s, 6H, C(CH3)2), 7.05-7.12 (m, 4H, phenoxy 2-H 
and 6-H and 2-fluorophenyl 3-H and 5-H), 7.13-7.20 (m, 1H, 2-fluorophenyl  
4-H), 7.45 (d, 3J =  8.6 Hz, 2H, benzoyl 3-H and 5-H,), 7.72 (d, 3J = 8.5 Hz, 
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2H, phenoxy 3-H and 5-H), 7.77 (d, 3J = 8.5Hz, 2H, benzoyl 2-H and 6-H), 
8.34 (m, 1H, 2-fluorophenyl 6-H), 8.61(s, 1H, NH).      
13C NMR (CDCl3): 25.26 (C(CH3)2), 82.66 (C(CH3)2), 115.1277 (d, 2JCF = 
18.9 Hz, 2-fluorophenyl 3-C), 120.30 (phenoxy 2-C and 6-C), 121.76 (2-
fluorophenyl 1-C), 124.79 (d, 4JCF = 3.7 Hz, 2-fluorophenyl 5-C), 125.00 (d, 
3JCF = 7.6 Hz, 2-fluorophenyl 6-C), 125.92 (d, 3JCF = 10.2 Hz, 2-fluorophenyl 
4-C), 128.79 (benzoyl 3-C and 5-C), 131.40 (phenoxy 3-C and 5-C), 132.12 
(benzoyl 2-C and 6-C), 132.36 (benzoyl 4-C), 137.52 (d, 1JCF = 271.5 Hz, 2-
fluorophenyl 2-C), 158.27 (phenoxy 1-C), 172.53 (amide C=O), 194.37 
(ketone C=O).  
Melting point: 92-95 °C
HPLC: System 1, Rt = 7.42 minutes.
 System 2, Rt = 19.50 minutes. 
m/z:  HRMS (ES-TOF+) C23H19ClFNO3 [MH]+ calculated 412.1110; found 
412.1148.  
FT-IR (KBr): 3270 (amide NH), 2991, 2981 (CH3 stretch), 1704 (amide 
C=O), 1634 (ketone C=O), 1600 (aryl CH stretch), 857 (para disubstituted 
ring). 
N-(3-Fluorophenyl)-2-(4-(4-chlorobenzoyl)phenoxy)-2-
methylpropanamide (51b) 
 
Following General Method B, Fenofibric acid (0.100 g, 0.314 mmol)and an 
excess of thionyl chloride (5ml)were refluxed for 1 hours and 30 minutes to 
afford the corresponding acid chloride (0.109 g, 0.323 mmol).  The acid 
chloride was then reacted directly with 3-fluoroaniline (0.03 ml, 0.32 mmol) 
and triethylamine (0.05 ml, 0.355 mmol) in DCM (6 ml) to afford 51b. 
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Yield: 26% 
Appearance: Yellow-white solid 
Purification: PLC 2.5% ethanol / 
97.5% DCM.   
1H NMR (CDCl3): 1.67 (s, C(CH3)2, 6H),  6.84-6.85 (m, 1H, 3-fluorophenyl 
4-H), 7.04 (d, 3J = 8.8 Hz, 2H, phenoxy 2-H and 6-H), 7.15-7.17 (m, 1H, 3-
fluorophenyl 6-H), 7.24-7.32 (m, 3H, 3-fluorophenyl 5-H), 7.46 (d, 3J = 8.5 
Hz, 2H, benzoyl 3-H and 5H), 7.25-7.29 (m, 1H, 3-fluorophenyl 2-H), 7.72 (d, 
3J = 8.5 Hz, 2H, phenoxy 3-H and 5-H), 7.78 (d, 3J = 8.8 Hz, 2H, benzoyl 2H 
and 6H ), 8.35 (broad s, NH, 1H).  
13C NMR (CDCl3): 25.19 (C(CH3)2), 82.62 (C(CH3)2), 107.53 (d, 2JCF = 27Hz, 
3-fluorophenyl 2-C/4-C), 111.53 (d, 2JCF =21Hz, 3-fluorophenyl 2-C/4-C), 
115.23 (d, 4JCF = 2Hz, fluorophenyl 5-C), 120.40 (phenoxy 2-C and 6-C), 
128.81 (benzoyl 3-C and 5-C),  130.33 (d, 3JCF=9Hz, fluorophenyl 4-C), 
131.37 (phenoxy 3-C and 5-C), 132.14 (benzoyl 2-C and 6-C), 132.52 
(phenoxy C-4), 136.09 (benzoyl 1-C), 138.93 (benzoyl 4-C), 158.09 (phenoxy 
1-C), 172.46 (amide C=O), 194.27 (ketone C=O). 
Melting point: 100 - 102 °C
HPLC: System 1, Rt = 7.45 minutes.
 System 2, Rt = 19.75 minutes. 
m/z:  HRMS (ES-TOF+) C23H19ClFNO3 [MH]+ calculated 412.1110; found 
412.1215.  
FT-IR (KBr): 3270 (amide NH), 2994, 2983 (para disubstituted), 1686 (amide 
C=O), 1637 (ketone C=O), 1603 (aryl CH stretch), 853, 840 (para disubstituted 
aromatic ring). 
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N-(4-Fluorophenyl)-2-(4-(4-chlorobenzoyl)phenoxy)-2-
methylpropanamide (51c) 
Following General Method B, Fenofibric acid (0.999 g, 0.313 mmol)and an 
excess of thionyl chloride (5ml)were refluxed for 1 hours and 30 minutes to 
afford the corresponding acid chloride (0.118 g, 0.350 mmol).  The acid 
chloride was then reacted directly with 4-fluoroaniline (0.03 ml, 0.350 mmol) 
and triethylamine (0.05 ml, 0.385 mmol) in DCM (6 ml) to afford 51c.  
Yield: 35% 
Appearance: Yellow white solid 
Purification: PLC 2.5% EtOH/ 97.5 
% DCM 
1H NMR (CDCl3): 1.67 (s, C(CH3)2, 6H), 6.99 (m, 4H, phenoxy 2-H and 6-H 
and 4-fluorophenyl 3-H and 5-H), 7.45 (d, 3J = 8.5 Hz, 2H, benzoyl 3-H and 5-
H), 7.47-7.53 (m, 2H, 4-fluorophenyl 2-H and 6-H), 7.71 (d, 3J = 8.5 Hz, 2H, 
phenoxy 3-H and 5-H), 7.76 (d, 3J = 8.8 Hz, 2H, benzoyl 2H and 6H), 8.31 
(broad s, 1H, NH).   
13C NMR (CDCl3): 25.23 (C(CH3)2), 82.57 (C(CH3)2), 115.92 (d, 2JCF = 22 
Hz, 4-fluorophenyl 3-C and 5-C), 120.29 (phenoxy 2-C and 6-C), 121.97 (d, 
3JCF = 7.8 Hz, 4-fluorophenyl 2-C and 6-C), 128.81 (benzoyl 3-C and 5-C), 
131.37 (benzoyl 2-C and 6-C), 132.14 (phenoxy 2-C and 6-C), 132.38 
(phenoxy 4-C), 133.36 (d, 4JCF = 2.8 Hz, 4-fluorophenyl 1-C), 136.09 (benzoyl 
4-C), 138.91 (benzoyl 1-C), 158.21 (phenoxy 1-C), 159.74 (d, 1JCF = 283.9 Hz, 
4-fluorophenyl 4-C) 172.32 (amide C=O), 194.30 (ketone C=O). 
 Melting point: 148-151 °C
HPLC: System 1, Rt = 7.27 minutes.
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 System 2, Rt = 19.39 minutes. 
m/z:  HRMS (ES-TOF+) C23H19ClFNO3 [MH]+ calculated 412.1110; found 
412.1200.          
FT-IR (KBr): 3326 (amide NH), 2990, 2976 (CH3 stretch), 1680 (amide 
C=O), 1636 (ketone C=O), 1543 (aryl CH stretch), 836 (para- substituted 
aromatic ring). 
N-(2-Methylphenyl)-2-(4-(4-chlorobenzoyl)phenoxy)2-methylpropanamide 
(51d) 
Following General Method B, Fenofibric acid (0.100 g, 0.314 mmol)and an 
excess of thionyl chloride (5ml)were refluxed for 1 hours and 30 minutes to 
afford the corresponding acid chloride (0.119 g, 0.352 mmol).  The acid 
chloride was then reacted directly with 3-methylaniline (0.04 ml, 0.352 mmol) 
and triethylamine (0.054 ml, 0.387 mmol) in DCM (6 ml) to afford 51d.  
Yield: 53% 
Appearance: Yellow-white solid 
Purification: 2.5 % EtOH/ 97.5 % PLC 
1H NMR (CDCl3): 1.72 (s, 6H, C(CH3)2), 2.12 (s, 3H, 2-methyl phenyl CH3), 
7.04-7.12 (m, 3H, phenoxy 2-H and 6-H, and 2-methyl phenyl 4-H), 7.15-7.25 
(m, CHAr, 2H, 2-methyl phenyl 5-H and 6-H), 7.46 (d, 3J = 8.6 Hz, 2H, 
benzoyl 3H and 5H), 7.71 (d, 3J = 8.6 Hz, 2H, phenoxy 3-H and 5-H), 7.78 (d, 
3J = 8.6 Hz, 2H, benzoyl 2-H and 6-H) 7.91-7.95 (m, 1H, 2-methyl phenyl 3-
H) 8.19 (s, 1H, NH).  
13C NMR (CDCl3): 17.54 (2-methyl phenyl CH3), 25.39 (C(CH3)2), 82.66 
(C(CH3)2), 119.66 (phenoxy 2-C and 6-C), 122.26 (2-methyl phenyl 6-C), 
125.36 (2-methyl phenyl 5-C), 127.07 (2-methyl phenyl 4-C), 128.64 (phenoxy 
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4-C), 128.79 (benzoyl 3-C and 5-C), 130.67 (2-methyl phenyl 2-C), 131.36 
(benzoyl 2-C and 6-C), 132.02 (2-methyl phenyl 3-C), 132.17 (benzoyl 2-C 
and 6-C), 135.26 (2-methyl phenyl 1-C), 136.16 (benzoyl 1-C), 138.86 
(benzoyl 4-C), 158.51 (phenoxy 1-C), 172.11 (amide C=O), 194.29 (ketone 
C=O). 
Melting point: 95-99 °C
HPLC: System 1, Rt = 7.28  minutes.
 System 2, Rt =  19.40 minutes. 
m/z:  HRMS (ES-TOF+) C24H22ClNO3 [MH]+ calculated 408.1361; found 
408.1368.          
FT-IR (KBr): 3355 (amide NH), 2979, 2939 (CH3 stretch), 1692 (amide 
C=O), 1647 (ketone C=O), 1566 (aryl CH stretch), 838 (para disubstituted 
aromatic ring). 
N-(3-Methylphenyl)-2-(4-(4-chlorobenzoyl)phenoxy)-2-
methylpropanamide (51e) 
Following General Method B, Fenofibric acid (0.101 g, 0.316 mmol)and an 
excess of thionyl chloride (5ml)were refluxed for 1 hours and 30 minutes to 
afford the corresponding acid chloride (0.118 g, 0.350 mmol).  The acid 
chloride was then reacted directly with 3-methylaniline (0.04 ml, 0.350 mmol) 
and triethylamine (0.054 ml, 0.385 mmol) in DCM (6 ml) to afford 51e. 
Yield: 49% 
Appearance: Yellow-white solid 
Purification: PLC 2.5 % EtOH/ 
97.5 % DCM 
 




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1H NMR (CDCl3): 1.67 (s, C(CH3)2, 6H), 2.34 (s, 3H, 3-methyl phenyl CH3), 
6.94 – 6.96 (m, 1H, 3-methyl phenyl 4-H), 7.04 (d, 3J = 8.8 Hz, 2H, phenoxy 
2-H and 6-H), 7.22 (dd, 3J = 7.8 Hz , 3J = 7.8 Hz , 1H, 3-methyl phenyl 5-H), 
7.29-7.34 (m, 1H, 3-methyl phenyl 6-H), 7.39 – 7.41 (m, 1H, 3-methyl phenyl 
2-H), 7.45 (d, 3J = 8.6 Hz, 2H, benzoyl 3-H and 5-H), 7.72 (d, 3J = 8.6 Hz, 2H, 
phenoxy 2-H and 6-H), 7.77 (d, 3J =  8.8 Hz, 2H, benzoyl 2-H and 6-H) 8.22 
(broad s, 1H, NH).  
13C NMR (CDCl3): 21.60 (3-fluoro phenyl CH3), 25.25 (C(CH3)2), 82.54 
(C(CH3)2), 117.05 (3-methyl phenyl 6-C), 120.11 (phenoxy 2-C and 6-C), 
120.62 (3-methyl phenyl 2-C), 125.66 (3-methyl phenyl 4-C), 128.79 (benzoyl 
3-C and 5-C), 129.07 (phenoxy 4-C), 131.38 (phenoxy 3-C and 5-C), 132.14 
(benzoyl 2-C and 6-C), 136.14 (benzoyl 1-C), 137.29 (benzoyl 4-C), 138.86 (3-
methyl phenyl 1-C), 139.25 (3-methyl phenyl 3-C), 158.35 (phenoxy 1-C), 
172.27 (amide C=O), 194.33 (ketone C=O).  
Melting point: 111-113 °C
HPLC: System 1, Rt = 7.52  minutes.
 System 2, Rt =  19.95 minutes. 
m/z:  HRMS (ES-TOF+) C24H22ClNO3 [MH]+ calculated 408.1361; found 
408.1431. 
FT-IR (KBr): 3267 (amide NH), 2996, 2942 (CH3 stretch), 1689 (amide 
C=O), 1642 (ketone C=O), 1539 (aryl CH stretch), 853 (para disubstituted 
ring). 
2-Methyl (4’-methoxy)benzophenone (54a) 
Following General Method D, 2-methylbenzoic acid (0.500 g, 3.68 mmol) was 
reacted with an excess of thionyl chloride (5 ml) for 1 hour.  The acid chloride 
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(0.568g, 3.68 mmol)  afforded was reacted with anisole (0.398 g, 3.68 mmol) 
and aluminium chloride (0.753g, 5.51 mmol) in DCM (10 ml) to give 54a.  
Yield: 32% 
Appearance: Colourless oil 
Purification: 5 % DCM / 95 % PE to 60 % DCM / 
40 % PE. 
Melting point: N/A 
1H NMR (CDCl3): 2.30 (s, 3H, 2-CH3,), 3.87 (s, 3H, OCH3), 6.92 (d, 3J = 8.5 
Hz, 2H, 2’-H and 6’-H), 7.20-7.40 (m, 4H, benzoyl CH), 7.78 (d, 3J = 8.5 Hz, 
2H, 3’-H and 5’-H). 
13C NMR (CDCl3): 20.12 (2-CH3), 55.85 (OCH3), 114.06 (3’-C and 5’-C), 
125.51 (5-C), 128.27 (6-C), 130.12 (1’-C), 130.92 (3-C), 131.16 (2’C and 6’-
C), 132.85 (4-C), 136.51 (2-C), 139.59 (1-C), 164.06 (4’-C), 197.71 (ketone 
C=O). 
m/z:  HRMS (ES-TOF+) C15H14O2 [MH]+ calculated 227.1067; found 
227.9815. 
FT-IR (KBr): 2966, 2840 (CH3 stretch), 1653 (ketone C=O), 1598 (aryl CH 
stretch), 847 (para disubtituted aromatic ring). 
3-Methyl(4’-methoxy)benzophenone (54b) 
Following General Method D, 3-methylbenzoic acid (0.501 g, 3.68 mmol) was 
reacted with an excess of thionyl chloride for 1 hour.  The acid chloride 
(0.568g, 3.68 mmol) afforded was then reacted with anisole (0.398 g, 3.68 
mmol) and aluminium chloride (0.753g, 5.51 mmol) 
in DCM (10 ml) to give 54b.  
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Yield: 51% 
Appearance: Colourless oil 
Purification: 5 % DCM / 95 % PE, to 60 % DCM / 40 % PE. 
Melting point: n/a 
1H NMR (CDCl3): 2.42 (s, 3H, 3-CH3), 3.89 (s, 3H, OCH3), 6.96 (d, 3J = 8.7 
Hz, 2H, phenoxy 2’-H and 6’-H), 7.32-7.40 (m, 2H 2-H/6-H), 7.50-7.60 (m, 
2H, 4-H/5-H), 7.83 (d, 3J = 8.6 Hz, 2H, 3’-H and 5’-H).  
13C NMR (CDCl3): 21.36 (3-CH3), 55.48 (OCH3), 113. 52 (3’-C and 5’-C), 
126.99 (2-C), 127.99 (6-C), 127.99 (5-C), 130.19 (4-C), 130.12 (1’-C), 132.55 
(2’-C and 6’-C), 132.66 (3-C), 138.33 (1-C), 163.17 (4’-C), 195.81 (ketone 
C=O). 
m/z:  HRMS (ES-TOF+) C15H14O2 [MH]+ calculated 227.1067; found 
227.0329.  
FT-IR (KBr): 2974, 2840 (CH3 stretch), 1672 (ketone C=O), 1595 (aryl CH 
stretch), 869, 845 (para disubstituted aromatic ring). 
4-Methyl-(4’-methoxy)-benzophenone (54c) 
Following General Method D, 4-methylbenzoic acid (0.500 g, 3.67 mmol) was 
reacted with an excess of thionyl chloride for 1 hour.  The acid chloride (0.568 
g, 3.68 mmol)  afforded was reacted with anisole (0.399 ml, 3.68 mmol) and 
aluminium chloride (0.735g, 5.51 mmol) in DCM (10 ml) to give 54c.  
Yield: 45 %   
Appearance: White needle-like crystals 
Purification: Column chromatography 100 % 
PE to 20% TBME / 80 % PE. 
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Melting point: 85 – 87 °C 
1H NMR (DMSO): 2.40 (s, 3H 4-CH3), 3.86 (s, 3H, OCH3), 7.08 (d, 3J = 8.9 
Hz, 2H, phenoxy 3’-H and 5’-H), 7.35 (d, 3J = 7.9 Hz, 2H, 3-H and 5-H), 7.60 
(d, 3J = 8.1 Hz, 2H, 2’-H and 6’-H), 7.73 (d, 3J = 8.9 Hz, 2H, 2-H and 6-H). 
13C NMR (DMSO): 21.59 (CH3), 56.01 (OCH3), 114.31 (phenoxy 2-C and 6-
C), 129.46 (benzoyl 3-C and 5-C), 130.00 (benzoyl 2-C and 6-C), 130.13 
(phenoxy 4-C), 132.49 (phenoxy 3-C and 5-C), 135.47 (benzoyl 1-C), 142.89 
(benzoyl 4-C), 163.25 (amide C=O), 194.59 (ketone C=O). 
m/z:  HRMS (ES-TOF+) [MH]+ calculated 227.1067; found 226.9554. 
FT-IR (KBr): 2918, 2844 (CH3 stretch), 1644 (ketone C=O), 848, 828 (p 
disubtituted aromatic ring).  
3-Cyano-(4’-methoxy)-benzophenone (54d) 
Following General Method D, 3-cyanobenzoic acid (0.501 g, 3.41 mmol) was 
reacted with an excess of thionyl chloride (5 ml) for 1 hour.  The acid chloride 
(0.565g, 3.41 mmol)  afforded was reacted with anisole (0.368 g, 3.41 mmol) 
and aluminium chloride (0.681 g, 5.11 mmol) in DCM (10 ml) to give 54d.  
Yield: 52% 
Appearance: Pale yellow solid 
Purification: Column chromatography, 5 % 
dichloromethane / 95 % petroleum ether to 100% dichloromethane. 
Melting point: 86 – 88 °C 
1H NMR (DMSO): 3.87 (s, 3H, OCH3), 7.11 (d, 3J = 8.9 Hz, 2H, 3’-H and 5’-
H), 7.73-7.79 (m, 3H, 2’-H, 6’-H, and 5-H), 7.98 (ddd, 3J = 7.9 Hz, 4J = 1.5 
Hz, 4J = 1.5 Hz, 1H, 6-H), 8.07-8.12 (m, 2H, 2-H and 4-H). 
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m/z:  HRMS (ES-TOF+) C15H11NO2 [MH]+ calculated 238.0863; found 
238.0865. 
FT-IR (KBr): 2938, 2845 (CH3 stretch), 2232 (CN), 1640 (ketone C=O), 1598 
(aryl CH stretch), 850, 811 (para disubstituted aromatic ring). 
4-Cyano-4’-methoxybenzophenone (54e) 
Following General Method D, 4-cyanobenzoic acid (0.500 g, 3.68 mmol) was 
reacted with an excess of thionyl chloride (5ml) for 1 hour.  The acid chloride 
(0.568g, 3.68 mmol)  afforded was reacted with anisole (0.367 g, 3.39 mmol) 
and aluminium chloride (0.678 g, 5.09 mmol) in DCM (10 ml) to give 54e.  
Yield: 29% 
Appearance: White solid 
Purification: 2.5 % EtOAc / 97.5 % petroleum 
ether to 100 % EtOAc  
1H NMR (DMSO): 3.86 (s, 1H, OCH3), 7.11 (d, 3J = 8.9 Hz, 2H, 3’-H and 5’-
H), 7.75 (d, 3J = 8.9 Hz, 2H, 2’-H and 6’-H), 7.82 (d, 3J = 8.6 Hz, 2H, 2-H and 
6-H), 8.02 (d, 3J = 8.6 Hz, 2H, 3-H and 5-H).  
13C NMR (CDCl3):  55.64 (OMe), 113.99 (4-C),  114.12 (3’-C and 5’-C), 
118.21 (CN), 128.45 (1’-C), 129.60 (2-C and 6-C), 132.38 (2’-C and 6’-C), 
132.45 (3-C and 5-C), 141.78 (1-C), 163.49 (4’-C), 193.26 (ketone C=O). 
Melting point: 133-134 °C 
m/z:  HRMS (ES-TOF+) C15H11NO2 [MH]+ calculated 238.0863; found 
238.079.   
FT-IR (KBr): 2231 (CN), 1642 (ketone C=O), 1599 (aryl CH stretch), 859, 
840 (para disubtituted aromatic ring). 
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2-Chloro (4’-methoxy)benzophenone (54f) 
Following General Method D, but using commercially available acid chloride, 
3-chlorobenzoyl chloride (5.000 g, 28.6 mmol) was reacted with anisole (3.089 
g, 28.6 mmol) and aluminium chloride (5.713 g, 42.9 mmol) in DCM (40 ml) 
to give 54f. 
Yield: 37 %   
Appearance: White solid 
Purification: Column chromatography, 1 % 
TBME / 99 % PE to 40% TBME / 60% PE.  Product then precipitated from 
EtOAc by addition of PE. 
Melting point: 83 – 85 °C 
1H NMR (DMSO): 3.88 (s, 3H, OCH3), 6.94 (d, 3J = 8.9 Hz, 2H, 3’-H and 5’-
H), 7.34-7.37 (m, 2H, 4-H and 5-H), 7.38-7.47 (m, 2H, 3-H and 6-H), 7.79 (d, 
3J = 9.0Hz, 2H, 2’-H and 6’-H). 
13C NMR (CDCl3): 55.68 (OCH3), 114.03 (3’-C and 5’-C), 126.78 (5-C), 
129.01 (6-C), 129.59 (1’-C), 130.10 (3-C), 130.92 (4-C), 131.24 (1-C), 132.67 
(2’-C and 6’-C), 139.17 (2-C), 164.25 (4’-C), 193.99 (ketone C=O). 
FT-IR: 1655 (ketone C=O), 1598 (aryl CH stretch). 
3-Chloro-(4’-methoxy)-benzophenone (54g)  
Following General Method D, but using commercially available acid chloride, 
2-chlorobenzoyl chloride (5.000 g, 28.6 mmol) was reacted with anisole (3.089 
g, 28.6 mmol) and aluminium chloride (5.713 g, 42.9 mmol) in DCM (40 ml) 
to give 54g. 
Yield: 46 %   
Appearance: White solid  
155 
Purification: Column chromatography, 1% TBME / 99% PE to 40% TBME / 
60% PE.  Product then precipitated from EtOAc by addition of PE. 
Melting point: 69 – 70 °C 
1H NMR (DMSO): 3.89 (s, 3H, OMe), 6.97 (d, 3J = 8.9 Hz, 2H, 3’-H and 5’-
H), 7.41 (dd, 3J = 7.8 Hz, 3J = 7.8 Hz, 2H, 5-H), 7.53 (ddd, 3J = 8.0 Hz, 4J = 
2.1 Hz, 4J = 1.1 Hz, 1H, 6-H) 7.62 (ddd, 3J = 7.6 Hz, 4J = 1.3 Hz, 4J = 1.3 Hz, 
1H, 4-H), 7.72 (dd, 4J = 1.8 Hz, 4J = 1.8 Hz, 1H, 2-H), 7.81 (d, 3J = 8.9 Hz, 2H, 
2’-H and 6’-H). 
13C NMR (CDCl3): 55.68 (OCH3), 114.03 (3’-C and 5’-C), 126.78 (6-C), 
129.01 (5-C) 129.59 (1’-C), 130.10 (2’-C and 6-C), 130.92 (2-C), 131.24 (4-
C), 132.67 (3-C), 139.17 (1-C), 164.25 (4’-C), 193.99 (ketone C=O). 
m/z:  HRMS (ES-TOF+) [MH]+ calculated 247.0520; found 247.0440 
FT-IR (KBr): 1648 (ketone C=O), 1596 (aryl CH stretch). 
3-Fluoro-(4’-methoxy)-benzophenone (54h) 
Following General Method D, 3-fluorobenzoic acid (0.502 g, 3.58 mmol) was 
reacted with an excess of thionyl chloride (5 ml) for 1 hour.  The acid chloride 
(0.568g, 3.58 mmol)  afforded was reacted with anisole (0.387 g, 3.58 mmol) 
and aluminium chloride (0.716 g, 5.37 mmol) in DCM (10 ml) to give 54h.  
 Yield: 15% 
Appearance: White solid 
Purification: Column chromatography, 2% 
TBME / 98 % PE to 40 % TBME / 60 % PE.  
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Melting point: 68 – 70 °C 
1H NMR (CDCl3): 3.89 (s, 3H, OCH3,), 6.97 (d, 3J = 8.9 Hz, 2H, 2’-H and 6’-
H), 7.22-7.29 (m, 1H, 2-H), 7.40-7.55 (m, 3H, 4-H, 5-H and 6-H), 7.82 (d, 3J = 
8.9 Hz, 2H, 3’-H and 5’-H). 
13C NMR (CDCl3): 55.53 (OCH3, 113.71 (3’-C and 5’-C), 116.49 (d, 2JCF = 
22.4 Hz, 2-C), 118.83 (d, 2JCF = 22.3 Hz, 4-C), 125.41 (d, 4JCF = 2.9 Hz, 6-C), 
129.41 (1’-C), 129.86 (1’-C), 132.54 (2’-C and 6’-C), 140.41 (d, 3JCF = 6.3 Hz, 
1-C), 162.44 (d, 1JCF = 247.8 Hz, 3-C), 163.51 (4’-C), 194.03 (ketone C=O). 
m/z:  HRMS (ES-TOF+) C14H11FO2 [MH]+ calculated 231.0816; found 
230.9698. 
3-Nitro-(4’-methoxy)-benzophenone (54i)  
Following General Method D, 3-nitrobenzoic acid (0.501 g, 2.99 mmol) was 
reacted with an excess of thionyl chloride (5 ml) for 1 hour 50 minutes.  The 
acid chloride (0.558g, 2.99 mmol)  afforded was reacted with anisole (0.324 g, 
2.99 mmol) and aluminium chloride (0.599 g, 4.49 mmol) in DCM (10 ml) to 
give 54i.  
Yield: 71% 
Appearance: Off white solid 
Purification: Column chromatography, 5 % 
DCM / 95 % PE to 60 % DCM / 40 % PE. 
Melting point: 87 – 89 °C 
1H NMR (DMSO): 3.91 (s, 3H, OCH3,), 7.00 (d, 3J = 9.1 Hz, 3’-H and 5’-H), 
7.69 (dd, 2J
 
= 7.8 Hz, 2J
 
= 7.8 Hz, 5-H), 7.82 (d, 3J
 
= 8.9 Hz, 2’-C and 6’-C),  
8.09 (ddd, 2J = 7.7 Hz, 3J = 1.3 Hz, 3J =1.3 Hz, 6-C), 8.42 (ddd, 2J = 8.2 Hz, 3J 
= 1.1 Hz, 3J =2.3 Hz, 4-C), 5.57 (dd, 4J
 
= 1.9 Hz, 4J
 
= 1.9 Hz, 1-C). 
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13C NMR (DMSO): 55.57 (OCH3), 114.18 (3’-C and 5’-C), 124.56 (2-C), 
126.37 (4-C), 129.03 (5-C), 130.38 (1’-C), 132.72 (2’-C and 6’-C), 135.32 (6-
C), 139.96 (1-C), 148.16 (3-C), 164.09 (4’-C), 192.98 (ketone C=O). 
m/z:  HRMS (ES-TOF+) C14H11NO4 [MH]+ calculated 258.0761; found 
258.0762 
FT-IR (KBr): 1648 (ketone C=O), 1597 (aryl CH stretch). 
2-Methyl-(4’-hydroxy)benzophenone (55a) 
Following General Method F, 2-methyl-(4’-methoxy)benzophenone (0.253 g, 
1.12 mmol) was irradiated in the microwave (300W at 150°C) with pyridine 
hydrochloride (0.645 g, 5.58 mmol) for 12 minutes to afford 55a.  
Yield: 8 % 
Appearance: Orange-brown solid.   
Purification: 2 % TBME / 98 % PE to 40 % TBME 60 
% PE.  
1H NMR (DMSO): 2.18 (2-CH3), 6.87 (d, 3J = 8.8 Hz, 3’-H and 5’-H), 7.21 – 
7.35 (m, 3H, 3-H/5-H/6-H), 7.42 (ddd, 3J = 7.3 Hz, 3J = 7.3 Hz, 4J = 1.5 Hz, 
1H, 4-H), 7.58 (d, 3J = 8.8 Hz, 2H, 2’-H and 6’-H). 
13C NMR (DMSO): 19.93 (2-CH3). 115.66 (3’-C and 5’-C), 125.39 (5-C), 
128.10 (6-C), 130.11 (1’-C), 130.17 (3-C), 131.02 (2’-C and 6’-C), 133.24 (4-
C), 136.25 (2-C), 139.05 (1-C), 161.43 (4’-C), 198.80 (ketone C=O).  
m/z:  HRMS (ES-TOF+) [MH]+ calculated 213.0910; found 213.0802 
3-Methyl-(4’-hydroxy)-benzophenone (55b) 
Following General Method F, 3-methyl-(4’-methoxy)benzophenone (0.250 g, 
1.11 mmol) was irradiated in the microwave (300W at 150°C) with pyridine 
hydrochloride (0.639 g, 5.52 mmol) for 10 minutes to give 55b.  
158 
Yield: 91% 
Appearance: Off white solid   
Purification: Used without further purification
 
 
Melting point: 164 – 166 °C 
1H NMR (DMSO): 2.38 (s, 3H, 3-CH3), 6.89 (d, 3J = 8.8 Hz, 2H, 3’-H and 5’-
H), 7.37-7.49 (m, 4H, 2-H, 4-H, 5-H and 6-H), 7.65 (d, 3J = 8.8 Hz, 2H, 2’-H 
and 6’-H), 10.39 (s, 1H, OH).   
13C NMR (DMSO): 20.87 (3-CH3), 115.20 (3’-C and 5’-C), 126.34 (2-C), 
128.01 (6-C), 128.17 (5-C), 129.44 (1’-C), 132.37 (4-C), 132.42 (3-C), 137.73 
(2’-C and 6’-C), 138.16 (1-C), 161.91 (4’-C), 194.40 (C=O). 
m/z:  HRMS (ES-TOF+) [MH]+ calculated 213.0910; found 213.0867. 
FT-IR (KBr): 3278 (phenol OH), 1636 (ketone C=O), 1598 (aryl CH stretch), 
849 (p disubtituted aromatic ring). 
4-Hydroxy (4’-methyl)-benzophenone (55c) 
Following General Method F, 4-methyl-(4’-methoxy)benzophenone (0.400 g, 
1.77 mmol) was irradiated in the microwave with pyridine hydrochloride 
(1.021 g, 8.89 mmol) for 2 minutes at 200W and 250°C,  and  then 2 minutes at 
200W and 200°C to give 55c.  
Yield: 66 %   
Appearance: Off white crystals 
Purification: Recrystallised from EtOAc / PE. 
Melting point: 169 -172 °C 
1H NMR (DMSO): 2.39 (s, 3H, phenoxy CH3), 6.89 (d, 3J = 8.7 Hz, 2H, 
phenoxy 2-H and 6-H), 7.33 (d, 3J = 7.9 Hz, 2H, benzoyl 3-H and 5-H) 7.58 (d, 


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3J = 8.1 Hz, 2H, phenoxy 3-H and 5-H), 7.63 (d, 3J = 8.7 Hz, 2H, benzoyl 2-H 
and 6-H), 10.37 (s, 1H, OH). 
13C NMR (DMSO): 21.56 (CH3), 115.64 (3’-C and 5’-C), 128.65 (1’-C), 
129.38 (3 and 5), 129.87 (2-C and 6-C), 132.81 (2’-C and 6’-C), 135.7 (1-C), 
142.53 (4-C), 162.23 (4’-C), 194.47 (ketone C=O). 
m/z:  HRMS (ES-TOF+) [MH]+ calculated 213.0910; found 213.0824. 
FT-IR (KBr): 3337 (phenol OH), 1642 (ketone C=O), 1599 (aryl CH stretch). 
3-Cyano-(4’-hydroxy)-benzophenone (55d)  
Following General Method F, 3-cyano-(4’-methoxy)benzophenone (1.007 g, 
4.24 mmol) was irradiated in the microwave with pyridine hydrochloride 
(2.452 g, 21.2 mmol) for 15 minutes at 300W and 150°C to give 55d. 
Yield: 54% 
Appearance: Off white solid. 
Purification: Product precipitated from EtOAc 
with addition of PE. 
Melting point: 164 – 166 °C 
1H NMR (DMSO): 6.92 (d, 3J = 8.7 Hz, 2H, 3’-H and 5’-H), 7.68 (d, 3J = 8.7 
Hz), 2H, 2’-H and 6’-H), 7.74 (dd, 1H, 3J = 7.8 Hz, 3J = 7.8 Hz, 5-H), 7.95 
(ddd, 3J = 1.3 Hz, 4J = 1.3 Hz, 4J = 7.8 Hz, 1H, 6-H), 8.04-8.10 (m, 2H, 2-H 
and 4-H), 10.55 (broad s, 1H, OH).  
13C NMR (DMSO): 111.64 (3-C), 115.48 (3’-C and 5’C), 118.19 (CN), 
127.00 (5’-C), 129.72 (1’-C), 132.38 (2’-C and 6’-C), 132.75 (2-C), 133.38 (6-
C), 134.97 (4-C), 139.22 (C-1), 162.54 (4’-C), 192.43 (C=O). 
m/z:  HRMS (ES-TOF-) C14H9NO2 [MH]- calculated 222.0561; found 
222.0502. 
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FT-IR (KBr): 3336 (phenol OH), 2230 (CN stretch), 1658 (ketone C=O), 
1601 (aryl CH stretch), 850, 818 (para disubtituted aromatic ring). 
4-Cyano-(4’-hydroxy)benzophenone (55e) 
Following General Method F, 4-cyano-(4’-methoxy)benzophenone (0.850 g, 
3.81 mmol) was irradiated in the microwave with pyridine hydrochloride 
(1.021 g, 19.0 mmol) for 4 minutes at 100W and 250°C to give 55e. 
Yield: 73 %   
Appearance: Yellow – white solid 
Purification: Product precipitated from EtOAc 
with addition of PE 
Melting point: 179 - 181 °C 
1H NMR (DMSO): 6.91 (d, 3J = 8.8 Hz, 2H, 3’-H and 5’-H), 7.67 (d, 3J = 8.6 
Hz, 2H, 2’-H and 6’-H), 7.79 (d, 3J = 8.6 Hz, 2H, 2-H and 6-H), 8.00 (d, 3J = 
8.3 Hz, 2H, 3-H and 5-H). 
13C NMR (DMSO): 112.76 (4-C), 144.49 (3’-C and 5’-C), 117.27 (CN), 
125.97 (2-C and 6-C), 128.50 (3-C and 5-C), 131.42 (2’-C and 6’-C), 131.74 
(3-C and 5-C), 141.20 (1-C), 161.64 (4’-C), 192.08 (ketone C=O). 
FT-IR: 3372 (phenol OH), 2238 (CN stretch), 1696 (ketone C=O), 1585 (aryl 
CH stretch). 
2-Chloro-(4’-hydroxy)benzophenone (55f) 
 
Following General Method F, 4-chloro-(4’-methoxy)benzophenone (1.000 g, 
4.29 mmol) was irradiated in the microwave with pyridine hydrochloride 
(2.483 g, 21.5 mmol) for 5 minutes at 200W and 250°C to give 55f. 
Yield: 27 %   
Appearance: White Solid 
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Purification: Column chromatography, 100 % PE to 100 % EtOAc 
Melting point: 129 – 131 °C 
1H NMR (DMSO): 6.88 (3’-H and 5’-H), 7.41 – 7.61 (m, 6H, 2’-H/6’H/3-H/4-
H/5-H/6-H), 10.62 (s, 1H, OH). 
13C NMR (DMSO): 115.68 (3’-C and 5’-C), 127.25 (5-C), 127.30 (6-C), 
128.63 (3-C), 129.51 (1’-C), 129.67 (4-C), 131.13 (1-C), 132.39 (2’-C and 6’-
C), 138.82 (2-C), 163. 05 (4’-C), 192.62 (ketone C=O). 
FT-IR: 3296 (phenol OH), 1644 (ketone C=O), 1570 (aryl CH stretch).  
3-Chloro-(4’-hydroxy)benzophenone (55g) 
Following General Method F, 3-chloro-(4’-methoxy)benzophenone (1.000 g, 
4.29 mmol) was irradiated in the microwave with pyridine hydrochloride 
(2.483 g, 21.5 mmol) for 5 minutes at 200W and 250°C to give 55g. 
Yield: 98 %   
Appearance: White solid 
Purification: Column chromatography, 100 % 
PE to 100 % EtOAc 
Melting point: 174 – 176 °C 
1H NMR (DMSO): 6.91 (d, 3J =  8.8 Hz, 2H, 3’-H and 5’-H), 7.52 – 7.72 (m, 
6H, 2’-H/ 6’-H/ 2-H/ 4-H/5-H/ 6-H), 10.51 (s, 1H, OH). 
13C NMR (DMSO): 115.39 (3’-C and 5’-C), 127.29 (6-C), 127.69 (5-C), 
128.48 (2-C), 130.33 (1’-C), 131.47 (4-C), 131.60 (2’-C and 6-C), 133.23 (3-
C), 140.14 (1-C), 162.35 (4’-C), 192.79 (ketone C=O). 
FT-IR: 3298 (phenol OH), 1633 (ketone C=O), 1599 (aryl CH stretch).  
 
 

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3-Fluoro-(4’-hydroxy)benzophenone (55h)  
Following General Method F, 3-fluoro-(4’-methoxy)benzophenone (0.090 g, 
0.19 mmol) was irradiated in the microwave with pyridine hydrochloride 
(0.226 g, 1.95 mmol) for 4 minutes at 215W and 200°C, to give 55h. 
Yield: 67% 
Appearance: Yellow-brown solid. 
Purification: Column chromatography, 100 % PE to 
100 % EtOAc. 
Melting point: 127 – 129 °C 
1H NMR (DMSO): 6.91 (d, 3J = 8.6 Hz, 2H, 3’-H and 5’-H), 7.41-7.51 (m, 
3H, 4-H, 5-H and 6-H), 7.55-7.62 (m, 1H, 2-H), 7.68 (d, 3J = 8.6 Hz, 2H, 2’-H 
and 6’-H), 10.49 (broad s, 1H, OH). 
13C NMR (DMSO): 115.35 (3’-C and 5’-C), 115.5 (2JCF = 22Hz, 3-C), 118.57 
(2JCF = 22Hz, 1-C), 125.22 (4JCF = 5-C), 127.34 (1’-C), 130.54 (3JCF = 8Hz, 6-
C), 132.57 (2’-C and 6’-C), 140.45 (4-C), 161.77 (C-2, 1JCF = 246 Hz), 194.80 
(ketone C=O). 
m/z:  HRMS (ES-TOF-) C13H9FO2 [MH]- calculated 215.0514; found 
215.0423. 
FT-IR (KBr): 3168 (phenol OH), 1602 (ketone C=O), 1560 (aryl CH stretch), 
883, 850 (p disubtituted aromatic ring). 
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3-Nitro (4’-hydroxy)-benzophenone (55j)  
Following General Method F, 3-nitro-(4’-methoxy)benzophenone (1.019 g, 
3.96 mmol) was irradiated in the microwave with pyridine hydrochloride 
(2.289 g, 19.8 mmol) for 20 minutes at 300W and 150°C, to give 55j. 
Yield: 32 % 
Appearance: Orange-brown solid. 
Purification: 100 % PE to 20 % PE / 80 % EtOAc.  
Melting point: 169 – 171 °C 
1H NMR (DMSO): 6.93 (d, 3J = 7.9 Hz, 2H, 3’-H and 5’-H),   7.71 (d, 3J = 7.9 
Hz, 2H, 2’-H and 6’-H), 7.83 (dd, 3J = 7.9 Hz, 3J = 7.9 Hz, 1H, 5-H), 8.10 
(ddd, 4J = 1.3 Hz 4J = 1.3 Hz, 3J = 7.9 Hz, 6-H), 8.37 (dd, 3J = 1.8 Hz, 3J = 1.8 
Hz, 1H, 2-H), 8.46 (ddd, 3J = 8.2 Hz, 4J = 2.4 Hz, 4J = 1.0 Hz, 1H, 4-H), 10.60 
(s, 1H, OH).   
13C NMR (DMSO): 115.49 (3’-C and 5’-C), 123.48 (2-C), 126.09 (4-C), 
126.94 (5-C), 130.21 (1’-C), 132.74 (2’-C and 6’-C), 135.16 (6-C), 139.39 (1-
C), 147.61 (3-C), 162.59 (4’-C), 192.12 (ketone C=O). 
m/z:  HRMS (ES-TOF-) C13H9NO4 [MH]- calculated 242.0459; found 
242.0381. 
FT-IR (KBr): 3368 (phenol OH), 1643 (ketone C=O), 1565 (aryl CH stretch), 
1346 (NO2).  
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4-Nitro-(4’-hydroxy)benzophenone (55k) 
Following General Method F, 4-nitro-(4’-methoxy)benzophenone (3.000 g, 
11.2 mmol) was irradiated in the microwave with pyridine hydrochloride 
(6.738 g, 58.3 mmol) for 18 minutes at 300W and 150°C,  to give 55k. 
Yield: 99% 
Appearance: Pale yellow solid 
Purification: Used without further purification. 
Melting point: 196 – 198 °C 
1H NMR (CDCl3): 6.92 (d, 3J = 8.8 Hz, 2H, 3’-H and 5’-H), 7.68 (d, 3J = 8.8 
Hz, 2H, 2’-H and 6’-H), 7.83 (d, 3J = 8.8 Hz, 2H, 2-H and 6-H), 8.27 (d, 3J = 
8.8 Hz, 2H, 3-H and 5-H), 9.57 (broad s, 1H, OH). 
13C NMR (CDCl3): 115.99 (3’-C and 5’-C), 123.66 (3-C and 5-C), 127.99 (2-
C and 6-C), 130.50 (1’-C), 133.19 (2-C and 6-C), 144.48 (1-C), 149.64 (4-C), 
163.01 (4’-C), 193.83 (C=O).  
m/z:  HRMS (ES-TOF+) [MH]+ calculated 244.0604; found 244.0653. 
FT-IR (KBr): 3333 (phenol OH), 1638 (ketone C=O), 1599 (aryl CH stretch), 
865, 850 (p disubtituted aromatic ring).  
Ethyl 2-methyl-2-(4-(2-methylbenzoyl)phenoxy)propanoate (56a) 
 
Following General Method E, 2-methyl-(4’-hydroxy)benzophenone (0.300 g, 
1.56 mmol) in MeCN (15 ml) was reacted with K2CO3 (0.324 g, 2.33 mmol) 
and ethyl-2-bromoisobutyric acid (0.364g, 1.87 mmol) for 24 hours to afford 
56a. 
Yield: 50 %   
Appearance: Colourless oil 
Purification: Used without further purification. 
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Melting point: N/A 
1H NMR (DMSO): 1.22 (t, 3J = 7.1 Hz, CH2CH3), 1.66 (s, C(CH3)2), 2.23 (s, 
benzoyl CH3), 4.22 (quartet, 3J = 7.2 Hz, CH2CH3), 6.81 (d, phenoxy 2-H and 
6-H), 7.20-7.29 (m, benzoyl 3-H/5-H/6-H) (ddd, 3J = 7.5, 3J = Hz 7.5, 4J = 1.6 
Hz, benzoyl 4-H), 7.72 (d, 3J = 8.9 Hz, phenoxy 3-H and 5-H). 
13C NMR (DMSO): 14.16 (CH2CH3), 25.53 (C(CH3)2), 61.83 (CH2CH3), 
79.48 (C(CH3)2), 117.38 (phenoxy 2-C and 6-C), 125.29 (benzoyl 5-C), 128.15 
(benzoyl 6-C), 129.99 (benzoyl 4-C), 130.98 (benzoyl 3-C), 131.15 (benzoyl 4-
C), 132.20 (phenoxy 3-C and 5-C), 136.39 (benzoyl 2-C), 139.15 (benzoyl 1-
C), 160.12 (phenoxy 1-C), 173.77 (ester C=O), 197.49 (ketone C=O). 
m/z:  HRMS (ES-TOF+) [MH]+ calculated 327.1591; found 327.1147. 
FT-IR: 2987, 2938 (CH3 stretch), 1735 (ester C=O), 1659 (ketone C=O), 1597 
(aryl CH stretch).  
Methyl 2-methyl-2-(4-(2-cyanobenzoyl)phenoxy)propanoate (56b) 
Following General Method H, 2-cyano-(4’-hydroxy)benzophenone (0.500 g, 
2.22 mmol) was reacted with PPh3 (0.704 g, 2.68 mmol), DIAD (0.543 g, 2.68 
mmol) and methyl-2-hydroxyisobutyrate (0.291 g, 2.46 mmol) in toluene (15 
ml) at 80°C for 2 hours 15 minutes to afford 56b. 
Yield: 51 %   
Appearance: Off – white solid. 
Purification: Column chromatography, 
100% PE to 80 % EtOAc / 20 % PE.  
Melting point: 76 – 77 °C 
1H NMR (DMSO): 1.62 (s, C(CH3)2, 6H), 3.71 (s, OCH3, 3H), 6.91 (d, 3J = 
8.9Hz, 2H, phenoxy 2-H and 6-H), 7.72-7.78 (m, 3H phenoxy 3-H and 5-H and 
166 
benzoyl 5-H), 7.98 (ddd, 4J = 1.4 Hz, 4J = 1.4 Hz, 3J = 7.9 Hz, 1H, benzoyl 6-
H), 8.08-8.12 (m, 2H, benzoyl 2-H and 4-H).  
13C NMR (DMSO): 25.03 (C(CH3)2), 52.63 (OCH3), 79.05 C(CH3)2), 111.70 
benzoyl 3-C), 117.30 (phenoxy 2-C and 6-C), 118.14 (CN), 129.02 (benzoyl 5-
C), 129.79 (phenoxy 4-C), 132.19 (phenoxy 3-C and 5-C), 133.50 (benzoyl 2-
C), 135.26 (benzoyl 6-C), 138.70 (benzoyl 4-C), 159.47 (phenoxy 1-C), 173.15 
(ester C=O), 192.54 (ketone C=O). 
m/z:  HRMS (ES-TOF+) [MH]+ calculated 324.1230; found 324.1248. 
FT-IR (KBr): 2998, 2957 (CH3 stretch), 2236 (CN stretch), 1736 (amide 
C=O), 1662 (ketone C=O), 1600 (aryl CH stretch), 888, 850 (p disubtituted 
aromatic ring). 
Methyl 2-methyl-2-(4-(4-cyanobenzoyl)phenoxy)propanoate (56c)  
 
Following General Method E, 4-cyano-(4’-hydroxy)benzophenone (0.250 g, 
1.12 mmol) in MeCN (15 ml) was reacted with K2CO3 (0.232 g, 1. 68mmol) 
and ethyl-2-bromoisobutyric acid (0.262 g, 1.34 mmol) for 24 hours to afford 
56c. 
Yield: 43 %   
Appearance: Yellow - white solid. 
Purification: Used without further purification. 
Melting point: 99 – 101 °C 
1H NMR (DMSO): 1.23 (t, 3J = 7.1 Hz, CH2CH3), 1.68 (s, C(CH3)2), 4.24 
(quartet 3J = 7.2 Hz), 6.87 (d, 3J = 8.8 Hz, phenoxy 2-H and 6-H), 7.74 (d, 3J = 
8.9 Hz, phenoxy 3-H and 5-H), 7.77 (d, 3J = 7.8 Hz, benzoyl 2-H and 6-H), 
7.81 (d, 3J = 8.5 Hz). 
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13C NMR (DMSO): 14.18 (CH2CH3), 25.54 (C(CH3)2), 61.90 (CH2CH3), 
79.65 (C(CH3)2), 115.38 (benzoyl 4-C), 117.57 (phenoxy 2-C and 6-C), 118.22 
(CN), 129.58 (phenoxy 4-C), 130.07 (phenoxy 3-C and 5-C), 132.25 (benzoyl 
2-C and 6-C), 132.30 (benzoyl 3-C and 5-C), 142.08 (benzoyl 1-C), 160.37 
(phenoxy 1-C), 173.64 (ester C=O), 193.84 (ketone C=O). 
m/z:  HRMS (ES-TOF+) [MH]+ calculated 338.1387; found 338.1434. 
FT-IR: 2983, 2938 (CH3 stretch), 2233 (CN stretch), 1730 (ester C=O), 1658 
(ketone C=O), 1595 (aryl CH stretch), 862, 848 (p disubtituted aromatic ring). 
Methyl 2-methyl-2-(4-(3-nitrobenzoyl)phenoxy)propanoate (56d)  
Following General Method H, 3-nitro-(4’-hydroxy)benzophenone (0.160 g, 
0.66 mmol) was reacted with PPh3 (0.207 g, 0.79 mmol), DIAD (0.159 g, 0.79 
mmol) and methyl-2-hydroxyisobutyrate (0.086g, 0.72 mmol) in toluene (10 
ml) at 80°C for 4 hours 45 minutes to afford 56d. 
Yield: 42 %   
Appearance: White solid 
Purification: Column chromatography, 
5 % EtOAc / 95 % PE to 40% EtOAc / 60 % PE. 
Melting point: 78.8 – 80.5 °C 
1H NMR (CDCl3): 1.69 (s, 6H, C(CH3)2,), 3.78 (s, 3H, CO2CH3), 6.89 (d, 3J = 
8.9 Hz, 2H, phenoxy 2-H and 6-H), 7.69 (dd, 3J = 7.9 Hz, 3J = 7.9 Hz, 1H, 
benzoyl 5-H), 7.76 (d, 3J = 8.9 Hz, 2H, phenoxy 3-H and 5-H), 8.09 (ddd, 3J = 
7.6 Hz, 4J = 1.4 Hz, 4J = 1.4 Hz, 1H, benzoyl 4-H), 8.42 (ddd, 1H, 3J = 8.3 Hz, 
4J = 2.3 Hz, 4J = 1.0 Hz, benzoyl 6-H), 8.57 (dd, 4J = 1.8 Hz, 4J = 1.8 Hz, 1H, 
benzoyl 2-H).  
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13C NMR (CDCl3): 25.56 (C(CH3)2), 52.91 (OCH3), 79.62 (C(CH3)2), 117.58 
(phenoxy 2-C and 6-C), 124.56 (benzoyl 2-C), 126.47 (benzoyl 4-C), 129.58 
(phenoxy 4-C), 129.71 (benzoyl 5-C), 132.34 (phenoxy 3-C and 5-C), 135.33 
(benzoyl 6-C), 139.76 (benzoyl 1-C), 148.16 (benzoyl 3-C), 160.32 (phenoxy 
1-C), 174.24 (amide C=O), 192.96 (ketone C=O). 
2-(4-(4-Nitrobenzoyl)phenoxy)2-methyl propanoate (56e) 
 
Following General Method H, 4-nitro-(4’-hydroxy)benzophenone (1.000 g, 
4.11 mmol) was reacted with PPh3 (1.294 g, 4.93 mmol), DIAD (0.998g, 4.93 
mmol) and methyl-2-hydroxyisobutyrate (0.534 g, 4.52 mmol) in toluene (25 
ml) at 80°C for 4 hours 15 minutes to afford 56e. 
Yield: 64 %   
Appearance: Yellow – white solid 
Purification: Used without further purification. 
Melting point: 86 – 88 °C 
1H NMR (DMSO): 1.62 (s, 6H, C(CH3)2), 3.71 (s, 3H, CO2CH3), 6.91 (d, 3J = 
8.8 Hz, 2H, phenoxy 2-H and 6-H), 7.75 (d, 3J = 8.9 Hz, 2H, phenoxy 3-H and 
5-H), 7.91 (d, 3J = 8.8 Hz, 2H, benzoyl 2-H and 6-H), 8.36 (d, 3J = 8.8 Hz, 2H, 
benzoyl 3-H and 5-H). 
13C NMR (DMSO): 25.04 (C(CH3)2), 52.67 (OCH3),  79.09 (C(CH3)2), 117.32 
(phenoxy 2-C and 6-C), 123.61 (benzoyl 3-C and 5-C), 128.99 (benzoyl 2-C 
and 6-C), 130.32 (phenoxy 4-C), 132.22 (phenoxy 3-C and 5-C), 143.25 
(benzoyl 1-C), 149.13 (benzoyl 4-C), 159.64 (phenoxy 1-C), 173.15 (ester 
C=O), 193.03 (benzoyl C=O). 
m/z:  HRMS (ES-TOF+) [MH]+ calculated 344.1129; found 343.9586. 
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FT-IR: 2986, 2951 (CH3 stretch), 1748 (ester), 1652 (ketone C=O), 1596 (aryl 
CH stretch), 1433 (NO2), 869, 849 (p disubtituted aromatic ring). 
Ethyl-2-(4-(3-chlorobenzoyl)phenoxy)-2-methylpropanoate (56f) 
Following General Method E, 3-chloro-(4’-hydroxy)benzophenone (0.250 g, 
1.07 mmol) in MeCN (15 ml) was reacted with K2CO3 (0.223 g, 1. 61 mmol) 
and ethyl-2-bromoisobutyric acid (0.430 g, 1.52 mmol) for 24 hours to afford 
56f. 
Yield: 84 %   
Appearance: Off-white solid 
Purification: Used without further 
purification. 
Melting point: 84 – 86 °C 
1H NMR (DMSO): 1.15 (t, 3J = 7.1 Hz, CH2CH3), 1.61 (s, C(CH3)2), 4.18 
(quartet, 3J = 7.2 Hz, CH2CH3), 6.91 (d, 3J = 8.8 Hz, phenoxy 2-H and 6-H), 
7.52-7.76 (m, phenoxy 3-H and 5-H and benzoyl 2-H/4-H/5-H/6-H). 
13C NMR (DMSO): 13.83 (CH2CH3), 25.06 (C(CH3)2), 61.34 (CH2CH3), 
79.06 (C(CH3)2), 115.27 (phenoxy 2-C and 6-C), 127.86 (benzoyl 6-C), 128.49 
(benzoyl 5-C), 128.60 (phenoxy 4-C), 129.30 (benzoyl 2-C), 130.45 (benzoyl 
4-C), 133.32 (benzoyl 3-C), 139.64 (benzoyl 1-C), 159.36 (phenoxy 1-C), 
172.62 (ester C=O), 192.93 (ketone C=O). 
m/z:  HRMS (ES-TOF+) [MH]+ calculated 347.1045; found 347.0742. 
FT-IR: 2992, 2941 (CH3 stretch), 1726 (ester C=O), 1658 (ketone C=O), 1598 
(aryl CH stretch). 
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2-(4-(2-Methylbenzoyl)phenoxy)2-methyl propanoic acid (57a) 
 
 Following General Method C, ethyl-2-methyl-2-(4-(2-
methylbenzoyl)phenoxy)2-propanoate (0.090g, 0.275 mmol), was reacted with  
lithium hydroxide (0.058 g, 1.38 mmol) in a mixture of water and THF (1:1, 10 
ml) for 22 hours to afford 57a.   
Yield: 85 %   
Appearance: Yellow solid 
Purification: Used without further 
purification. 
1H NMR (DMSO): 1.58 (s, 6H, C(CH3)2), 2.19 (s, 3H, CH3), 6.89 (d, 3J = 8.9 
Hz, 2H, phenoxy 2-H and 6-H), 7.25-7.36 (m, 3H, benzoyl 3-H/5-H/6-H), 7.44 
(ddd, 3J = 7.3 Hz, 3J = 7.3 Hz, 4J = 1.6 Hz, 1H, benzoyl 4-H), 7.65 (d, 3J = 8.9 
Hz, 2H, phenoxy 3-H and 5-H), 13.23 (s, 1H, OH). 
13C NMR (DMSO): 19.25 (benzoyl CH3), 25.09 (C(CH3)2), 78.83 (C(CH3)2), 
117.08 (phenoxy 2-C and 6-C), 125.39 (benzoyl 5-C), 127.49 (benzoyl 6-C), 
129.87 (phenoxy 4-C), 130.72 (phenoxy 3-C and 5-C), 131.69 (benzoyl 3-C), 
135.22 (benzoyl 2-C), 138.78 (benzoyl 1-C), 159.91 (phenoxy 1-C), 174.32 
(carboxylic acid C=O), 196.19 (ketone C=O). 
m/z:  HRMS (ES-TOF+) [MH]+ calculated 299.1278; found 299.1268. 
2-(4-(3-Methylbenzoyl)phenoxy)-2-methyl propanoic acid (57b) 
Following General Method E, 55b (0.1310 g, 0.62 mmol) in MeCN (10 ml) 
was reacted with NaOH (0.155 g, 0.92 mmol) and α-bromoisobutyric acid 
(0.136 g, 3.39 mmol) for 3 hours to afford 57b. 
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Yield: 61 %   
Appearance: Pale yellow solid   
Purification: Used without further 
purification  
Melting point: 92 – 94 °C 
1H NMR (CDCl3): 1.69 (s, C(CH3)2, 6H), 2.41 (s, benzoyl CH3, 3H,), 6.94 (d, 
3J = 8.8 Hz, 2H, phenoxy 2-H and 6-H), 7.31-7.40 (m, 2H, benzoyl 4-H and 5-
H), 7.50-7.59 (m, 2H, 2-H and 6-H), 7.78 (d, 3J = 8.8 Hz, 2H, phenoxy 3-H and 
5-H).  
13C NMR (CDCl3): 21.49 (benzoyl CH3), 25.46 (C(CH3)2), 79.45 C(CH3)2),  
118.18 (phenoxy 2-C and 6-C), 127.26 (benzoyl 2-C), 128.18 (benzoyl 6-C), 
130.40 (benzoyl 5-C), 131.57 (phenoxy 4-C), 132.30 (phenoxy 3-C and 5-C), 
133.07 (benzoyl 4-C), 138.09 (benzoyl 3-C),  138.27 (benzoyl 1-C), 159.09 
(phenoxy 1-C), 177.53 (carboxylic acid C=O), 196.21 (ketone C=O). 
m/z:  HRMS (ES-TOF+) [MH]+ calculated 299.1278; found 299.1109 
FT-IR (KBr): 2985 (carboxylic acid OH), 1744 (carboxylic acid C=O), 1632 
(ketone C=O), 1595 (aryl CH stretch), 847, 811 (p disubtituted aromatic ring). 
2-(4-(4-Methylbenzoyl)phenoxy)-2-methylpropanoic acid  (57c)  
Following General Method E, 55c (0.073 g, 0.34 mmol) in MeCN (5 ml) was 
reacted with NaOH (0.075 g, 1.87 mmol) and α-bromoisobutyric acid (0.086 g, 
1.87 mmol) for 24 hours to afford 57c. 
Yield: 63 % 
Appearance: White needle like crystals. 
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Purification: Recrystallised from toluene. 
Melting point: 162 – 164 °C 
1H NMR (CDCl3): 1.69 (s, 6H, C(CH3)2), 2.43 (s, 3H, benzoyl CH3), 6.94 (d, 
3J = 8.8 Hz, 2H, phenoxy 2-H and 6-H), 7.26 (d, 3J = 8.1 Hz, 2H, benzoyl 3-H 
and 5-H), 7.68 (d, 3J = 8.1 Hz, 2H, phenoxy 3-H and 5-H), 7.76 (d, 3J = 8.8 Hz, 
2H, benzoyl 2-H and 6-H). 
13C NMR (CDCl3): 21.96 (benzoyl CH3), 25.64 (C(CH3)2), 79.70 (C(CH3)2), 
118.52 (phenoxy 2-C and 6-C), 129.28 (benzoyl 3-C and 5-C), 130.47 
(phenoxy 4-C), 132.07 (benzoyl 2-C and 6-C), 132.39 (phenoxy 3-C and 5-C), 
135.48 (benzoyl 1-C), 143.32 (benzoyl 4-C), 159.06 (phenoxy 1-C), 177.69 
(carboxylic acid C=O), 195.98 (ketone C=O). 
m/z:  HRMS (ES-TOF+) C19H17O4 [MH]+ calculated 297.1278; found 
297.1045. 
FT-IR (KBr): 2950 (carboxylic acid OH), 1742 (carboxylic acid C=O), 1625 
(ketone C=O), 1591 (aryl CH stretch), 888, 849 (p disubtituted aromatic ring). 
 2-(4-(3-Cyanobenzoyl)phenoxy)-2-methyl propanoic acid (57d) 
Following General Method C, ethyl-2-methyl-2-(4-(3-
cyanobenzoyl)phenoxy)2-propanoate (0.275 g, 0.85 mmol), was reacted with  
lithium hydroxide (0.102 g, 4.24 mmol) in a mixture of water and THF (1:1, 10 
ml) for 3 hours 30 minutes to afford 57d. 
Yield: 71 %   
Appearance: Orange brown solid 
Purification: Used without further 
purification. 
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Melting point: 99 – 101 °C 
1H NMR (CDCl3): 1.72 (C(CH3)2), 6.96 (d, 3J = 8.9 Hz, 2H, phenoxy 2-H and 
6-H), 7.62 (dd, 3J = 7.8 Hz, 3J = 7.8 Hz, 1H, benzoyl 5-H), 7.75 (d, 3J = 8.9 Hz, 
2H, phenoxy 3-H and 5-H), 7.84 (ddd, 3J = 7.9 Hz, 4J = 1.4 Hz, 4J = 1.4 Hz, 
1H, benzoyl 6-C), 7.97 – 8.03 (m, 2H, benzoyl 2-H and 4-H).  
13C NMR (CDCl3): 25.48 (C(CH3)2), 79.50 (C(CH3)2), 112.86 (benzoyl 3-C), 
118.11 (CN), 118.23 (phenoxy 2-C and 6-C), 129.50 (benzoyl 5-C), 129.97 
(phenoxy 1-C), 132.31 (phenoxy 3-C and 5-C), 133.32 (benzoyl 6-C), 133.79 
(benzoyl 2-C), 135.20 (benzoyl 4-C), 139.18 (benzoyl 1-C), 159.90 (phenoxy 
1-C), 177.55 (carboxylic acid C=O), 193.36 (ketone C=O).  
m/z:  HRMS (ES-TOF+) C18H16NO4 [MH]+ calculated 310.1074; found 
309.9905. 
FT-IR (KBr): 2986 (carboxylic acid OH), 2227 (CN), 1741 (carboxylic acid 
C=O), 1639 (ketone C=O), 1592 (aryl CH stretch). 
2-(4-(4-Cyanobenzoyl)phenoxy)-2-methyl propanoic acid (57e) 
 
Following General Method C, ethyl-2-
methyl-2-(4-(4-cyanobenzoyl)phenoxy)2-
propanoate (0.100 g, 0.29 mmol), was reacted with  lithium hydroxide (0.036 
g, 1.48 mmol) in a mixture of water and THF (1:1, 10 ml) for 21 hours to 
afford 57e. 
Yield: 92 %   
Appearance: White solid 
Purification: Used without further purification. 
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Melting point: 158 – 159 °C 
1H NMR (DMSO): 1.59 (s, 3H, C(CH3)2), 6.93 (d, 3J = 8.9 Hz, 2H, phenoxy 
2-H and 6-H), 7.73 (d, 3J = 8.8 Hz, 2H, phenoxy 3-H and 5-H), 7.82 (d, 3J = 
8.6 Hz, 2H benzoyl 2-H and 6-H), 8.01 (d, 3J =8.6 Hz, 2H, benzoyl 3-H and 5-
H), 8.13 (s, 1H, OH). 
m/z:  HRMS (ES-TOF+) [MH]+ calculated 310.1074; found 310.1135. 
FT-IR: 2995 (carboxylic acid OH stretch), 2230 (CN stretch), 1743 (ketone 
C=O), 1596 (aryl CH stretch), 862, 842 (p disubtituted aromatic ring). 
2-(4-(3-Chlorobenzoyl)phenoxy)-2-methyl propanoic acid (57f) 
 
Following General Method C, 56f (0.150 g, 0.43 mmol), was reacted with  
lithium hydroxide (0.091 g, 2.16 mmol) in a mixture of water and THF (1:1, 10 
ml) for 2 hours 30 minutes to afford 57f. 
Yield: 50 %   
Appearance: Yellow solid 
Purification: Used without further 
purification. 
1H NMR (DMSO): 1.60 (C(CH3)2), 6.93 (d, 3J = 8.9 Hz, 2H, phenoxy 2-C and 
6-C), 7.55 -7.75 (m, 6H, benzoyl 2-H/4-H/5-H/6-H, phenoxy 3-H and 5-H), 
13.27 (caboxylic acid OH).  
13C NMR (DMSO): 25.09 (C(CH3)2), 78.90 (C(CH3)2), 117.06 (phenoxy 2-C 
and 6-C), 127.88 (benzoyl 6-C), 128.59 (benzoyl 5-C), 129.01 (phenoxy 3-C 
and 5-C), 130.44 (benzoyl C-2), 131.97 (benzoyl 4-C), 133.36 (benzoyl 3-C), 
139.68 (benzoyl 1-C), 159.69 (phenoxy 1-C), 174.38 (carboxylic acid C=O), 
192.93 (ketone C=O). 
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2-(4-(2-Fluorobenzoyl)-phenoxy-2-methylpropanoic acid (57g) 
Following General Method E, 55g (0.501 g, 2.31 mmol) in MeCN (10 ml) was 
reacted with NaOH (0.509 g, 13.0 mmol) and α-bromoisobutyric acid (0.579 g, 
3.46 mmol) for 21 hours to afford 57g.  
Yield: 76% 
Appearance: Off – white solid 
Purification: Precipitated from EtOAc with 
PE.  The solid afforded was collected by vacuum filtration. 
Melting point: 133 – 135 °C 
1H NMR (DMSO): 1.69 (s, 6H, C(CH3)2), 6.91 (d, 3J = 8.9 Hz, 2H, phenoxy 
2-H and 6-H), 7.15 (m, 1H, benzoyl CH), 7.23-7.26 (m, 1H, benzoyl CH), 
7.48-7.51 (m, 2H, benzoyl CH), 7.52 (d, 3J = 8.8 Hz, 2H, phenoxy 3-H and 5-
H).   
13C NMR (DMSO): 25.45 (C(CH3)2), 79.39 (C(CH3)2), 116.34 (d, 2JCF = 21.9 
Hz, benzoyl 3-C), 118.12 (phenoxy 2-C and 6-C), 124.39 (d, 4JCF = 3 Hz, 
benzoyl 5-C), 127.32 (d, 2JCF = 15.0 Hz, benzoyl 1-C), 130.65 (d, 3JCF = 3 Hz, 
benzoyl 6-C), 131.25 (phenoxy 4-C), 132.12 (phenoxy 3-C and 5-C), 132.85 
(d, 3JCF = 8.0 Hz, benzoyl 4-C), 159.89 (phenoxy 1-C), 159.93 (d, 1JCF = 
251.53 Hz, benzoyl 2-C), 178.68 (carboxylic acid C=O), 192.36 (ketone C=O).  
m/z:  HRMS (ES-TOF-) C17H14FO4- [MH]- calculated 301.0882; found 
301.0907. 
FT-IR (KBr): 3089 (carboxylic acid OH), 2603, 2492 (CH3 stretch), 1745 
(carboxylic acid C=O), 1633 (ketone C=O), 1591 (aryl CH stretch), 849, 826 
(para disubstituted aromatic ring). 
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2-(4-(3-Fluorobenzoyl)phenoxy)-2-methyl propanoic acid (57h) 
Following General Method E, 55h (0.350 g, 1.62 mmol) in MeCN (10 ml) was 
reacted with NaOH (0.356 g, 8.90 mmol) and α-bromoisobutyric acid (0.406 g, 
2.43 mmol) for 4 hours to afford 57h.  
Yield: 59 %   
Appearance: White solid 
Purification: Precipitated from EtOAc by addition of PE. 
Melting point: 104 – 106 °C 
1H NMR (DMSO): 1.60 (s, 6H, C(CH3)2), 6.93 (d, 3J = 8.9 Hz, 2H, phenoxy 
2-H and 6-H), 7.44-7.53 (m, 3H, benzoyl 4-H, 5-H, 6-H), 7.56-7.63 (m, 1H, 
benzoyl 2-H), 7.74 (d, 3J = 8.9 Hz, 2H, phenoxy 3-H and 5-H). 
13C NMR (DMSO): 25.09 (C(CH3)2), 78.91 (C(CH3)2), 115.64 (d, 2JCF = 22.1 
Hz, benzoyl 2-C), 117.07 (phenoxy 2-C and 6-C), 118.94 (d, 2JCF = 21.1 Hz, 
benzoyl 4-C), 125.43 (d, 4JCF=3.0 Hz, benzoyl 6-C), 129.08 (phenoxy 4-C), 
130.66 (d, 3JCF = 8.0 Hz, benzoyl 5-C), 131.94 (phenoxy 3-C and 5-C), 139.95 
(d, 3JCF = 7.0 Hz, benzoyl 1-C), 159.65 (phenoxy 1-C), 161.81 (d, 1JCF = 245 
Hz, benzoyl 3-C), 174.38 (carboxylic acid C=O), 192.97 (ketone C=O). 
m/z:  HRMS (ES-TOF+) [MH]+ calculated 303.1027; found 303.0894. 
FT-IR (KBr): 2989 (carboxylic acid OH stretch), 1744 (carboxylic acid C=O), 
1641 (ketone C=O), 1593 (aryl CH stretch). 
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2-(4-(4-Fluorobenzoyl)phenoxy-2-methylpropanoic acid (57i) 
Following General Method E, 55i (0.500 g, 2.31 mmol) in butan-2-one (20 ml) 
was reacted with NaOH (0.508 g, 12.1 mmol) and α-bromoisobutyric acid 
(0.579 g, 3.47 mmol) for 24 hours to afford 57i.  
Yield: 11 % 
Appearance: White solid 
Purification: Column chromatography, 1% 
MeOH: 99% DCM to 5% MeOH / 95 % DCM.  Then recrystallised from 
toluene. 
Melting point: 159-160 °C 
1H NMR (DMSO): 1.59 (s, 6H, C(CH3)2), 6.92 (d, 3J = 8.8 Hz, 2H, phenoxy 
2-H and 6-H), 7.37 (dd, 2H, 3J = 8.8 Hz, 3JCF = 8.8 Hz, benzoyl 3-H and 5-C), 
7.71 (d, 3J = 8.8 Hz, 2H, phenoxy 3-H and 5-H), 7.78 (dd, 2H, 3J = 8.8 Hz, 
4JHF = 5.6 Hz, benzoyl 2-H and 6-H) 13.21 (s, 1H, OH). 
13C NMR (DMSO): 25.44 (C(CH3)2), 79.49 (C(CH3)2), 115.57 (d, 2JCF = 21.8 
Hz benzoyl 3-C and 5-C), 118.32 (phenoxy 2-C and 6-C), 131.37 (phenoxy 4-
C), 132.17 (phenoxy 3-C and 5-C), 132.59 (d, 3J = 9.5 Hz, benzoyl 2-C and 6-
C), 134.19 (d, 4JCF = 2.9 Hz, benzoyl 1-C), 159.09 (phenoxy 1-C), 165.39 (d, 
1JCF = 253.9 Hz, benzoyl 4-C), 177.99 (carboxylic acid C=O), 194.49 (ketone 
C=O). 
m/z:  HRMS (ES-TOF-) C17H14FO4 [MH]- calculated 301.0882; found 
301.0828. 
FT-IR (KBr): 3059 (carboxylic acid OH), 1735 (carboxylic acid C=O), 1626 
(ketone C=O), 1598 (aryl CH stretch), 864, 852 (para disubtituted aromatic 
ring). 
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2-(4-(3-Nitrobenzoyl) phenoxy)-2-methyl propanoic acid (57j) 
Following General Method C, 56d (0.090 g, 0.26 mmol), was reacted with  
lithium hydroxide (0.044 g, 1.83 mmol) in a mixture of water and THF (1:1, 10 
ml) for 24 hours 30 minutes to afford 57j. 
Yield: 83 %   
Appearance: Brown solid 
Purification: Used without further 
purification 
1H NMR (DMSO): 1.72 (C(CH3)2), 6.97 (d, 3J = 8.8 Hz, phenoxy 2-H and 6-
H), 7.69 (dd, 3J = 7.9 Hz, 3J = 7.9 Hz, benzoyl 5-H), 7.78 (d, 3J = 8.9 Hz, 
phenoxy 3-H and 5-H), 8.09 (ddd, 3J = 7.8 Hz, 4J = 1.4 Hz, 4J = 1.4 Hz, 
benzoyl 6-H), 8.42 (ddd, 3J = 8.2 Hz, 4J = benzoyl 4-H) 8.57 (dd, 4J = 1.8 Hz, 
4J = 1.8 Hz, benzoyl 2-H).  
13C NMR (DMSO): 25.47 (C(CH3)2), 79.55 (C(CH3)2), 118.29 (phenoxy 2-C 
and 6-C), 124.59 (benzoyl 2-C), 126.57 (benzoyl 4-C), 129.75 (benzoyl 5-C), 
130.02 (phenoxy 4-C), 132.33 (phenoxy 3-C and 5-C), 135.38 (benzoyl 6-C), 
139.62 (benzoyl 1-C), 148.16 (benzoyl 3-C), 159.89 (phenoxy 1-C), 176.69 
(carboxylic acid C=O), 193.04 (ketone C=O). 
m/z:  HRMS (ES-TOF+) [MH]+ calculated 330.0972; found 330.1026. 
FT-IR: 3090 (carboxylic acid OH), 1743 (carboxylic acid C=O), 1638 (ketone 
C=O), 1596 (aryl CH stretch), 843, 821 (p disubtituted aromatic ring). 
2-(4-(4-Nitrobenzoyl)phenoxy)-2-methyl propanoic acid (57k) 
 
Following General Method C, 56e (0.600 g, 1.75 mmol), was reacted with  
lithium hydroxide (0.209 g, 8.73 mmol) in a mixture of water and THF (1:1, 10 
ml) for 4 hours to afford 57k. 
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Yield: 64 %   
Appearance: Yellow solid 
Purification: Used without further 
purification. 
Melting point: 170 – 172 °C 
1H NMR (DMSO): 1.60 (s, C(CH3)2, 6H), 6.94 (d, 3J = 8.8 Hz, 2H, phenoxy 
2-H and 6-H), 7.75 (d, 3J = 8.9 Hz, 2H, phenoxy 3-H and 5-H), 7.91 (d, 3J = 
8.8 Hz, 2H, benzoyl 2-H and 6-H), 8.36 (d, 3J = 8.8 Hz, 2H, benzoyl 3H and 5-
H).  
13C NMR (DMSO): 25.48 (C(CH3)2), 79.47 (C(CH3)2), 118.20 (phenoxy 2-C 
and 6-C), 123.67 (benzoyl 3-C and 5-C), 130.02 (benzoyl 2-C and 6-C), 130.55 
(phenoxy 4-C), 132.41 (phenoxy 3-C and 5-C), 143.54 (benzoyl 1-C), 149.78 
(benzoy; 4-C), 160.00 (phenoxy 1-C), 177.91 (carboxylic acid C=O), 193.73 
(ketone C=O).  
m/z:  HRMS (ES-TOF+) [MH]+ calculated 330.0972; found 330.0834. 
FT-IR: 3249 (carboxylic acid OH), 1710 (carboxylic acid C=O), 1647 (ketone 
C=O), 1595 (aryl CH stretch), 1471 (NO2). 
(4-Benzoyl)-phenoxy-2-methylpropanoic acid (57l) 
 
Following General Method E, 55l (0.500 g, 2.52 mmol) in MeCN (20 ml) was 
reacted with NaOH (0.555 g, 13.9 mmol) and α-
bromoisobutyric acid (0.632 g, 3.78 mmol) for 2 
hours 30 minutes to afford 57l. 
Yield: 76% 
Appearance: Off – white solid 
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Purification: Precipitated with petroleum ether.  The solid afforded was 
collected by vacuum filtration. 
Melting point: 130 – 132 °C 
1H NMR (CDCl3): 1.70 (s, 3H, C(CH3)2), 6.93 (d, 3J = 8.9 Hz, 2H, phenoxy 
2-H and 6-H), 7.46 (dd, 3J = 7.5 Hz, 3J = 7.5 Hz, 2H, benzoyl 3-H and 5-H), 
7.57 (t, 3J = 7.4 Hz, 1H, benzoyl 4-H) 7.74-7.79 (m, 4H, phenoxy 3-H and 5-H 
and benzoyl 2-H and 6-H).   
13C NMR (CDCl3): 25.31 (C(CH3)2), 79.33 (C(CH3)2), 118.15 (phenoxy 2-C 
and 6-C), 128.24 (benzoyl 3-C and 5-C), 129.83 (benzoyl 2-C and 6-C),  
131.35 (phenoxy 4-C), 132.18 (phenoxy 3-C and 5-C), 137.90 (benzoyl 4-C), 
158.94 (phenoxy 1-C), 177.76 (carboxylic acid C=O), 194.3 (ketone C=O). 
m/z:  HRMS (ES-TOF-) C17H16O4 [MH]- calculated 283.0976; found 283.0920. 
FT-IR (KBr): 3060 (carboxylic acid OH), 2988 (CH3 stretch), 1741 
(carboxylic acid C=O), 1633 (ketone C=O), 1595 (aryl CH stretch), 848, 823 
(para disubtituted aromatic ring). 
N-Morpholino-2-(4-(2-methylbenzoyl)phenoxy)-2-methylpropanamide 
(58a) 
Following General Method G, 57a (0.025 g, 0.084 mmol) was reacted with 
HBTU (0.034 g, 0.092 mmol), 4-aminomorpholine (0.009 g, 0.084 mmol) and 
triethylamine (17.4 >l, 0.092 mmol) in DCM (3 ml) for 21 hours 30 minutes to 
afford 58a. 
Yield: 89 %   
Appearance: White solid 
Purification: Preparative TLC, 3 PE / 7 EtOAc. 
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Melting point: 111 – 112 °C 
1H NMR (CDCl3): 1.60 (C(CH3)2), 2.77-2.81 (m, 4H, morpholino 2-H and 6-
H), 3.78-3.85 (m, 4H, morpholino 3-H and 5-H), 6.93 (d, 3J = 8.8 Hz, 2H, 
phenoxy 2-H and 6-H), 7.21-7.30 (m, benzoyl 3-H, 4-H, 6-H), 7.38 (ddd, 3J = 
7.5 Hz, 3J = 7.5 Hz, 4J = 1.8 Hz, 1H, benzoyl 5-H), 7.75 (d, 2H, 3J = 8.8 Hz, 
phenoxy 3-H and 5-H). 
13C NMR (CDCl3): 20.14 (benzoyl CH3), 25.55 (C(CH3)2), 55.89 (morpholino 
3-C and 5-C), 66.60 (morpholino 2-C and 6-C), 81.92 (C(CH3)2), 119.56 
(phenoxy 2-C and 6-C), 125.48 (benzoyl 5-C), 128.42 (benzoyl 6-C), 130.41 
(benzoyl 3-C), 131.27 (benzoyl 4-C), 132.26 (phenoxy 3-C and 5-C), 132.62 
(phenoxy 4-C), 136.73 (benzoyl 2-C), 138.87 (benzoyl 1-C), 158.83 (phenoxy 
1-C), 171.44 (amide C=O), 197.48 (ketone C=O). 
HPLC: System 2, Rt = 15.95 minutes 
 System 3, Rt = 2.64 minutes 
  System 4, Rt = 2.65 minutes  
m/z:  HRMS (ES-TOF+) C22H27N2O4 [MH]+ calculated 383.1965; found 
383.1958.  
FT-IR: 2936, 2861 (CH3 stretch), 1684 (ketone C=O), 1652 (amide C=O), 
1598 (aryl CH stretch). 
N-Morpholino-2-(4-(3-methylbenzoyl)phenoxy)-2-methylpropanamide 
(58b) 
Following General Method G, 57b (0.059 g, 0.20 mmol) was reacted with 
HBTU (0.085 g, 0.22 mmol), 4-aminomorpholine (0.020 g, 0.20 mmol) and 
triethylamine (42 >l, 0.22 mmol) in DCM (3 ml) for 19 hours 30 minutes to 
afford 58b. 
182 
 
Yield: 31 %   
Appearance: White solid 
Purification: Precipitated from 
EtOAc with addition of PE. 
Melting point: 129 – 130 °C 
1H NMR (CDCl3): 1.61 (s, C(CH3)2, 6H), 2.42 (s, 3H, benzoyl CH3), 2.80 (m, 
4H, morpholino 2-CH2 and 6-CH2), 3.81 (m, 4H, morpholino 3-CH2 and 5-
CH2), 6.97 (d, 3J = 8.8 Hz, 2H, phenoxy 2-H and 6-H), 7.24 (broad s, 1H, NH), 
7.33-7.42 (m, 2H, benzoyl 3-H and 6-H), 7.50-7.59 (m, 2H, benzoyl 2-H and 6-
H), 7.78 (d, 3J = 8.8 Hz, 2H, phenoxy 3-H and 5-H). 
13C NMR (CDCl3): 21.51 (benzoyl CH3) 25.42 (C(CH3)2), 55.78 (morpholino 
3-C and 5-C), 66.47 (morpholino 2-C and 6-C), 81.74 (C(CH3)2), 119.39 
(phenoxy 2-C and 6-C), 127.20 (benzoyl 2-C), 128.21 (benzoyl 6-C), 130.34 
(benzoyl 5-C), 132.11 (phenoxy 3-C and 5-C), 132.38 (phenoxy 4-C), 133.16 
(benzoyl 4-C), 137.91 (3-C), 138.33 (benzoyl 1-C), 158.08 (phenoxy 1-C), 
171.39 (amide C=O), 195.77 (ketone C=O). 
HPLC: System 2, Rt = 16.30 minutes 
 System 3, Rt = 2.67 minutes   
  System 4, Rt = 2.69 minutes   
m/z:  HRMS (ES-TOF+) C22H27N2O4 [MH]+ calculated 383.1965; found 
382.9665 
FT-IR (KBr): 3297 (amide NH), 2928, 2850 (CH3 stretch), 1687 (ketone 
C=O), 1597 (aryl CH stretch), 882, 858 (p disubtituted aromatic ring). 
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N-Morpholino-2-(4-(4-methylbenzoyl)phenoxy)-2-methylpropanamide 
(58c)  
Following General Method G, 57c (0.028 g, 0.094 mmol) was reacted with 
HBTU (0.039 g, 0.104 mmol), 4-aminomorpholine (0.009 g, 0.094 mmol) and 
triethylamine (19.0 >l, 0.104 mmol) in DCM (3 ml) for 2 hours 45 minutes to 
afford 58c. 
Yield: 59 %   
Appearance: White solid 
Purification: Column chromatography, 5 % EtOAc / 95 % PE to 100 % 
EtOAc.  
1H NMR (CDCl3): 1.61 (s, C(CH3)2, 6H), 2.44 (s, 3H, benzoyl CH3), 2.81 (m, 
4H, morpholino 3-CH2 and 5- CH2), 3.81 (m, 4H, morpholino 2-CH2 and 6- 
CH2), 6.97 (d, 3J = 8.8 Hz, 2H, phenoxy 2-H and 6-H), 7.24-7.30 (m, 2H, 
benzoyl 3-H and 5-H), 7.68 (d, 3J = 8.2 Hz 2H, phenoxy 3-H and 5-H), 7.77 (d, 
3J = 8.8 Hz, 2H, benzoyl 2-H and 6-H). 
13C NMR (CDCl3): 21.65 (benzoyl CH3), 25.29 (C(CH3)2), 55.68 (morpholino 
2-C and 6-C), 66.35 (morpholino 3-C and 5-C), 81.62 (C(CH3)2), 119.31 
(phenoxy 2-C and 6-C), 128.99 (benzoyl 3-C and 5-C), 130.06 (phenoxy 3-C 
and 5-C), 131.87 (benzoyl 2-C and 6-C), 135.01 (phenoxy 4-C), 143.09 
(benzoyl C-4), 157.79 (phenoxy  1-C), 171.30 (amide C=O), 195.21 (ketone 
C=O). 
HPLC: System 2, Rt = 16.28 minutes 
 System 3, Rt = 2.65 minutes  
  System 4, Rt = 2.69 minutes 
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m/z:  HRMS (ES-TOF+) C22H27N2O4 [MH]+ calculated 383.1965; found 
383.0093. 
N-Morpholino-2-(4-(3-cyanobenzoyl)phenoxy)-2-methylpropanamide 
(58d) 
Following General Method G, 57d (0.044 g, 0.14 mmol) was reacted with 
HBTU (0.059 g, 0.16 mmol), 4-aminomorpholine (0.014 g, 0.14 mmol) and 
triethylamine (30.0 >l, 0.092 mmol) in DCM (3 ml) for 21 hours 30 minutes to 
afford 58d. 
Yield: 46%   
Appearance: White solid  
Purification: Recrystallised from 
PE / EtOAc 
Melting point: 89 – 91 °C 
1H NMR (CDCl3): 1.63 (s, 6H C(CH3)2), 2.80 (m,  4H, morpholino CH2), 3.80 
(m, 4H, morpholino CH2), 7.01 (d, 3J = 8.8 Hz, 2H, phenoxy 2-H and 6-H), 
7.19 (broad s, 1H, NH), 7.63 (dd, 1H, 3J = 7.9 Hz, 3J = 7.5 Hz, benzoyl 5-H), 
7.75 (d, 3J = 8.8 Hz, 2H, phenoxy 3-H and 5-H), 7.86 (ddd, 3J = 7.7 Hz, 4J = 
1.3 Hz, 4J = 1.3 Hz, 1H, benzoyl 6-H), 7.97-8.03 (m, 2H, benzoyl 2-H and 4-
H).  
13C NMR (CDCl3): 25.62 (C(CH3)2), 55.97 (morpholino 3-C and 5-C), 66.66 
(morpholino 2-C and 6-C), 82.13 (C(CH3)2), 113.17 (benzoyl 3-C), 118.217 
(CN), 119.78 (phenoxy 2-C and 6-C), 129.77 (benzoyl 5-C), 131.08 (phenoxy 
4-C), 132.34 (phenoxy 3-C and 5-C), 133.53 (benzoyl 2-C), 133.92 (benzoyl 6-
C), 135.53 (benzoyl 4-C), 139.17 (benzoyl 1-C), 159.12 (phenoxy 1-C), 171.38 
(amide C=O), 193.36 (ketone C=O). 
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HPLC: System 2, Rt = 14.20 minutes 
 System 3, Rt = 2.51 minutes 
  System 4, Rt = 2.58 minutes 
m/z:  HRMS (ES-TOF+) C22H26N3O4 [MH]+ calculated 394.1761; found 
394.1651 
FT-IR (KBr): 3302 (amide NH), 2948, 2851 (CH3 stretch), 2229 (CN), 1734 
(amide C=O), 1646 (ketone C=O), 1572 (aryl CH stretch), 882, 856 (p 
disubtituted aromatic ring).  
N-Morpholino-2-(4-(4-cyanobenzoyl)phenoxy)-2-methylpropanamide 
(58e) 
Following General Method G, 57e (0.020 g, 0.065 mmol) was reacted with 
HBTU (0.027 g, 0.071 mmol), 4-aminomorpholine (0.007 g, 0.065 mmol) and 
triethylamine (13.4 >l, 0.092 mmol) in DCM (3 ml) for 24 hours to afford 58e. 
Yield: 72 %   
Appearance: White solid 
Purification: Column 
chromatography, 5% EtOAc / 95 % PE to 100 % EtOAc. 
Melting point: 145 – 147 °C 
1H NMR (DMSO): 1.63 (C(CH3)2), 2.77- 2.81 (m, 2H, morpholino 3-CH2 and 
5-CH2), 3.78 – 3.82 (m, 2H, morpholino 2-CH2 and 6-CH2), 6.99 (d, 2H, 3J = 
8.9 Hz, phenoxy 2-H and 6-H), 7.76 (d, 2H, 3J = 8.8 Hz, phenoxy 3-H and 5-
H), 7.79 (d, 2H, 3J = 8.6 Hz, benzoyl 2-H and 6-H), 7.83 (d, 2H, 3J = 8.6 Hz, 
benzoyl 3-H and 5-H).   
13C NMR (DMSO): 25.62 (C(CH3)2), 55.98 (morpholino 3-C and 5-C), 66.67 
(morpholino 2-C and 6-C), 119.72 (phenoxy 2-C and 6-C), 130.32 (phenoxy 3-
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C and 5-C), 132.42 (benzoyl 2-C and 6-C), 132.54 (benzoyl 3-C and 5-C), 
207.33 (ketone C=O).  
m/z:  HRMS (ES-TOF+) [MH]+ calculated 393.1761; found 394.1703. 
HPLC: System 2, Rt= 14.37 minutes 
 System 3, Rt = 2.52 minutes 
    System 4, Rt = 2.59 minutes  
FT-IR: 3367 (amide NH stretch), 2922, 2849 (CH3 stretch), 2228 (CN stretch), 
1683 (ketone C=O), 1644 (amide C=O), 1599 (aryl CH stretch), 878, 861 (p 
disubtituted aromatic ring). 
N-Morpholino-2-(4-(3-chlorobenzoyl)phenoxy)-2-methylpropanamide 
(58f) 
Following General Method G, 57f (0.026 g, 0.080 mmol) was reacted with 
HBTU (0.033g, 0.089 mmol), 4-aminomorpholine (0.008g, 0.081mmol) and 
triethylamine (16.8 >l, 0.089 mmol) in DCM (3 ml) for 21 hours 30 minutes to 
afford 58f. 
Yield: 85 %   
Appearance: White solid 
Purification: PLC, 30 % PE / 70 % 
EtOAc. 
Melting point: 130 – 132 °C 
1H NMR (CDCl3): 1.62 (s, 6H, C(CH3)2), 2.78 – 2.82 (m, 4H, morpholino 3-
CH2 and 5-CH2), 3.78 – 3.82 (m, 4H, morpholino 2-CH2 and 6-CH2), 6.98 (d, 3J 
= 8.8 Hz, 2H, phenoxy 2-H and 6-H), 7.22 (s, 1H, NH), 7.42 (dd, 1H, 3J = 7.9 
Hz, 3J = 8.0 Hz, benzoyl 5-C), 7.55 (ddd, 3J = 7.9 Hz, 4J = 2.0 Hz, 4J = 1.0 Hz, 
1H, benzoyl 6-C), 7.62 (ddd, 3J = 7.7 Hz, 4J = 1.3 Hz, 4J = 1.3 Hz,  1H, 
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benzoyl 4-C), 7.72 (dd, 4J = 1.8 Hz, 4J = 1.8 Hz, 1H, benzoyl 2-C), 7.77 (d, 3J 
= 8.8 Hz, 2H, phenoxy 3-H and 5-H). 
13C NMR (CDCl3): 25.63 (C(CH3)2), 55.99 (morpholino 3-C and 5-C), 66.67 
(morpholino 2-C
 
and 6-C), 82.00 (C(CH3)2), 119.65 (phenoxy 2-C and 6-C), 
128.14 (benzoyl 6-C), 130.00 (benzoyl 5-C), 131.74 (phenoxy 4-C), 132.34 
(phenoxy 3-C and 5-C), 132.53 (benzoyl 2-C), 134.91 (benzoyl 4-C), 139.78 
(benzoyl 3-C), 158.75 (phenoxy 1-C), 171.51 (amide C=O), 194.26 (ketone 
C=O).
 
m/z:  HRMS (ES-TOF+) C21H24ClN2O4 [MH]+ calculated 403.1419; found 
403.1315. 
HPLC:  System 2,  Rt = 17.05 minutes 
  System 3, Rt = 2.73 minutes 
   System 4, Rt = 2.74 minutes  
FT-IR: 2846 (CH3 stretch), 1683 (amide C=O), 1644 (ketone C=O), 1597 (aryl 
CH stretch).  
N-Morpholino-2-(4-(2-fluorobenzoyl)phenoxy)-2-methylpropanamide 
(58g) 
Following General Method B, 57g (0.454 g, 0.501 mmol) and an excess of 
thionyl chloride (5ml)were reacted for 3 hours and 20 minutes to afford the 
corresponding acid chloride (0.241 g, 0.750 mmol).  The acid chloride was 
then reacted directly with 4-aminomorpholine (0.115 g, 1.13 mmol) and 
triethylamine (0.105 ml, 0.750 mmol) in DCM (3 ml) to afford 58g. 
Yield: 27 % 
Appearance: Yellow Solid 
Purification: PLC, 2% methanol / 98% 
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DCM 
 1H NMR (CDCl3): 1.63 (s, 6H, C(CH3)2), 2.81 (m, 4H, morpholino 2-H and 
6-H), 3.82 (m, 4H, morpholino 3-H and 5-H), 6.98 (d, 3J = 8.8 Hz, 2H, 
phenoxy 2H and 6H), 7.14-7.21 (m, 2H, 2-fluorophenyl 3-H and 5-H), 7.26-
7.32 (m, 1H, 2-fluorophenyl 6-H), 7.51-7.57 (m, 2H, 2-fluorophenyl 2-H and 
4-H), 7.81 (d, 3J = 8.8 Hz, 2H, phenoxy 3-H and 5-H).  
13C NMR (DMSO): 25.45 (C(CH3)2), 55.76 (morpholino 3-C/5-C), 66.48 
(morpholino 2-C/6-C), 81.80 (C(CH3)2), 116.37 (d, 2JCF = 22 Hz, benzoyl 3-C), 
119.28 (phenoxy 2-C and 6-C), 124.51 (d, 4JCF= 3 Hz, benzoyl 5-C), 127.22 (d, 
2JCF = benzoyl 1-C), 130.68 (d, 3JCF = 3 Hz, benzoyl 6-C), 131.90 (phenoxy 3-
C and 5-C), 132.12 (phenoxy 4-C), 133.07 (d, 3JCF = 8 Hz, benzoyl 4-C), 
158.99 (phenoxy 1-C), 159.98 (d, 1JCF = 251 Hz, benzoyl C-2), 171.27 (amide 
C=O), 192.06 (benzoyl C=O). 
Melting point: 154-155 °C 
HPLC: System 2, Rt =14.84 minutes. 
 System 3, Rt = 2.57 minutes 
  System 4, Rt = 2.59 minutes  
m/z:  HRMS (ES-TOF+) C21H23FN2O4 [MH]+ calculated 387.1715; found 
386.9297. 
FT-IR (KBr): 3288 (amide C=O), 2940, 2830 (CH3 stretch), 1689 (amide 
C=O), 1644 (ketone C=O), 1596 (aryl CH stretch), 881, 857 (para disubtituted 
aromatic ring). 
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N-Morpholino-2-(4-(3-fluorobenzoyl)phenoxy)-2-methylpropanamide 
(58h) 
Following General Method G, 57h (0.100 g, 0.33 mmol) was reacted with 
HBTU (0.138 g, 0.36 mmol), 4-aminomorpholine (0.034 g, 0.33 mmol) and 
triethylamine (68.8 >l, 0.33 mmol) in DCM (5 ml) for 4 hours to afford 58h. 
Yield: 37 %   
Appearance: White solid 
Purification: Column 
chromatography, 5 % EtOAc / 95 % PE to 100% EtOAc. 
Melting point: 152 – 154 °C 
1H NMR (CDCl3): 1.62 (s, 6H, C(CH3)2), 2.80 (m, 4H, morpholino CH2), 3.80 
(m, 4H morpholino CH2), 6.98 (d, 3J = 8.8 Hz, 2H, phenoxy 2-H and 6-H), 
7.22 (s, 1H, NH), 7.29 (dddd, 3J = 8.3 Hz, 3J = 8.3 Hz, 4J = 2.7 Hz, 4J = 1.2 Hz, 
1H, benzoyl 4-H), 7.43-7.49 (m,  2H, benzoyl 2-H and 5-H), 7.53 (ddd, 1H, 3J 
= 7.7 Hz, 4J = 1.2 Hz, 4J = 1.2 Hz, benzoyl 6-H), 7.78 (d, 3J = 8.9 Hz, 2H, 
phenoxy 3-H and 5-H).    
13C NMR (CDCl3): 25.42 (C(CH3)2), 55.79 (morpholino 3-C and 5-C), 66.47 
(morpholino 2-C and 6-C), 81.83 (C(CH3)2), 116.7 (d, 2JCF = 22.1 Hz, benzoyl 
2-C), 119.37 (d, 2JCF = 18.1 Hz, benzoyl 4-C), 119.49 (phenoxy 2-C and 6-C), 
125.64 (d, 4JCF = 3.0Hz, benzoyl 6-C), 130.14 (d, 3JCF = 8.0 Hz, benzoyl 5-C), 
131.63 (phenoxy 4-C), 132.13 (phenoxy 3-C and 5-C), 139.67 (d,3JCF = 7.0Hz, 
benzoyl 1-C), 158.48 (phenoxy 1-C), 162.59 (d, 1JCF = 247.4 Hz, benzoyl 3-C), 
171.30 (amide C=O), 194.09 (ketone C=O). 
HPLC: System 2 Rt= 17.60 minutes 
 System 3, Rt = 2.60 minutes 
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  System 4, Rt = 2.67 minutes  
m/z:  HRMS (ES-TOF+) C21H24FN2O4 [MH]+ calculated 387.1715; found 
387.1680. 
FT-IR (KBr): 3298 (amide NH), 2929, 2845 (CH3 stretch), 1686 (amide 
C=O), 1648 (ketone C=O), 1584 (aryl CH stretch). 
N-Morpholino-2-(4-(4-fluorobenzoyl)phenoxy-2-methylpropanamide (58i) 
Following General Method B, 57i (0.214 g, 0.71 mmol) and an excess of 
thionyl chloride (5ml)were reacted for 3 hours and 30 minutes to afford the 
corresponding acid chloride (0.227 g, 0.71 mmol).  The acid chloride was then 
reacted directly with 4-aminomorpholine (0.072 g, 1.06 mmol) and  
triethylamine (0.099 ml, 0.71 mmol) in DCM (3 ml) to afford 58i. 
Yield: 38% 
Appearance: White solid 
Purification: PLC 20%  petroleum 
ether/ 80% ethyl acetate 
 1H NMR (DMSO): 1.65 (s, 6H, C(CH3)2), 2.81 (broad t, 3J = 4.5 Hz, 4H, 
morpholino 3-CH2 and 5- CH2), 3.80 (broad t, 3J = 4.5 Hz, 4H, morpholino 2-
CH2 and 6-CH2), 6.98 (d, 3J = 8.7 Hz, 2H, phenoxy 2-H and 6-H), 7.16 (dd, 3J 
= 8.6 Hz, 3J = 8.6 Hz, 2H, benzoyl 3-H and 5-H), 7.23 (broad s, NH, 1H), 7.75 
(d, 3J = 8.8 Hz, 2H, phenoxy 3-H and 5-H), 7.80 (dd, 3J = 8.6 Hz, 4J = 5.4 Hz, 
2H, benzoyl 2-H and 6-H). 
13C NMR (DMSO): 25.42 (C(CH3)2), 55.78 (morpholino 3-C/5-C), 66.49 
(morpholino 2-C/6-C), 81.84 (C(CH3)2), 115.62 (d, 2JCF = 22 Hz, benzoyl 3-C 
and 5-C), 119.51 (phenoxy 2-C and 6-C), 131.97 (phenoxy 3-C and 5-C), 
132.16 (phenoxy 4-C), 132.52 (d, 3JCF = 9 Hz, benzoyl 2-C and 6-C), 134.09 
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(d, 4JCF = 3 Hz, benzoyl 1-C), 158.23 (phenoxy 1-C), 165.42 (d, 1JCF = 254 Hz, 
benzoyl 4-C), 171.34 (amide C=O), 194.07 (ketone C=O). 
Melting point: 165-167 °C 
HPLC: System 2,  Rt = 15.95 minutes. 
 System 3, Rt = 2.60 minutes 
  System 4, Rt = 2.66 minutes  
m/z:  HRMS (ES-TOF+) C21H23FN2O4 [MH]+ calculated 387.1715; found 
386.9297.   
FT-IR (KBr): 3273 (amide C=O), 2855, 2824 (CH3 stretch), 1688 (amide 
C=O), 1648 (ketone C=O), 1598 (aryl CH stretch), 882, 856 (para disubtituted 
aromatic ring). 
N-Morpholino-2-(4-(3-nitrobenzoyl)phenoxy)-2-methylpropanamide (58j) 
 
Following General Method G, 57j (0.022 g, 0.066 mmol) was reacted with 
HBTU (0.028 g, 0.074 mmol), 4-aminomorpholine (0.007 g, 0.067 mmol) and 
triethylamine (13.9 >l, 0.074 mmol) in DCM (3 ml) for 21 hours to afford 58j. 
Yield: 78 %   
Appearance: White solid 
Purification: PLC, 30% PE / 70% 
EtOAc. 
Melting point: 114 – 115 °C 
1H NMR (DMSO): 1.64 (C(CH3)2), 2.78-2.83 (m, 4H, morpholino 2-H and 6-
H), 3.78-3.85 (m, 4H, morpholino 3-H and 5-H), 7.02 (d, 3J = 8.8 Hz, 2H, 
phenoxy 2-H and 6-H), 7.71 (dd, 3J = 8.0 Hz, 3J = 8.0 Hz, 1H, benzoyl 5-H), 
7.78 (d, 3J = 8.8 Hz, phenoxy 3-H and 5-H), 8.11 (ddd, 3J = 7.7 Hz, 4J = 1.3 
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Hz, 4J = 1.2 Hz, 1H, benzoyl 6-C), 8.44 (ddd, 3J = 8.2 Hz, 4J = 2.3 Hz, 4J = 1.1 
Hz, 1H, benzoyl 4-C), 8.56 (dd, 4J = 1.8 Hz, 4J = 1.8 Hz, 1H, benzoyl C-2).  
13C NMR (DMSO): 25.64 (C(CH3)2), 56.00 (morpholino 3-C and 5-C), 66.68 
(morpholino 2-C and 6-C), 82.10 (C(CH3)2), 119.71 (phenoxy 2-C and 6-C), 
124.85 (benzoyl 2-C), 126.93 (benzoyl 4-C), 130.06 (benzoyl 5-C), 130.98 
(phenoxy 4-C), 132.37 (phenoxy 3-C and 5-C), 135.54 (benzoyl 6-C), 139.60 
(benzoyl 1-C), 148.55 (benzoyl 3-C), 171.36 (amide C=O), 193.12 (ketone 
C=O). 
HPLC: System 2, Rt = 15.34 minutes 
 System 1, Rt = 2.57 minutes 
  System 2, Rt = 2.66 minutes  
m/z:  HRMS (ES-TOF+) C21H24N3O6 [MH]+ calculated 414.1660; found 
414.1671 
FT-IR: 2925, 2860 (CH3 stretch), 1681 (amide C=O), 1652 (ketone C=O), 
1598 (aryl CH stretch), 1539 (C-NO2). 
N-Morpholino-2-(4-(4-nitrobenzoyl)phenoxy)-2-methylpropanamide (58k) 
Following General Method G, 57k 
(0.100 g, 0.30 mmol) was reacted 
with HBTU (0.127 g, 0.33 mmol), 
4-aminomorpholine (0.031 g, 0.30 
mmol) and triethylamine (60.0 >l, 0.33 mmol) in DCM (5 ml) for 4 hours 15 
minutes to afford 58k. 
Yield: 19 %   
Appearance: Yellow – white solid 
193 
Purification: Column chromatography, 5 % EtOAc / 95 % PE to 100% 
EtOAc. 
Melting point: 131- 132 °C 
1H NMR (CDCl3): 1.63 (C(CH3)2), 2.77-2.82 (m, 4H, morpholino 3-CH2 and 
5-CH2), 3.76 – 3.82 (m, 4H, 2-CH2 and 6-CH2), 7.00 (d, 3J = 8.8 Hz, 2H, 
phenoxy 2-H and 6-H), 7.19 (s, 1H, NH), 7.77 (d, 3J = 8.8 Hz, 2H, phenoxy 3-
H and 5-H), 7.88 (d, 3J = 8.8 Hz, 2H, benzoyl 2-H and 6-H), 8.33 (d, 3J = 8.8 
Hz, 2H, benzoyl 3-H and 5-H). 
13C NMR (CDCl3): 25.41 (C(CH3)2), 55.76 (morpholino 3-C and 5-C), 66.45 
(morpholino 2-C and 6-C), 81.92 (C(CH3)2), 119.50 (phenoxy 2-C and 6-C), 
123.70 (benzoyl 3-C and 5-C), 130.53 (benzoyl 2-C and 6-C), 130.82 (phenoxy 
4-C), 132.23 (phenoxy 3-C and 5-C), 143.29 (benzoyl 1-C), 149.84 (benzoyl 4-
C), 159.08 (phenoxy 1-C), 171.14 (amide C=O), 193.50 (ketone C=O).  
HPLC: System 3, Rt = 2.61 minutes 
  System 4, Rt = 2.81 minutes 
m/z:  HRMS (ES-TOF+) [MH]+ calculated 414.1660; found 414.1729. 
FT-IR (KBr): 3369 (amide NH), 2938, 2857 (CH3 stretch), 1686 (ketone 
C=O), 1597 (aryl CH stretch), 1454 (NO2), 869, 852 (para disubtituted 
aromatic ring). 
N-Morpholino-2-(4-(benzoyl)phenoxy)-2-methylpropanamide (58l) 
Following General Method B, 57l (0.487 g, 1.71 mmol) and an excess of 
thionyl chloride (5ml)were reacted for 3 hours and 45 minutes to afford the 
corresponding acid chloride (0.517 g, 1.71 mmol).  Some of the acid chloride 
(0.259 g, 0.86 mmol) was then reacted directly with 4-aminomorpholine (0.132 
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g, 1.29 mmol) and triethylamine (0.119 ml, 0.86 mmol) in DCM (3 ml) to 
afford 58l. 
Yield: 41% 
Appearance: Pale yellow solid 
Purification: 5 % EtOAc / 95 PE to 40 % 
EtOAc / 60 % PE. 
 1H NMR (CDCl3): 1.62 (s, 6H, (CH3)2), 2.81 (m, 4H, morpholino 2-H and 6-
H), 3.80 (m, 4H, morpholino 3-H and 5-H), 6.98 (d, 3J = 8.8 Hz, 2H, phenoxy 
2-H and 6-H), 7.24 (broad s, 1H, NH), 7.47 (dd, 3J = 7.8 Hz, 3J = 7.8 Hz, 2H, 
benzoyl 3-H and 5-H), 7.58 (dd, 3J = 7.4 Hz, 1H, benzoyl 4-H), 7.74-7.81 (m,  
4H, phenoxy 3-H and 5-H and benzoyl 2H and 6H). 
13C NMR (DMSO): 25.43 (C(CH3)2), 55.79 (morpholino 3-C/5-C), 66.48 
(morpholino 2-C/6-C), 81.80 (C(CH3)2), 119.46 (phenoxy 2-C and 6-C), 
128.45 (benzoyl 3-C and 5-C) 129.93 (benzoyl 2-C and 6-C), 132.13 (phenoxy 
3-C and 5-C), 132.28 (phenoxy 4-C), 132.39 (benzoyl 4-C), 137.92 (benzoyl 1-
C), 158.18 (phenoxy 1-C), 171.39 (amide C=O), 195.55 (ketone C=O).  
Melting point: 106-107 °C 
HPLC: System 2, Rt = 17.77 minutes. 
 System 1, Rt = 3.02 minutes 
  System 2, Rt = 3.04 minutes  
m/z:  HRMS (ES-TOF+) C21H24N2O4 [MH]+ calculated 369.1809; found 
368.9694. 
FT-IR (KBr): 3342 (amide NH), 2986, 2937 (CH3 stretch), 1634 (amide 
C=O), 1652 (ketone C=O), 1598 (aryl CH stretch), 875, 850 (para disubtituted 
aromatic ring). 
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N-Piperidinyl-2-(4-(2-methylbenzoyl)phenoxy)-2-methylpropanamide 
(59a) 
Following General Method G, 57a (0.025 g, 0.08 mmol) was reacted with 
HBTU (0.035 g, 0.09 mmol), 1-aminopiperidine (0.008 g, 0.08 mmol) and 
triethylamine (17.4 >l, 0.09 mmol) in DCM (3 ml) for 21 hours 30 minutes to 
afford 59a. 
Yield: 89 %   
Appearance: White solid 
Purification: PLC, 50 % PE / 50 % 
EtOAc. 
Melting point: 96 – 97 °C 
1H NMR (CDCl3): 1.34 – 1.42 (m, 2H, piperidinyl 4-CH2), 1.59 (s, 6H, 
C(CH3)2), 1.67 (quintet, 3J = 5.7 Hz, 4H, piperidinyl 3-CH2 and 5-CH2), 2.62 – 
2.65 (m, 4H, piperidinyl 2-CH2 and 6-CH2), 6.93 (d, 3J = 8.9 Hz), 7.09 (s, 1H, 
NH), 7.21 – 7.30 (m, benzoyl 3-H/5-H/6-H), 7.38 (ddd, 3J = 7.5 Hz, 3J = 7.5 
Hz, 3J = 1.8 Hz, 1H, benzoyl 4-H), 7.74 (d, 3J =8.9 Hz, 2H, phenoxy 3-H and 
5-H). 
13C NMR (CDCl3): 20.20 (C(CH3)2), 23.52 (piperidinyl 4-C), 25.68 
(piperidinyl 3-C and 5-C), 57.08 (piperidinyl 2-C and 6-C), 81.93 (C(CH3)2), 
119.43 (phenoxy 2-C and 6-C), 125.54 (benzoyl 5-C), 128.49 (benzoyl 6-C), 
130.44 (benzoyl 3-C), 131.31 (phenoxy 3-C and 5-C), 132.45 (phenoxy 4-C), 
136.77 (benzoyl 2-C), 139.09 (benzoyl 1-C), 159.12 (phenoxy 1-C), 171.02 
(amide C=O). 
m/z:  HRMS (ES-TOF+) C23H29N2O3 [MH]+ calculated 381.2173; found 
381.2076 
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HPLC: System 2, Rt = 17.32 minutes 
 System 3, Rt = 2.84 minutes 
  System 4, Rt = 2.82 minutes  
FT-IR: 2940, 2852 (CH3 stretch), 1698 (amide C=O), 1646 (ketone C=O), 
1597 (aryl CH stretch),   
N-Piperidinyl-2-(4-(3-methylbenzoyl)phenoxy)-2-methylpropanamide 
(59b) 
Following General Method G, 57b (0.100 g, 0.34 mmol) was reacted with 
HBTU (0.139 g, 0.37 mmol), 1-aminopiperidine (0.034 g, 0.34 mmol) and 
triethylamine (69.7 >l, 0.37 mmol) in DCM (5 ml) for 24 hours to afford 59b. 
Yield: 21 %   
Appearance: Off-White solid 
Purification: Column 
chromatography, 50 % EtOAc / 50 %  PE. 
Melting point: 128 – 130 °C 
1H NMR (CDCl3): 1.35-1.43 (m, 2H, piperidinyl 4-CH2), 1.61 (s, 6H, 
C(CH3)2), 1.69 (m, 4H, piperidinyl 3-CH2 and 5-CH2), 2.42 (s, 3H, benzoyl 
CH3), 2.70 (m, 4H, piperidinyl 2-CH2 and 6-CH2), 6.97 (d, 3J = 8.8 Hz, 2H, 
phenoxy 2-H and 6-H), 7.15 (broad s, NH, 1H), 7.32-7.41 (m, 2H, benzoyl 4-H 
and 5-H), 7.50-5.59 (m, 2H, benzoyl 2-H and 6-H), 7.77 (d, 3J = 8.8 Hz, 2H, 
phenoxy 3-H and 5-H).   
13C NMR (CDCl3): 21.52 (CH3), 23.33 (piperidinyl 4-C), 25.37 (C(CH3)2), 
25.49 (piperidinyl 3-C and 5-C), 56.89 (piperidinyl 2-C and 6-C), 81.68 
(C(CH3)2), 119.18 (phenoxy 2-C and 6-C), 127.22 (benzoyl 2-C), 128.22 
(benzoyl 5-C), 130.37 (phenoxy 4-C), 132.11 (phenoxy 3-C and 5-C), 133.12 
197 
(benzoyl 4-C), 138.00 (benzoyl 3-C), 138.31 (benzoyl 1-C), 158.31 (phenoxy 
1-C), 170.96 (amide C=O), 195.84 (ketone C=O). 
HPLC: System 2, Rt= 17.65 minutes 
 System 3, Rt = 2.86 minutes 
  System 4, Rt = 2.84 minutes  
m/z:  HRMS (ES-TOF+) [MH]+ calculated 381.2173; found 381.1673 
FT-IR (KBr): 3279 (amide NH), 2982, 2861 (CH3 stretch), 1691 (amide 
C=O), 1635 (ketone C=O), 1594 (aryl CH stretch). 
N-Piperidinyl-2-(4-(4-methylbenzoyl)phenoxy)-2-methylpropanamide 
(59c) 
Following General Method G, 57c (0.200 g, 0.67 mmol) was reacted with 
HBTU (0.293 g, 0.74 mmol), 1-aminopiperidine (0.067 g, 0.67 mmol) and 
triethylamine (146.0 >l, 0.74 mmol) in DCM (5 ml) for 2 hours 30 minutes to 
afford 59c. 
Yield: 29 %   
Appearance: White solid 
Purification: Column chromatography, 5 % EtOAc / 95 % PE to 100% 
EtOAc. 
Melting point: 160 – 162 °C  
1H NMR (CDCl3): 1.34-1.44 (m, 2H, piperidinyl CH2), 1.61 (s, C(CH3)2, 6H), 
1.69 (m, 4H, piperidinyl 3-CH2 and 5- CH2), 2.44 (s, 3H, benzoyl CH3), 2.69 
(m, 4H, piperidinyl 2-CH2 and 6-CH2), 6.97 (d, 3J = 8.8 Hz, 2H, phenoxy 2-H 
and 6-H), 7.13 (s, 1H, NH), 7.28 (d, 3J = 7.9 Hz, 2H, benzoyl 3-H and 5-H), 
7.67 (d, 3J = 8.1 Hz, 2H, phenoxy 3-H and 5-H), 7.76 (d, 3J = 8.8 Hz, 2H, 2-H 
and 6-H). 
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13C NMR (CDCl3): 21.78 (benzoyl CH3), 23.33 (piperidinyl 4-C), 25.37 
(piperidinyl 3-C and 5-C), 25.48 (C(CH3)2), 56.92 (piperidinyl 2-C and 6-C), 
81.67 (C(CH3)2), 119.21 (phenoxy 2-C and 6-C), 129.10 (benzoyl 3-C and 5-
C), 130.20 (benzoyl 2-C and 6-C), 131.99 (pnenoxy 3-C and 5-C), 132.36 
(phenoxy 4-C), 135.21 (benzoyl 1-C), 143.15 (benzoyl 4-C), 158.15 (phenoxy 
1-C), 170.95 (amide C=O), 195.40 (ketone C=O). 
HPLC: System 2, Rt= 17.60 minutes 
 System 3, Rt = 2.83 minutes 
  System 4, Rt = 2.82 minutes  
m/z:  HRMS (ES-TOF+) C23H29N2O3 [MH]+ calculated 381.2173; found 
381.1966. 
FT-IR (KBr): 3296 (amide NH), 2941, 2854 (CH3 stretch), 1677 (amide 
C=O), 1636 (ketone C=O), 1601 (aryl CH stretch), 877, 854 (p disubtituted 
aromatic ring).  
N-Piperidinyl-2-(4-(3-cyanobenzoyl)phenoxy)-2-methylpropanamide (59d) 
Following General Method G, 57d (0.044 g, 0.14 mmol) was reacted with 
HBTU (0.069 g, 0.16 mmol), 1-aminopiperidine (0.014 g, 0.14 mmol) and 
triethylamine (30.0 >l, 0.16 mmol) in DCM (3 ml) for 28 hours 40 minutes to 
afford 59d. 
Yield: 8%   
Appearance: White solid 
Purification: Column 
Chromatography, 5 % EtOAc / 95 % PE to 100 % EtOAc.  
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Melting point: 146 – 148 °C 
1H NMR (CDCl3): 1.35 – 1.42 (m, 2H, piperidinyl 4-CH2), 1.63 (C(CH3)2), 
1.69 (quintet, 3J = 5.7 Hz, 4H, piperidinyl 3-CH2 and 5-CH2), 2.68 – 2.71 (m, 
4H, piperidinyl 2-CH2 and 6-CH2), 7.00 (d, 3J = 8.8 Hz, 2H, phenoxy 2-H and 
6-H), 7.07 (s, 1H, NH), 7.63 (dd, 3J = 7.8 Hz, 3J = 7.8 Hz, 1H, benzoyl 5-H), 
7.74 (d, 3J = 8.8 Hz, 2H, phenoxy 3-H and 5-H), 7.86 (ddd, 3J = 7.8 Hz, 4J = 
1.4 Hz, 4J = 1.4 Hz, benzoyl 4-H), 7.96 – 8.24 (m, 2H, benzoyl 2-H and 6-H). 
13C NMR (CDCl3): 23.32 (piperidinyl 4-C), 25.38 (piperidinyl 3-C and 5-C), 
25.49 (C(CH3)2), 56.93 (piperininyl 2-C and 6-C), 81.85 (C(CH3)2), 112.96 
(benzoyl 3-C), 119.34 (phenoxy 2-C and 6-C), 129.55 (CN), 130.63 (benzoyl 
5-C), 132.13 (phenoxy 3-C and 5-C), 133.34 (phenoxy 4-C), 133.73 (benzoyl 
6-C), 135.29 (benzoyl 4-C), 139.05 (benzoyl 1-C), 159.13 (phenoxy 1-C), 
170.70 (amide C=O).  
HPLC: System 2, Rt = 15.67 minutes 
 System 3, Rt = 2.68 minutes 
  System 4, Rt = 2.72 minutes 
m/z:  HRMS (ES-TOF+) [MH]+ calculated 394.2125; found 394.2108. 
FT-IR (KBr): 3285 (amide NH), 2942, 2851 (CH3 stretch), 2228 (CN), 1691 
(amide C=O), 1639 (ketone C=O), 1595 (aryl CH stretch), 885, 851 (p 
disubtituted aromatic ring). 
N-Piperidinyl-2-(4-(4-cyanobenzoyl)phenoxy)-2-methylpropanamide (59e) 
 
Following General Method G, 57e (0.020 g, 0.06 mmol) was reacted with 
HBTU (0.027 g, 0.07 mmol), 1-aminopiperidine (0.006 g, 0.06 mmol) and 
triethylamine (13.4 >l, 0.07 mmol) in DCM (3 ml) for 24 hours to afford 59e. 
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Yield: 85 %   
Appearance: White solid 
Purification: Column 
chromatography, 5% EtOAc / 95 % PE to 100 % EtOAc. 
Melting point: 144 – 146 °C 
1H NMR (DMSO): 1.35 – 1.42 (m, piperidinyl 4-CH2), 1.62 (s, 6H, (C(CH3)2), 
1.69 (quintet, 4H, 3J = 5.7 Hz, piperidinyl 3-CH2 and 5-CH2), 2.66 – 2.72 (m, 
4H, piperidinyl 2-CH2 and 6-CH2), 6.99 (d, 3J = 8.8 Hz, 2H, phenoxy 2-H and 
6-H),  7.75 (d, 3J = 8.8 Hz, 2H, phenoxy 3-H and 5-H), 7.79 (d, 3J = 8.5 Hz, 
2H, benzoyl 2-H and 6-H), 7.83 (d, 3J = 8.6 Hz, 2H, benzoyl 3-H and 5-H). 
m/z:  HRMS (ES-TOF+) [MH]+ calculated 392.1969; found 392.1553. 
FT-IR: 2935, 2852 (CH3 stretch), 2229 (CN stretch), 1702 (amide C=O), 1652 
(ketone C=O), 1594 (aryl CH stretch), 865, 850 (p disubtituted aromatic ring).  
 
N-Piperidinyl-2-(4-(3-chlorobenzoyl)phenoxy)-2-methylpropanamide (59f) 
 
Following General Method G, 57f (0.027 g, 0.08 mmol) was reacted with 
HBTU (0.035 g, 0.09 mmol), 1-aminopiperidine (0.009 g, 0.08 mmol) and 
triethylamine (17.6 >l, 0.09 mmol) in DCM (3 ml) for 21 hours 30 minutes to 
afford 59f. 
Yield: 80 %   
Appearance: White solid 
Purification: PLC, 50 %  PE / 50 % 
EtOAc. 
Melting point: 135 – 137 °C 
1H NMR (CDCl3): 1.35 – 1.45 (piperidinyl 4-CH2), 1.56 (s, 3H, C(CH3)2), 
1.62 (s, 3H, C(CH3)2), 1.69 (quintet, 4H, piperidinyl 3-CH2 and 5-CH2), 2.65 – 
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2.72 (m, 4H, piperidinyl 2-CH2 and 6-CH2), 6.98 (d, 3J = 8.8 Hz, 2H, phenoxy 
2-H and 6-H), 7.08 (s, 1H, NH), 7.42 (dd, 1H, 3J =7.9 Hz, 3J = 8.0 Hz, benzoyl 
5-C), 7.55 (ddd, 3J = 7.9 Hz, 4J = 2.0 Hz, 4J = 1.0 Hz, 1H, benzoyl 6-C), 7.62 
(ddd, 3J = 7.7 Hz, 4J = 1.3 Hz, 4J = 1.3 Hz,  1H, benzoyl 4-C), 7.72 (dd, 4J = 
1.8 Hz, 4J = 1.8 Hz, 1H, benzoyl 2-C), 7.77 (d, 3J = 8.8 Hz, 2H, phenoxy 3-H 
and 5-H). 
13C NMR (CDCl3): 25.24 (piperidinyl 4-C), 25.35 (C(CH3)2), 30.94 
(piperidinyl 3-C
 
and 5-C), 56.79 (piperidinyl 2-C
 
and 6-C), 81.62 (C(CH3)2), 
119.09 (phenoxy 2-C and 6-C), 127.40 (benzoyl 6-C), 127.81 (benzoyl 5-C), 
131.99 (phenoxy 3-C and 5-C), 132.2 (benzoyl 2-C) 139.6 (benzoyl 3-C), 
170.6 (amide C=O). 
m/z:  HRMS (ES-TOF+) [MH]+ calculated 401.1626; found 401.1545 
HPLC: System 2, Rt = 18.35 minutes 
 System 3, Rt = 2.92 minutes 
  System 4, Rt = 2.90 minutes  
FT-IR 2941, 2858 (CH3 stretch), 1687 (amide C=O), 1645 (ketone C=O), 1596 
(aryl CH stretch).   
2-(4-(2-Fluorobenzoyl)phenoxy)-2-methyl-N-(piperidin-1-yl)propanamide 
(59g) 
Following General Method G, 57g (0.400 g, 1.32 mmol) was reacted with 
HBTU (0.5524 g, 1.46 mmol), 1-aminopiperidine (0.133 g, 1.32 mmol) and 
triethylamine (0.275 ml, 1.46 mmol) in DCM (5 ml) for 1 hour 45 minutes to 
afford 59g. 
Yield: 54% 
Appearance: White needle-like crystals 
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Purification: 5 % EtOAc / 95 % PE to 100% EtOAc, then recrystallised from 
toluene. 
Melting point: 131 – 133 °C 
1H NMR (CDCl3): 1.32-1.42 (m, 2H, piperidinyl 4-CH2), 1.60 (s, 6H, 
C(CH3)2,), 1.68 (quintet, 3J = 5.7 Hz, 4H, piperidinyl 3-CH2 and 4-CH2), 2.67 
(broad t, 3J = 4.9 Hz, 4H, piperidinyl 2-CH2 and 6-CH2), 6.94 (d, 3J = 8.5 Hz, 
2H, phenoxy 2-H and 6-H), 7.06 (s, NH, 1H), 7.15 (dd, 3J = 8.9 Hz, 3J = 8.9 
Hz, 1H, benzoyl 5-H), 7.26 (dd, 3JCF = 7.4 Hz, 3J = 7.4 Hz, 1H, benzoyl 3-H), 
7.46-7.54 (m, 2H, benzoyl 6-H and 4-H), 7.78 (d, 3J = 7.9 Hz, 2H, phenoxy 3-
H and 5-H).     
13C NMR (CDCl3): 23.19 (piperidinyl 4-C), 25.22 (C(CH3)2), 25.36 
(piperidinyl 3-C and 5-C), 56.75 (piperidinyl 2-C and 6-C), 81.59 (C(CH3)2), 
116.23 (d, 2JCF = 21.9 Hz, benzoyl 3-C), 118.96 (phenoxy 2-C and 6-C), 
124.33 (d, 4JCF=3.5Hz, benzoyl 5-C), 127.12 (d, 2JCF = 14.6 Hz, benzoyl 1-C), 
130.55 (d, 3JCF = 3Hz, benzoyl 5-C), 131.70 (benzoyl 6-C), 131.76 (phenoxy 3-
C and 5-C), 132.9 (d, 3JCF = 8.2 Hz, benzoyl 4-C), 159.05 (phenoxy 1-C), 
159.83 (d, 1JCF = 251.7 Hz), 170.62 (amide C=O), 191.98 (ketone C=O).  
HPLC:  System 2, Rt=16.24 minutes 
  System 3, Rt = 2.77 minutes 
   System 4, Rt = 2.78 minutes 
m/z:  HRMS (ES-TOF+) [MH]+ calculated 385.1922; found 385.1414 
FT-IR (KBr): 3261 (amide NH), 2945, 2812 (CH3 stretch), 1685 (amide 
C=O), 1595 (aryl CH stretch), 885, 848 (p disubtituted aromatic ring). 
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N-Piperidinyl-2-(4-(3-fluorobenzoyl)phenoxy)-2-methylpropanamide (59h) 
Following General Method G, 57h (0.100 g, 0.33 mmol) was reacted with 
HBTU (0.138 g, 0.36 mmol), 1-aminopiperidine (0.033 g, 0.33 mmol) and 
triethylamine (68.8 >l, 0.36 mmol) in DCM (5 ml) for 4 hours to afford 59h. 
Yield: 65 %   
Appearance: White solid 
Purification: Column 
chromatography, 50 % EtOAc / 50 % PE. 
Melting point: 117 – 119 °C 
1H NMR (CDCl3): 1.34-1.43 (m, 2H, piperidinyl CH2), 1.62 (s, C(CH3)2, 6H), 
1.69 (m, 4H, piperidinyl 3-CH2 and 5- CH2), 2.69 (m, 4H, piperidinyl 2-CH2 
and 6-CH2), 6.98 (d, 3J = 8.8 Hz, 2H, phenoxy 2-H and 6-H), 7.09 (s, NH, 1H), 
7.24-7.31 (m, 1H, benzoyl CH), 7.42-7.49 (m, 2H, benzoyl CH), 7.53 (ddd, 3J 
= 7.7 Hz, 4J = 1.2 Hz, 4J = 1.2 Hz, 1H, benzoyl 6-H), 7.77 (d, 3J = 8.8 Hz, 2H, 
phenoxy 3-H and 5-H).  
13C NMR (CDCl3): 23.24 (piperidinyl 4-C), 25.38 (C(CH3)2), 25.49 
(piperidinyl 3-C and 5-C), 56.92 (piperidinyl 2-C and 6-C), 81.76 (C(CH3)2), 
116.7 (d, 2JCF = 23.0 Hz, benzoyl 2-C), 119.23 (phenoxy 2-C and 6-C), 119.34 
(d, 2JCF = 21.0 Hz, benzoyl 4-C), 125.65 (d, 4JCF = 3.0Hz, benzoyl 6-C), 130.12 
(d, 3JCF = 8.0 Hz, benzoyl 5-C), 131.37 (phenoxy 4-C), 132.12 (phenoxy 3-C 
and 5-C), 140.06 (d, 3JCF = 6.0Hz, benzoyl 1-C), 158.71 (phenoxy 1-C), 162.61 
(d, 1JCF = 248.5 Hz, benzoyl 3-C), 170.80 (amide C=O), 194.12 (ketone C=O). 
HPLC: System 2, Rt= 17.18 minutes 
 System 3, Rt = 2.79 minutes 
  System 4, Rt = 2.81 minutes  
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m/z:  HRMS (ES-TOF+) C22H26FN2O3 [MH]+ calculated 385.1922; found 
385.1735. 
FT-IR (KBr): 3302 (amide NH), 1688 (amide C=O), 1647 (ketone C=O), 
1596 (aryl CH stretch). 
N-Piperidinyl-2-(4-(4-fluorobenzoyl)-phenoxy)-2-methylpropanamide (59i) 
Following General Method B, 57i (0.562 g, 1.85 mmol) and an excess of 
thionyl chloride (10 ml)were reacted for 2 hours and 30 minutes to afford the 
corresponding acid chloride (0.596 g, 1.85 mmol).  Some of the acid chloride 
(0.298 g, 0.93 mmol) was then reacted directly with 1-aminopiperidine (0.139 
g, 1.39 mmol) in the presence of triethylamine (0.129 ml, 0.93 mmol) to afford 
59i.  
Yield: 27% 
Appearance: Yellow solid 
Purification: Column chromatography, 2% EtOAc / PE, to 100% EtOAc. 
 1H NMR (DMSO): 1.29 (m, 2H, piperidinyl 4-CH2,), 1.46-1.55 (m, 10H, 
overlap of  piperidinyl 3-CH2 and 5- CH2 and C(CH3)2), 2.64 (m, 4H, 
piperidinyl 3-CH2 and 5- CH2), 6.97 (d, 3J = 8.8 Hz, 2H, phenoxy 2-H and 6-
H), 7.37 (dd, 3J = 8.8 Hz, 3JHF=8.8 Hz, 2H, benzoyl 3-H and 5-H), 7.71 (d, 3J 
= 8.8 Hz, 2H, phenoxy 3-H and 5-H), 7.77 (dd, 3J = 8.8 Hz, 3JHF = 5.6 Hz, 2H, 
benzoyl 2-H and 6-H), 9.04 (broad s, NH, 1H). 
13C NMR (DMSO): 22.98 (piperidinyl 4-C), 25.06 (C(CH3)2), 25.26 
(piperidinyl 3-C/5-C), 54.71 (piperininyl  2-C/6-C), 80.24 (C(CH3)2), 115.50 
(d, 2J = 22 Hz, benzoyl 3-C and 5-C) 118.03 (phenoxy 2-C and 6-C), 129.86 
(phenoxy 4-C), 131.53 (phenoxy 3-C and 5-C), 132.15 (d, 3J = 9.3 Hz, benzoyl 
2-C and 6-C), 134.09 (d, 4J = 2.8 Hz,   benzoyl 1-C), 159.0 (phenoxy 1-C), 
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164.35 (d, 1J =245 Hz, benzoyl 4-C), 169.67 (amide C=O), 193.04 (ketone 
C=O).  
Melting point: 141-142 °C 
HPLC: System 2, Rt = 16.93 minutes. 
 System 3, Rt = 2.79 minutes 
  System 4, Rt = 2.81 minutes  
m/z:  HRMS (ES-TOF+) C23H27FNO3 [MH]+ calculated 385.1922; found 
384.9540.   
FT-IR (KBr): 2203 (amide NH), 1675 (amide C=O), 1641 (ketone C=O), 
1598 (aryl CH stretch), 879, 858 (para disubtituted aromatic ring). 
N-Piperidinyl-2-(4-(4’-nitrobenzoyl)-phenoxy)-2-methylpropanamide (59j) 
Following General Method G, 57k (0.155 g, 0.47 mmol) was reacted with 
HBTU (0.196 g, 0.52 mmol), 1-aminopiperidine (0.047 g, 0.47 mmol) and 
triethylamine (97.8 >l, 0.52 mmol) in DCM (5 ml) for 2 hours 25 minutes to 
afford 59j. 
Yield: 28 %   
Appearance: Yellow solid  
Purification: Column chromatography, 5% EtOAc / 95 % PE to 100% EtOAc. 
Melting point: 152 – 153 °C 
1H NMR (CDCl3): 1.36 – 1.42 (m, 2H, piperidinyl 4-CH2), 1.62 (C(CH3)2), 
2.66 - 2.72 (m, 4H, piperidinyl 3-CH2 and piperidiny; 5-CH2),  1.69 (quintet, 
4H, piperidinyl 3-CH2 and 5-CH2), 2.66 (m, 4H, piperidinyl 2-CH2 and 
piperidiny; 6-CH2), 6.99 (d, 3J = 9.1 Hz, phenoxy 2-H and 6-H), 7.06 (s, 1H, 
NH), 7.77 (d, 3J = 8.9 Hz, 2H, phenoxy 3-H and 5-H), 7.88 (d, 3J = 8.8 Hz, 2H, 
benzoyl 2-H and 6-H), 8.33 (d, 3J = 8.8 Hz, 2H, benzoyl 3-H and 5-H),  
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13C NMR (CDCl3): 23.31 (piperidinyl 4-C) 25.37 (piperidinyl 3-C and 5-C), 
25.48 (C(CH3)2), 56.89 (piperidinyl 2-C and 6-C), 81.85 (C(CH3)2), 119.29 
(phenoxy 2-C and 6-C), 123.70 (benzoyl 3-C and 5-C), 130.54 (benzoyl 2-C 
and 6-C), 130.57 (phenoxy 4-C), 132.23 (phenoxy 3-C and 5-C ), 143.39 
(benzoyl 1-C), 149.83 (benzoyl 4-C), 159.31 (phenoxy 1-C), 170.66 (amide 
C=O), 193.56 (ketone C=O).  
HPLC: System 1, Rt = 2.79 minutes 
     System 2, Rt = 2.81 minutes 
FT-IR (KBr): 3319 (amide NH), 2935, 2856 (CH3 stretch), 1701 (amide 
C=O), 1666 (ketone C=O), 1595 (aryl CH stretch) 1470 (NO2 stretch), 875, 
852 (p disubtituted aromatic ring)  
2-(4-(Benzoyl)-phenoxy)-2-methyl-N-(piperidin-1-yl)-propanamide (59h) 
 
Following General Method G, 57l (0.402 g, 1.41 mmol) was reacted with 
HBTU (0.589 g, 1.55 mmol), 1-aminopiperidine (0.142 g, 1.55 mmol) and 
triethylamine (0.217 ml, 1.55 mmol) in DCM (5 ml) for 3 hours 25 minutes to 
afford 59h. 
Yield: 56% 
Appearance: White solid 
Purification:  Column chromatography, 5 % EtOAc / 95 PE to 100% EtOAc. 
Melting point: 125 – 127 °C 
1H NMR (CDCl3): 1.33-1.43 (m, 1H, piperidinyl 4-CH2,), 1.61 (s, 6H, 
C(CH3)2,), 1.69 (quintet, 3J = 5.8 Hz, 4H, piperidinyl 3-CH2 and 5- CH22.69 
(m, 4H, piperidinyl 2-CH2 and 6-CH2), 6.97 (d, 3J = 8.8 Hz, 2H, phenoxy 2-H 
and 6-H), 7.13 (s, NH, 1H), 7.47 (dd, 3J = 7.6 Hz, 4J = 7.6 Hz, 2H, benzoyl 3-H 
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and 5-H), 7.58 (t, 3J = 7.3 Hz, 1H, benzoyl 4-H), 7.73-7.81 (m, 4H, phenoxy 3-
H and 5-H and benzoyl 2-H and 6-H).  
13C NMR (CDCl3): 23.19 (piperidinyl 4-C), 25.24 (C(CH3)2), 25.35 
(piperidinyl 3-C and 5-C), 56.76 (piperidinyl 2-C and 6-C), 81.57 (C(CH3)2), 
119.08 (phenoxy 2-C and  6-C), 128.28 (benzoyl 3-C and 5-C), 129.81 
(benzoyl 2-C and 6-C), 131.85 (phenoxy 4-C), 131.99 (3-C and 5-C), 132.22 
(benzoyl 4-C), 137.83 (benzoyl 1-C), 158.23 (phenoxy 1-C), 170.77 (amide 
C=O), 195.49 (ketone C=O). 
HPLC: System 2, Rt = 16.55 minutes 
 System 3, Rt = 2.74 minutes 
  System 4, Rt = 2.76 minutes  
m/z:  HRMS (ES-TOF+) [MH]+ calculated 367.2016; found 367.1537 
FT-IR (KBr): 3302 (amide NH), 2941, 2858 (CH3 stretch), 1676 (amide 
C=O), 1641 (ketone C=O), 1599 (aryl CH stretch). 
Ethyl 2-(4-(4-chlorobenzoyl)phenoxy)ethanoate (60) 
Following General Method E, 4-chloro-(4’-hydroxy)benzophenone (1.000 g, 
4.29 mmol) in MeCN was reacted with 
K2CO3 (0.891 g, 6.45 mmol) and 
ethylbromoacetate (0.861 g, 5.16 mmol) 
for 5 hours 20 minutes to afford 60. 
Appearance:  White solid 
Purification: Precipitated from ethyl acetate by addition of petroleum ether.  
Product was isolated by vacuum filtration. 
 Melting point: 103.9 – 105.2 °C 
208 
1H NMR (CDCl3): 1.31 (t, 3J = 7.1 Hz, 3H, CH3), 4.29 (q, CH2, 2H, 3J = 7.1 
Hz), 6.97 (d, 3J = 8.9 Hz, 2H, phenoxy 2-H and 6-H), 7.45 (d, 3J = 8.6 Hz, 2H, 
benzoyl 3-H and 5-H), 7.71 (d, 3J = 8.6 Hz, 2H, phenoxy 2-H and 6-H), 7.79 
(d, 3J = 9.0 Hz, 2H, benzoyl 2-H and 6-H). 
13C NMR (CDCl3): 14.30 (OCH2CH3), 61.78 (OCH2CH3) 65.38 (OCH2C=O), 
144.43 (phenoxy 2-C and 6-C), 128.71 (benzoyl 3-C and 5-C), 130.92 
(phenoxy 4-C), 131.32 (phenoxy 3-C and 5-C), 132.54 (benzoyl 2-C and 6-C), 
136.48 (benzoyl 1-C), 138.59 (benzoyl 4-C), 161.59 (phenoxy 1-C), 168.35 
(ester C=O), 194.29 (ketone C=O). 
FT-IR (KBr): 2995, 2972 (CH3 stretch), 1762 (ester C=O), 1647 (ketone 
C=O), 853, 829 (p-disubstituted aromatic ring). 
2-(4-(4-Chlorobenzoyl)phenoxy)ethanoic acid (61) 
 
Following General Method C, 60 (0.400g, 1.25 mmol), was reacted with  
lithium hydroxide (0.150 g, 6.27 mmol) in a mixture of water and THF (15 ml, 
1:1) for 3 hours 45 minutes to afford 61.  
Yield: 87 %   
Appearance: White solid 
Purification: Used without further purification. 
Melting point: 184 – 186 °C 
1H NMR (DMSO): 4.82 (s, 2H, methylene CH2), 7.07 (d, 3J = 8.9 Hz, 2H, 
phenoxy 2-H and 6-H), 7.61 (d, 3J = 8.6 Hz, benzoyl 3-H and 5-H), 7.71 (d, 3J 
= 8.6 Hz, phenoxy 3-H and 5-H),  7.73 (d, 3J = 8.6 Hz, benzoyl 2-H and 6-H), 
13.13 (s, 1H, CO2H). 
13C NMR (DMSO): 64.57 (CH2), 114.47 (phenoxy 2-C and 6-C), 128.59 
(benzoyl 3-C and 5-C), 129.50 (benzoyl 4-C), 131.17 (phenoxy 3-C and 5-C), 
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132.06 (benzoyl 2-C and 6-C), 136.33 (benzoyl 1-C), 137.01 (benzoyl 4-C), 
161.58 (phenoxy 1-C), 169.68 (carboxylic acid C=O), 193.26 (ketone C=O). 
m/z:  HRMS (ES-TOF+) C15H10ClO4- [MH]+ calculated 289.0273; found 
289.0269 
FT-IR: 2913 (carboxylic acid OH), 1737 (carboxylic acid C=O), 1649 (ketone 
C=O), 856, 834 (p disubtituted aromatic ring) 
N-Piperidinyl-2-(4-(4-chlorobenzoyl)phenoxy)acetamide (62a) 
Following General Method G, 61 (0.100 g, 0.34 mmol) was reacted with 
HBTU (0.144 g, 0.38 mmol), 1-aminopiperidine (0.03 g, 0.34 mmol) and 
triethylamine (71.4 >l, 0.38 mmol) in DCM (5 ml) for 23 hours to afford 62a. 
Yield: 25 %   
Appearance: White solid 
Purification: 2 % MeOH / DCM  to 0 
% MeOH/ DCM. 
Compound was not pure enough for further characterisation. 
N-Morpholino-2-(4-(4-chlorobenzoyl)phenoxy)acetamide (62b) 
Following General Method G, 61 (0.100 g, 0.34 mmol) was reacted with 
HBTU (0.144 g, 0.70 mmol), 4-aminomorpholine (0.04 g, 0.34 mmol) and 
triethylamine (71.4 >l, 0.38 mmol) in DCM (5 ml) for 23 hours to afford 62b. 
Yield: 23 %   
Appearance: White solid 
Purification: 5 % EtOAc / 95 % PE 
to 100 % EtOAc. 
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Compound was not pure enough for further characterisation. 
2-(4-(4-Chlorobenzoyl)phenoxy)-2-methyl-1-morpholinopropan-1-one 
(63a) 
Following General Method G, 10b (0.200 g, 0.63 mmol) was reacted with 
HBTU (0.267 g, 0.70 mmol), 
morpholine (0.06 g, 0.70 mmol) and 
triethylamine (98.0 >l, 0.70 mmol) in 
DCM (5 ml) for 3 hours to afford 63a. 
Compound prepared as described in General Method G 
Yield: 50 % 
Appearance: Off – white solid. 
Purification: Column chromatography, 5 % EtOAc / 95 % PE to 40 % EtOAc 
/ 60 % PE. 
Melting point: 148 – 150 °C 
1H NMR (CDCl3): 1.70 (s, C(CH3)2, 6H), 3.29 (m, 2H, morpholino 3-CH2 and 
5- CH2), 3.55-3.59 (m, 2H, morpholino 2-CH2 and 6- CH2), 3.61-3.66 (m, 2H, 
morpholino CH2), 6.91 (d, 3J = 8.8 Hz, 2H, phenoxy 2-H and 6-H), 7.45 (d, 3J 
= 8.5 Hz, 2H benzoyl 3-H and 5-H), 7.70 (d, 3J = 8.5 Hz, 2H, phenoxy 3-H and 
5-H), 7.75 (d, 3J = 8.8 Hz, 2H, benzoyl 2-H and 6-H). 
13C NMR (CDCl3): 26.29 (C(CH3)2), 43.75 (piperidinyl 2-C/6-C), 47.14 
(piperidinyl 2-C/6-C), 66.76 (piperidinyl 3-C/5-C), 67.22 (piperidinyl 2-C/6-
C), 81.84 (C(CH3)2), 116.70 (phenoxy 2-C and 6-C), 128.93 (benzoyl 3-C and 
5-C), 130.81 (phenoxy 4-C), 131.49 (phenoxy 3-C and 5-C), 132.64 (benzoyl 
2-C and 6-C), 136.59 (benzoyl 1-C), 138.84 (benzoyl 4-C), 159.55 (phenoxy 1-
C), 171.27 (amide C=O), 194.41 (ketone C=O). 
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HPLC: System 2, Rt=18.07 minutes 
 System 3, Rt = 2.95 minutes  
  System 4, Rt = 2.95 minutes 
m/z:  HRMS (ES-TOF-) C21H23ClNO4 [MH]- calculated 388.1310; found 
388.1312. 
FT-IR (KBr): 2992, 2858 (CH3 stretch), 1645 (ketone C=O), 1599 (aryl CH 
stretch), 855, 837 (p disubtituted aromatic ring). 
2-(4-(4-Chlorobenzoyl)phenoxy)-2-methyl-1-piperidinylpropan-1-one 
(63b) 
Following General Method G, 10b (0.250 g, 0.63 mmol) was reacted with 
HBTU (0.327 g, 0.70 mmol), piperidine (0.07 g, 0.79 mmol) and triethylamine 
(0.120 ml, 0.86 mmol) in DCM (5 ml) for 3 hours to afford 63b. 
Yield: 62% 
Appearance: White solid 
Purification: Column chromatography, 
5 % EtOAc / 95 % PE to 40 % EtOAc / 60 % PE. 
Melting point: 161 – 163 °C 
1H NMR (CDCl3): 1.23 (m,  2H, piperidinyl CH2), 1.49 (m, 4H,  piperidinyl 4-
CH2,), 1.69 (s, 6H, C(CH3)2), 3.56 (m, 2H, piperidinyl 3-CH2 and 5- CH2), 3.69 
(m, 2H, piperidinyl 3-CH2 and 5-CH2), 6.91 (d, 3J = 8.9 Hz, 2H, phenoxy 2-H 
and 6-H ), 7.44 (d, 3J = 8.6 Hz, 2H, benzoyl 3-H and 5-H), 7.69 (d, 3J = 8.6 Hz, 
2H, phenoxy 3-H and 5-H), 7.73 (d,  3J = 8.9 Hz, 2H, benzoyl 2-H and 6-H). 
13C NMR (CDCl3): 24.83 (C(CH3)2), 26.04 (piperidinyl CH2) 26.57 
(piperidinyl CH2), 81.99 (C(CH3)2), 116.82 (phenoxy C-2 and C-6), 128.90 
(benzoyl 3-C and 5-C), 130.48 (phenoxy 4-C), 131.50 (phenoxy 3-C and 5-C), 
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132.53 (benzoyl 2-C and 6-C), 136.74 (benzoyl 1-C), 138.76 (benzoyl 4-C), 
160.05 (phenoxy 1-C), 170.89 (amide C=O), 194.52 (ketone C=O). 
HPLC: System 2, Rt = 19.80 minutes 
 System 3, Rt = 3.16 minutes  
  System 4, Rt = 3.12  minutes 
m/z:  HRMS (ES-TOF-) C22H25ClNO3 [MH]- calculated 386.1517; found 
385.9038. 
FT-IR (KBr): 2930, 2852 (CH3 stretch), 1647 (ketone C=O), 1597 (aryl CH 
stretch). 
213 
7. References 
1. Berger, J.; Moller, D. E. The mechanisms of action of ppars. Annu. Rev. 
Med. 2002, 53, 409-435. 
2. Forman, B. M.; Chen, J.; Evans, R. M. Hypolipidemic drugs, 
polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome 
proliferator-activated receptors alpha and delta. Proc. Natl. Acad. Sci. U. 
S. A. 1997, 94, 4312-4317. 
3. Klein, T. W. Cannabinoid-based drugs as anti-inflammatory therapeutics. 
Nature Reviews Immunology 2005, 5, 400-411. 
4. O'Sullivan, S. E. Cannabinoids go nuclear: Evidence for activation of 
peroxisome proliferator-activated receptors. Br. J. Pharmacol. 2007, 152, 
576-582. 
5. Sun, Y.; Alexander, S. P. H.; Garle, M. J.; Gibson, C. L.; Hewitt, K.; 
Murphy, S. P.; Kendall, D. A.; Bennett, A. J. Cannabinoid activation of 
ppar alpha; a novel neuroprotective mechanism. Br. J. Pharmacol. 2007, 
152, 734-743. 
6. Issemann, I.; Green, S. Activation of a member of the steroid-hormone 
receptor superfamily by peroxisome proliferators. Nature 1990, 347, 645-
650. 
7. Dreyer, C.; Krey, G.; Keller, H.; Givel, F.; Helftenbein, G.; Wahli, W. 
Control of the peroxisomal beta-oxidation pathway by a novel family of 
nuclear hormone receptors. Cell 1992, 68, 879-887. 
8. Willson, T. M.; Moore, J. T. Genomics versus orphan nuclear receptors - 
a half-time report. Mol. Endocrinol. 2002, 16, 1135-1144. 
9. Willson, T. M.; Brown, P. J.; Sternbach, D. D.; Henke, B. R. The ppars: 
From orphan receptors to drug discovery. J. Med. Chem. 2000, 43, 527-
550. 
10. Henke, B. R. Peroxisome proliferator-activated receptor alpha/gamma 
dual agonists for the treatment of type 2 diabetes. J. Med. Chem. 2004, 
47, 4118-4127. 
11. Xu, H. E.; Lambert, M. H.; Montana, V. G.; Plunket, K. D.; Moore, L. B.; 
Collins, J. B.; Oplinger, J. A.; Kliewer, S. A.; Gampe, R. T.; McKee, D. 
D.; Moore, J. T.; Willson, T. M. Structural determinants of ligand binding 
selectivity between the peroxisome proliferator-activated receptors. Proc. 
Natl. Acad. Sci. U. S. A. 2001, 98, 13919-13924. 
12. Kota, B. P.; Huang, T. H. W.; Roufogalis, B. D. An overview on 
biological mechanisms of ppars. Pharmacol. Res. 2005, 51, 85-94. 
13. Chinetti, G.; Lestavel, S.; Bocher, V.; Remaley, A. T.; Neve, B.; Torra, I. 
P.; Teissier, E.; Minnich, A.; Jaye, M.; Duverger, N.; Brewer, H. B.; 
Fruchart, J. C.; Clavey, V.; Staels, B. Ppar-alpha and ppar-gamma 
activators induce cholesterol removal from human macrophage foam 
cells through stimulation of the abca1 pathway. Nat. Med. 2001, 7, 53-58. 
14. Staels, B.; Koenig, W.; Habib, A.; Merval, R.; Lebret, M.; Torra, I. P.; 
Delerive, P.; Fadel, A.; Chinetti, G.; Fruchart, J. C.; Najib, J.; Maclouf, J.; 
Tedgui, A. Activation of human aortic smooth-muscle cells is inhibited 
by ppar alpha but not by ppar gamma activators. Nature 1998, 393, 790-
793. 
214 
15. Mandard, S.; Muller, M.; Kersten, S. Peroxisome proliferator-activated 
receptor alpha target genes. Cell. Mol. Life Sci. 2004, 61, 393-416. 
16. Delerive, P.; Fruchart, J. C.; Staels, B. Peroxisome proliferator-activated 
receptors in inflammation control. J. Endocrinol. 2001, 169, 453-459. 
17. Cronet, P.; Petersen, J. F. W.; Folmer, R.; Blomberg, N.; Sjoblom, K.; 
Karlsson, U.; Lindstedt, E. L.; Bamberg, K. Structure of the ppar alpha 
and -gamma ligand binding domain in complex with az 242; ligand 
selectivity and agonist activation in the ppar family. Structure 2001, 9, 
699-706. 
18. Xu, H. E.; Lambert, M. H.; Montana, V. G.; Parks, D. J.; Blanchard, S. 
G.; Brown, P. J.; Sternbach, D. D.; Lehmann, J. M.; Wisely, G. B.; 
Willson, T. M.; Kliewer, S. A.; Milburn, M. V. Molecular recognition of 
fatty acids by peroxisome proliferator-activated receptors. Mol. Cell 
1999, 3, 397-403. 
19. Xu, H. E.; Stanley, T. B.; Montana, V. G.; Lambert, M. H.; Shearer, B. 
G.; Cobb, J. E.; McKee, D. D.; Galardi, C. M.; Plunket, K. D.; Nolte, R. 
T.; Parks, D. J.; Moore, J. T.; Kliewer, S. A.; Willson, T. M.; Stimmel, J. 
B. Structural basis for antagonist-mediated recruitment of nuclear co-
repressors by ppar alpha. Nature 2002, 415, 813-817. 
20. Krey, G.; Braissant, O.; LHorset, F.; Kalkhoven, E.; Perroud, M.; Parker, 
M. G.; Wahli, W. Fatty acids, eicosanoids, and hypolipidemic agents 
identified as ligands of peroxisome proliferator-activated receptors by 
coactivator-dependent receptor ligand assay. Mol. Endocrinol. 1997, 11, 
779-791. 
21. Keating, G. M.; Croom, K. F. Fenofibrate - a review of its use in primary 
dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. 
Drugs 2007, 67, 121-153. 
22. Liu, K.; Xu, L.; Berger, J. P.; MacNaul, K. L.; Zhou, G.; Doebber, T. W.; 
Forrest, M. J.; Moller, D. E.; Jones, A. B. Discovery of a novel series of 
peroxisome proliferator-activated receptor î±/î³ dual agonists for the 
treatment of type 2 diabetes and dyslipidemia. J. Med. Chem. 2005, 48, 
2262-2265. 
23. Glynne, W. M., J. Thorpe, J.M. Waring, W.S. Pharmaceutical 
compositions comprising alpha-aryloxy-aliphatic carboxylic acids and/or 
alpha-arylimino-aliphatic carboxylic acids, their esters and salts. 
GB860303, 1961. 
24. Thorp, J. M.; Waring, W. S. Modification of metabolism and distribution 
of lipids by ethyl chlorophenoxyisobutyrate. Nature 1962, 194, 948-&. 
25. Reddy, J. K.; Azarnoff, D. L.; Hignite, C. E. Hypolipemic hepatic 
peroxisome proliferators form a novel class of chemical carcinogens. 
Nature 1980, 283, 397-398. 
26. Mieville. Composes hypolipidemiantes. FR2300552, 1976. 
27. Keech, A.; Simes, R. J.; Barter, P.; Best, J.; Scott, R.; Taskinen, M. R.; 
Forder, P.; Pillai, A.; Davis, T.; Glasziou, P.; Drury, P.; Kesaniemi, Y. 
A.; Sullivan, D.; Hunt, D.; Colman, P.; d'Emden, M.; Whiting, M.; 
Ehnholm, C.; Laakso, M. Effects of long-term fenofibrate therapy on 
cardiovascular events in 9795 people with type 2 diabetes mellitus (the 
field study): Randomised controlled trial. Lancet 2005, 366, 1849-1861. 
215 
28. Staels, B.; Dallongeville, J.; Auwerx, J.; Schoonjans, K.; Leitersdorf, E.; 
Fruchart, J. G. Mechanism of action of fibrates on lipid and lipoprotein 
metabolism. Circulation 1998, 98, 2088-2093. 
29. Backes, J. M.; Gibson, C. A.; Ruisinger, J. E.; Moriarty, P. M. Fibrates: 
What have we learned in the past 40 years? Pharmacotherapy 2007, 27, 
412-424. 
30. Tomarelli, R. M.; Bauman, L. M.; Savini, S. Effect of wy-14,643 on 
cholesterol-metabolism in normal and hypercholesterolemic rats. 
Atherosclerosis 1978, 30, 301-311. 
31. Sirtori, C. R.; Gomarasca, P.; Datri, G.; Cerutti, S.; Tronconi, G.; 
Scolastico, C. Pharmacological profile of br-931, a new hypolipidemic 
agent that increases high-density lipoproteins. Atherosclerosis 1978, 30, 
45-56. 
32. Brown, P. J.; Smith-Oliver, T. A.; Charifson, P. S.; Tomkinson, N. C. O.; 
Fivush, A. M.; Sternbach, D. D.; Wade, L. E.; Orband-Miller, L.; Parks, 
D. J.; Blanchard, S. G.; Kliewer, S. A.; Lehmann, J. M.; Willson, T. M. 
Identification of peroxisome proliferator-activated receptor ligands from 
a biased chemical library. Chem. Biol. 1997, 4, 909-918. 
33. Brown, P. J.; Winegar, D. A.; Plunket, K. D.; Moore, L. B.; Lewis, M. C.; 
Wilson, J. G.; Sundseth, S. S.; Koble, C. S.; Wu, Z. D.; Chapman, J. M.; 
Lehmann, J. M.; Kliewer, S. A.; Willson, T. M. A ureido-thioisobutyric 
acid (gw9578) is a subtype-selective ppar alpha agonist with potent lipid-
lowering activity. J. Med. Chem. 1999, 42, 3785-3788. 
34. Brown, P. J.; Stuart, L. W.; Hurley, K. P.; Lewis, M. C.; Winegar, D. A.; 
Wilson, J. G.; Wilkinson, W. O.; Ittoop, O. R.; Willson, T. M. 
Identification of a subtype selective human ppar alpha agonist through 
parallel-array synthesis. Bioorg. Med. Chem. Lett. 2001, 11, 1225-1227. 
35. Millar, R. P.; Newton, C. L. The year in g protein-coupled receptor 
research. Mol. Endocrinol. 24, 261-274. 
36. Karnik, S. S.; Gogonea, C.; Patil, S.; Saad, Y.; Takezako, T. Activation of 
g-protein-coupled receptors: A common molecular mechanism. Trends 
Endocrinol. Metab. 2003, 14, 431-437. 
37. Lodish, H.; Baltimore, D.; Berk, A.; Zipursky, S. L.; Matsudaira, P.; 
Darnell, J.; Lodish, H.; Baltimore, D.; Berk, A.; Zipursky, S. L.; 
Matsudaira, P.; Darnell, J. Molecular cell biology; fifth edition. 1995. 
38. Barren, B.; Artemyev, N. O. Mechanisms of dominant negative g-protein 
alpha subunits. J. Neurosci. Res. 2007, 85, 3505-3514. 
39. Harrison, C.; Traynor, J. R. The [s-35]gtp gamma s binding assay: 
Approaches and applications in pharmacology. Life Sci. 2003, 74, 489-
508. 
40. Hart, M. J.; Jiang, X. J.; Kozasa, T.; Roscoe, W.; Singer, W. D.; Gilman, 
A. G.; Sternweis, P. C.; Bollag, G. Direct stimulation of the guanine 
nucleotide exchange activity of p115 rhogef by g alpha(13). Science 
1998, 280, 2112-2114. 
41. Henderson, R.; Baldwin, J. M.; Ceska, T. A.; Zemlin, F.; Beckmann, E.; 
Downing, K. H. Model for the structure of bacteriorhodopsin based on 
high-resolution electron cryomicroscopy. J. Mol. Biol. 1990, 213, 899-
929. 
42. Trumppkallmeyer, S.; Hoflack, J.; Bruinvels, A.; Hibert, M. Modeling of 
g-protein-coupled receptors - application to dopamine, adrenaline, 
216 
serotonin, acetylcholine, and mammalian opsin receptors. J. Med. Chem. 
1992, 35, 3448-3462. 
43. Luecke, H.; Schobert, B.; Richter, H. T.; Cartailler, J. P.; Lanyi, J. K. 
Structure of bacteriorhodopsin at 1.55 angstrom resolution. J. Mol. Biol. 
1999, 291, 899-911. 
44. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; 
Fox, B. A.; Le Trong, I.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; 
Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: A g protein-
coupled receptor. Science 2000, 289, 739-745. 
45. Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S. G. F.; 
Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Kuhn, P.; Weis, W. I.; Kobilka, 
B. K.; Stevens, R. C. High-resolution crystal structure of an engineered 
human beta(2)-adrenergic g protein-coupled receptor. Science 2007, 318, 
1258-1265. 
46. Rasmussen, S. G. F.; Choi, H. J.; Rosenbaum, D. M.; Kobilka, T. S.; 
Thian, F. S.; Edwards, P. C.; Burghammer, M.; Ratnala, V. R. P.; 
Sanishvili, R.; Fischetti, R. F.; Schertler, G. F. X.; Weis, W. I.; Kobilka, 
B. K. Crystal structure of the human beta(2) adrenergic g-protein-coupled 
receptor. Nature 2007, 450, 383-U384. 
47. Di Marzo, V.; De Petrocellis, L. Plant, synthetic, and endogenous 
cannabinoids in medicine. Annu. Rev. Med. 2006, 57, 553-574. 
48. Rhee, M. H.; Vogel, Z.; Barg, J.; Bayewitch, M.; Levy, R.; Hanus, L.; 
Breuer, A.; Mechoulam, R. Cannabinol derivatives: Binding to 
cannabinoid receptors and inhibition of adenylylcyclase. J. Med. Chem. 
1997, 40, 3228-3233. 
49. Gaoni, Y.; Mechoulam, R. Isolation, structure and partial synthesis of 
active constituent of hashish. J. Am. Chem. Soc. 1964, 86, 1646-&. 
50. Devane, W. A.; Dysarz, F. A.; Johnson, M. R.; Melvin, L. S.; Howlett, A. 
C. Determination and characterization of a cannabinoid receptor in rat-
brain. Mol. Pharmacol. 1988, 34, 605-613. 
51. Matsuda, L. A.; Lolait, S. J.; Brownstein, M. J.; Young, A. C.; Bonner, T. 
I. Structure of a cannabinoid receptor and functional expression of the 
cloned cdna. Nature 1990, 346, 561-564. 
52. Chakrabarti, A.; Onaivi, E. S.; Chaudhuri, G. Cloning and sequencing of 
a cdna-encoding the mouse brain-type cannabinoid receptor protein. DNA 
Sequence 1995, 5, 385-388. 
53. Gerard, C. M.; Mollereau, C.; Vassart, G.; Parmentier, M. Molecular-
cloning of a human cannabinoid receptor which is also expressed in 
testis. Biochem. J 1991, 279, 129-134. 
54. Howlett, A. C.; Barth, F.; Bonner, T. I.; Cabral, G.; Casellas, P.; Devane, 
W. A.; Felder, C. C.; Herkenham, M.; Mackie, K.; Martin, B. R.; 
Mechoulam, R.; Pertwee, R. G. International union of pharmacology. 
Xxvii. Classification of cannabinoid receptors. Pharmacol. Rev. 2002, 54, 
161-202. 
55. Herkenham, M.; Lynn, A. B.; Little, M. D.; Johnson, M. R.; Melvin, L. 
S.; Decosta, B. R.; Rice, K. C. Cannabinoid receptor localization in brain. 
Proc. Natl. Acad. Sci. U. S. A. 1990, 87, 1932-1936. 
56. Felder, C. C.; Joyce, K. E.; Briley, E. M.; Mansouri, J.; Mackie, K.; 
Blond, O.; Lai, Y.; Ma, A. L.; Mitchell, R. L. Comparison of the 
217 
pharmacology and signal-transduction of the human cannabinoid cb1 and 
cb2 receptors. Mol. Pharmacol. 1995, 48, 443-450. 
57. Shire, D.; Calandra, B.; RinaldiCarmona, M.; Oustric, D.; Pessegue, B.; 
BonninCabanne, O.; LeFur, G.; Caput, D.; Ferrara, P. Molecular cloning, 
expression and function of the murine cb2 peripheral cannabinoid 
receptor. Biochimica Et Biophysica Acta-Gene Structure and Expression 
1996, 1307, 132-136. 
58. Griffin, G.; Tao, Q.; Abood, M. E. Cloning and pharmacological 
characterization of the rat cb2 cannabinoid receptor. J. Pharmacol. Exp. 
Ther. 2000, 292, 886-894. 
59. Van Sickle, M. D.; Duncan, M.; Kingsley, P. J.; Mouihate, A.; Urbani, P.; 
Mackie, K.; Stella, N.; Makriyannis, A.; Piomelli, D.; Davison, J. S.; 
Marnett, L. J.; Di Marzo, V.; Pittman, Q. J.; Patel, K. D.; Sharkey, K. A. 
Identification and functional characterization of brainstem cannabinoid 
cb2 receptors. Science 2005, 310, 329-332. 
60. Nunez, E.; Benito, C.; Pazos, M. R.; Barbachano, A.; Fajardo, O.; 
Gonzalez, S.; Tolon, R. M.; Romero, J. Cannabinoid cb2 receptors are 
expressed by perivascular microglial cells in the human brain: An 
immunohistochemical study. Synapse 2004, 53, 208-213. 
61. Reggio, P. H. Pharmacophores for ligand recognition and 
activation/inactivation of the cannabinoid receptors. Curr. Pharm. Des. 
2003, 9, 1607-1633. 
62. Di Marzo, V.; Breivogel, C. S.; Tao, Q.; Bridgen, D. T.; Razdan, R. K.; 
Zimmer, A. M.; Zimmer, A.; Martin, B. R. Levels, metabolism, and 
pharmacological activity of anandamide in cb1 cannabinoid receptor 
knockout mice: Evidence for non-cb1, non-cb2 receptor-mediated actions 
of anandamide in mouse brain. J. Neurochem. 2000, 75, 2434-2444. 
63. Hajos, N.; Ledent, C.; Freund, T. F. Novel cannabinoid-sensitive receptor 
mediates inhibition of glutamatergic synaptic transmission in the 
hippocampus. Neuroscience 2001, 106, 1-4. 
64. Jarai, Z.; Wagner, J. A.; Varga, K.; Lake, K. D.; Compton, D. R.; Martin, 
B. R.; Zimmer, A. M.; Bonner, T. I.; Buckley, N. E.; Mezey, E.; Razdan, 
R. K.; Zimmer, A.; Kunos, G. Cannabinoid-induced mesenteric 
vasodilation through an endothelial site distinct from cb1 or cb2 
receptors. Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 14136-14141. 
65. Ho, W. S. V.; Hiley, C. R. Vasodilator actions of abnormal-cannabidiol 
in rat isolated small mesenteric artery. Br. J. Pharmacol. 2003, 138, 
1320-1332. 
66. Kaplan, B. L. F.; Rockwell, C. E.; Kaminski, N. E. Evidence for 
cannabinoid receptor-dependent and -independent mechanisms of action 
in leukocytes. J. Pharmacol. Exp. Ther. 2003, 306, 1077-1085. 
67. Wagner, J. A.; Varga, K.; Jarai, Z.; Kunos, G. Mesenteric vasodilation 
mediated by endothelial anandamide receptors. Hypertension 1999, 33, 
429-434. 
68. Calignano, A.; La Rana, G.; Giuffrida, A.; Piomelli, D. Control of pain 
initiation by endogenous cannabinoids. Nature 1998, 394, 277-281. 
69. Ryberg, E.; Larsson, N.; Sjogren, S.; Hjorth, S.; Hermansson, N. O.; 
Leonova, J.; Elebring, T.; Nilsson, K.; Drmota, T.; Geasley, P. J. The 
orphan receptor gpr55 is a novel cannabinoid receptor. Br. J. Pharmacol. 
2007, 152, 1092-1101. 
218 
70. Henstridge, C. M.; Balenga, N. A. B.; Ford, L. A.; Ross, R. A.; 
Waldhoer, M.; Irving, A. J. The gpr55 ligand l-alpha-
lysophosphatidylinositol promotes rhoa-dependent ca(2+) signaling and 
nfat activation. FASEB J. 2009, 23, 183-193. 
71. Oka, S.; Toshida, T.; Maruyama, K.; Nakajima, K.; Yamashita, A.; 
Sugiura, T. 2-arachidonoyl-sn-glycero-3-phosphoinositol: A possible 
natural ligand for gpr55. J. Biochem. 2009, 145, 13-20. 
72. Di Marzo, V.; Goparaju, S. K.; Wang, L.; Liu, J.; Batkai, S.; Jarai, Z.; 
Fezza, F.; Miura, G. I.; Palmiter, R. D.; Sugiura, T.; Kunos, G. Leptin-
regulated endocannabinoids are involved in maintaining food intake. 
Nature 2001, 410, 822-825. 
73. Zajicek, J.; Fox, P.; Sanders, H.; Wright, D.; Vickery, J.; Nunn, A.; 
Thompson, A.; Grp, U. M. R. Cannabinoids for treatment of spasticity 
and other symptoms related to multiple sclerosis (cams study): 
Multicentre randomised placebo-controlled trial. Lancet 2003, 362, 1517-
1526. 
74. Klein, T. W.; Newton, C.; Larsen, K.; Lu, L.; Perkins, I.; Nong, L.; 
Friedman, H. The cannabinoid system and immune modulation. J. 
Leukocyte Biol. 2003, 74, 486-496. 
75. Wilson, R. I.; Nicoll, R. A. Endogenous cannabinoids mediate retrograde 
signalling at hippocampal synapses. Nature 2001, 410, 588-592. 
76. Devane, W. A.; Hanus, L.; Breuer, A.; Pertwee, R. G.; Stevenson, L. A.; 
Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. 
Isolation and structure of a brain constituent that binds to the cannabinoid 
receptor. Science 1992, 258, 1946-1949. 
77. RinaldiCarmona, M.; Calandra, B.; Shire, D.; Bouaboula, M.; Oustric, D.; 
Barth, F.; Casellas, P.; Ferrara, P.; LeFur, G. Characterization of two 
cloned human cb1 cannabinoid receptor isoforms. J. Pharmacol. Exp. 
Ther. 1996, 278, 871-878. 
78. Hanus, L.; Gopher, A.; Almog, S.; Mechoulam, R. 2 new unsaturated 
fatty-acid ethanolamides in brain that bind to the cannabinoid receptor. J. 
Med. Chem. 1993, 36, 3032-3034. 
79. Mechoulam, R.; Benshabat, S.; Hanus, L.; Ligumsky, M.; Kaminski, N. 
E.; Schatz, A. R.; Gopher, A.; Almog, S.; Martin, B. R.; Compton, D. R.; 
Pertwee, R. G.; Griffin, G.; Bayewitch, M.; Barg, J.; Vogel, Z. 
Identification of an endogenous 2-monoglyceride, present in canine gut, 
that binds to cannabinoid receptors. Biochem. Pharmacol. 1995, 50, 83-
90. 
80. Sugiura, T.; Kondo, S.; Sukagawa, A.; Nakane, S.; Shinoda, A.; Itoh, K.; 
Yamashita, A.; Waku, K. 2-arachidonoylgylcerol - a possible endogenous 
cannabinoid receptor-ligand in brain. Biochem. Biophys. Res. Commun. 
1995, 215, 89-97. 
81. Huang, S. M.; Bisogno, T.; Trevisani, M.; Al-Hayani, A.; De Petrocellis, 
L.; Fezza, F.; Tognetto, M.; Petros, T. J.; Krey, J. F.; Chu, C. J.; Miller, J. 
D.; Davies, S. N.; Geppetti, P.; Walker, J. M.; Di Marzo, V. An 
endogenous capsaicin-like substance with high potency at recombinant 
and native vanilloid vr1 receptors. Proc. Natl. Acad. Sci. U. S. A. 2002, 
99, 8400-8405. 
82. Bisogno, T.; Melck, D.; Bobrov, M. Y.; Gretskaya, N. M.; Bezuglov, V. 
V.; De Petrocellis, L.; Di Marzo, V. N-acyl-dopamines: Novel synthetic 
219 
cb1 cannabinoid-receptor ligands and inhibitors of anandamide 
inactivation with cannabimimetic activity in vitro and in vivo. Biochem. J 
2000, 351, 817-824. 
83. Hanus, L.; Abu-Lafi, S.; Fride, E.; Breuer, A.; Vogel, Z.; Shalev, D. E.; 
Kustanovich, I.; Mechoulam, R. 2-arachidonyl glyceryl ether, an 
endogenous agonist of the cannabinoid cb1 receptor. Proc. Natl. Acad. 
Sci. U. S. A. 2001, 98, 3662-3665. 
84. Shoemaker, J. L.; Joseph, B. K.; Ruckle, M. B.; Mayeux, P. R.; Prather, 
P. L. The endocannabinoid noladin ether acts as a full agonist at human 
cb2 cannabinoid receptors. J. Pharmacol. Exp. Ther. 2005, 314, 868-875. 
85. Porter, A. C.; Sauer, J. M.; Knierman, M. D.; Becker, G. W.; Berna, M. 
J.; Bao, J. Q.; Nomikos, G. G.; Carter, P.; Bymaster, F. P.; Leese, A. B.; 
Felder, C. C. Characterization of a novel endocannabinoid, virodhamine, 
with antagonist activity at the cb1 receptor. J. Pharmacol. Exp. Ther. 
2002, 301, 1020-1024. 
86. Wilson, R. S.; May, E. L.; Martin, B. R.; Dewey, W. L. "9-nor-9-
hydroxyhexahydrocannabinols - synthesis, some behavioral and analgesic 
properties, and comparison with tetrahydrocannabinols. J. Med. Chem. 
1976, 19, 1165-1167. 
87. Palmer, S. L.; Thakur, G. A.; Makriyannis, A. Cannabinergic ligands. 
Chem. Phys. Lipids 2002, 121, 3-19. 
88. Mechoulam, R.; Lander, N.; Srebnik, M.; Breuer, A.; Segal, M.; 
Feigenbaum, J. J.; Jarbe, T. U.; Consroe, P. Stereochemical requirements 
for cannabimimetic activity. NIDA Res. Monogr. 1987, 79, 15-30. 
89. Howlett, A. C.; Champion, T. M.; Wilken, G. H.; Mechoulam, R. 
Stereochemical effects of 11-oh-delta-8-tetrahydrocannabinol-
dimethylheptyl to inhibit adenylate-cyclase and bind to the cannabinoid 
receptor. Neuropharmacology 1990, 29, 161-165. 
90. Huffman, J. W.; Yu, S.; Showalter, V.; Abood, M. E.; Wiley, J. L.; 
Compton, D. R.; Martin, B. R.; Bramblett, R. D.; Reggio, P. H. Synthesis 
and pharmacology of a very potent cannabinoid lacking a phenolic 
hydroxyl with high affinity for the cb2 receptor. J. Med. Chem. 1996, 39, 
3875-3877. 
91. Huffman, J. W.; Liddle, J.; Yu, S.; Aung, M. M.; Abood, M. E.; Wiley, J. 
L.; Martin, B. R. 3-(1 ',1 '-dimethylbutyl)-1-deoxy-delta(8)-thc and 
related compounds: Synthesis of selective ligands for the cb2 receptor. 
Biorg. Med. Chem. 1999, 7, 2905-2914. 
92. Melvin, L. S.; Johnson, M. R.; Harbert, C. A.; Milne, G. M.; Weissman, 
A. A cannabinoid derived prototypical analgesic. J. Med. Chem. 1984, 
27, 67-71. 
93. Huffman, J. W.; Thompson, A. L. S.; Wiley, J. L.; Martin, B. R. 
Synthesis and pharmacology of 1-deoxy analogs of cp-47,497 and cp-
55,940. Biorg. Med. Chem. 2008, 16, 322-335. 
94. Griffin, G.; Wray, E. J.; Martin, B. R.; Abood, M. E. Cannabinoid 
agonists and antagonists discriminated by receptor binding in rat 
cerebellum. Br. J. Pharmacol. 1999, 128, 684-688. 
95. Drake, D. J.; Jensen, R. S.; Busch-Petersen, J.; Kawakami, J. K.; 
Fernandez-Garcia, M. C.; Fan, P. S.; Makriyannis, A.; Tius, M. A. 
Classical/nonclassical hybrid cannabinoids: Southern aliphatic chain-
220 
functionalized c-6 beta methyl, ethyl, and propyl analogues. J. Med. 
Chem. 1998, 41, 3596-3608. 
96. Harrington, P. E.; Stergiades, I. A.; Erickson, J.; Makriyannis, A.; Tius, 
M. A. Synthesis of functionalized cannabinoids. J. Org. Chem. 2000, 65, 
6576-6582. 
97. Bell, M. R.; Dambra, T. E.; Kumar, V.; Eissenstat, M. A.; Herrmann, J. 
L.; Wetzel, J. R.; Rosi, D.; Philion, R. E.; Daum, S. J.; Hlasta, D. J.; 
Kullnig, R. K.; Ackerman, J. H.; Haubrich, D. R.; Luttinger, D. A.; 
Baizman, E. R.; Miller, M. S.; Ward, S. J. Antinociceptive 
(aminoalkyl)indoles. J. Med. Chem. 1991, 34, 1099-1110. 
98. Dambra, T. E.; Estep, K. G.; Bell, M. R.; Eissenstat, M. A.; Josef, K. A.; 
Ward, S. J.; Haycock, D. A.; Baizman, E. R.; Casiano, F. M.; Beglin, N. 
C.; Chippari, S. M.; Grego, J. D.; Kullnig, R. K.; Daley, G. T. 
Conformationally restrained analogs of pravadoline - nanomolar potent, 
enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. 
J. Med. Chem. 1992, 35, 124-135. 
99. Gallant, M.; Dufresne, C.; Gareau, Y.; Guay, D.; Leblanc, Y.; Prasit, P.; 
Rochette, C.; Sawyer, N.; Slipetz, D. M.; Tremblay, N.; Metters, K. M.; 
Labelle, M. New class of potent ligands for the human peripheral 
cannabinoid receptor. Bioorg. Med. Chem. Lett. 1996, 6, 2263-2268. 
100. Rinaldicarmona, M.; Barth, F.; Heaulme, M.; Shire, D.; Calandra, B.; 
Congy, C.; Martinez, S.; Maruani, J.; Neliat, G.; Caput, D.; Ferrara, P.; 
Soubrie, P.; Breliere, J. C.; Lefur, G. Sr141716a, a potent and selective 
antagonist of the brain cannabinoid receptor. FEBS Lett. 1994, 350, 240-
244. 
101. Richardson, J. D.; Kilo, S.; Hargreaves, K. M. Cannabinoids reduce 
hyperalgesia and inflammation via interaction with peripheral cb1 
receptors. Pain 1998, 75, 111-119. 
102. Campbell, F. A.; Tramer, M. R.; Carroll, D.; Reynolds, D. J.; Moore, R. 
A.; McQuay, H. J. Are cannabinoids an effective and safe treatment 
option in the management of pain? A qualitative systematic review. Br. 
Med. J. 2001, 323, 13-16. 
103. Buggy, D. J.; Toogood, L.; Maric, S.; Sharpe, P.; Lambert, D. G.; 
Rowbotham, D. J. Lack of analgesic efficacy of oral delta-9-
tetrahydrocannabinol in postoperative pain. Pain 2003, 106, 169-172. 
104. Williams, C. M.; Kirkham, T. C. Observational analysis of feeding 
induced by delta(9)-thc and anandamide. Physiol. Behav. 2002, 76, 241-
250. 
105. Despres, J. P.; Golay, A.; Sjostrom, L.; Rimonabant Obesity Lipids 
Study, G. Effects of rimonabant on metabolic risk factors in overweight 
patients with dyslipidemia. New Engl. J. Med. 2005, 353, 2121-2134. 
106. Pacher, P.; Batkai, S.; Kunos, G. The endocannabinoid system as an 
emerging target of pharmacotherapy. Pharmacol. Rev. 2006, 58, 389-462. 
107. Bensaid, M.; Gary-Bobo, M.; Esclangon, A.; Maffrand, J. P.; Le Fur, G.; 
Oury-Donat, F.; Soubrie, P. The cannabinoid cb1 receptor antagonist 
sr141716 increases acrp30 mrna expression in adipose tissue of obese 
fa/fa rats and in cultured adipocyte cells. Mol. Pharmacol. 2003, 63, 908-
914. 
108. Cota, D.; Marsicano, G.; Tschop, M.; Grubler, Y.; Flachskamm, C.; 
Schubert, M.; Auer, D.; Yassouridis, A.; Thone-Reineke, C.; Ortmann, 
221 
S.; Tomassoni, F.; Cervino, C.; Nisoli, E.; Linthorst, A. C. E.; Pasquali, 
R.; Lutz, B.; Stalla, G. K.; Pagotto, U. The endogenous cannabinoid 
system affects energy balance via central orexigenic drive and peripheral 
lipogenesis. J. Clin. Invest. 2003, 112, 423-431. 
109. Le Foll, B.; Gorelick, D. A.; Goldberg, S. R. The future of 
endocannabinoid-oriented clinical research after cb1 antagonists. 
Psychopharmacology 2009, 205, 171-174. 
110. Pertwee, R. G. Emerging strategies for exploiting cannabinoid receptor 
agonists as medicines. Br. J. Pharmacol. 2009, 156, 397-411. 
111. Wade, D. T.; Makela, P.; Robson, P.; House, H.; Bateman, C. Do 
cannabis-based medicinal extracts have general or specific effects on 
symptoms in multiple sclerosis? A double-blind, randomized, placebo-
controlled study on 160 patients. Multiple Sclerosis 2004, 10, 434-441. 
112. Pharmaceuticals, G. Gw announces uk launch of worlds first prescription 
cannabis medicine. In 2010. 
113. Malan, T. P.; Ibrahim, M. M.; Deng, H. F.; Liu, Q.; Mata, H. P.; 
Vanderah, T.; Porreca, F.; Makriyannis, A. Cb2 cannabinoid receptor-
mediated peripheral antinociception. Pain 2001, 93, 239-245. 
114. Guindon, J.; Hohmann, A. G. Cannabinoid cb2 receptors: A therapeutic 
target for the treatment of inflammatory and neuropathic pain. Br. J. 
Pharmacol. 2008, 153, 319-334. 
115. Steffens, S.; Veillard, N. R.; Arnaud, C.; Pelli, G.; Burger, F.; Staub, C.; 
Karsak, M.; Zimmer, A.; Frossard, J. L.; Mach, F. Low dose oral 
cannabinoid therapy reduces progression of atherosclerosis in mice (vol 
434, pg 782, 2005). Nature 2005, 435, 528-528. 
116. Neubig, R. R.; Spedding, M.; Kenakin, T.; Christopoulos, A. 
International union of pharmacology committee on receptor nomenclature 
and drug classification. Xxxviii. Update on terms and symbols in 
quantitative pharmacology. Pharmacol. Rev. 2003, 55, 597-606. 
117. Davis, R. D.; Fitzgerald, R. N.; Guo, J. S. Improved method for the 
synthesis of 2-methyl-2-aryloxypropanoic acid derivatives. Synthesis-
Stuttgart 2004, 1959-1962. 
118. Kulkarni, P. P.; Kadam, A. J.; Mane, R. B.; Desai, U. V.; Wadgaonkar, P. 
P. Demethylation of methyl aryl ethers using pyridine hydrochloride in 
solvent-free conditions under microwave irradiation. Journal of Chemical 
Research-S 1999, 394-395. 
 
 
